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Abstract 
Aim: To use published literature to obtain estimates of large, medium and small 
differences in quality of life (QOL) data for the European Organisation for the Research 
and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). 
Methods: An innovative method combining systematic review of published studies, 
expert opinions and meta-analysis was used to obtain estimates of large, medium and 
small differences for QLQ-C30 scores. Published mean data were identified from the 
literature. Differences between groups of patients and over time within patients were 
reviewed by 34 experts in QOL measurement and cancer treatment. The experts, 
blinded to QOL results, were asked to predict these differences. Differences were 
combined using meta-analytic techniques to obtain estimates of small, medium and 
large effects. Qualitative interviews with patients and experts were used to assess the 
new methodology. 
Results: 911 articles were identified, with 211 relevant articles (3444 contrasts) for the 
analysis. Our systematic review of the randomised controlled trials (RCTs) showed that 
the clinical relevance of OOL differences was rarely discussed. Our meta-analysis 
estimates varied depending on the subscale and on whether QOL was improving or 
deteriorating. Thus, the recommended minimum to detect medium differences between 
groups ranges from 7 (diarrhoea) to 19 points (role functioning). When interpreting 
differences over time a minimum of 7 points represents a medium difference but for 
most subscales a larger difference is required for a medium deterioration compared 
with a medium improvement. 
Conclusion: Guidelines for interpreting the size of effects are provided for the QLQ-
C30 subscales. These guidelines can be used for sample size calculations for clinical 
trials and to interpret differences in OLQ-C30 scores. The novel methodology was 
shown to be robust in sensitivity analyses but benefitted from a thorough quality 
assessment and using only the best quality evidence to derive the guidelines. 
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SE Standard Error 
SEM Standard Error of Measurement 
SF Social Functioning 
SL Sleep 
SSQ Subjective Significance Questionnaire 
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1 Introduction 
1.1 Structure and content of the thesis 
This study aimed to produce guidelines for the interpretation of a questionnaire 
used to measure quality of life in cancer patients. the European Organization for 
Research and Treatment of Cancer (EORTC) QLQ-C30. The study is referred to as the 
'Evidence-Based Interpretation Guidelines' (EBIG) project. Chapter 1 introduces the 
concept of health-related quality of life and describes the two most commonly used 
questionnaires in cancer research. the EORTC QLQ-C30 and the Functional 
Assessment of Cancer Therapy General (FACT-G) questionnaire. Chapter 2 reviews 
the techniques currently available for interpreting quality of life scores and includes a 
discussion of methodology developed by King et a/(1 ;2) which used published data 
from the FACT-G to create guidelines for the interpretation of scores 'evidence-based 
effect sizes' (EBES). Chapter 3 provides the background to the research and highlights 
the need for interpretation guidelines. This chapter reports a systematic review I carried 
out to assess the quality of the reporting from randomised controlled trials (RCT) using 
the QLQ-C30. I also investigated how widely the currently available guidelines for 
interpreting QOL scores were being used in these papers. This chapter has been 
published in the European Journal of Cancer(3). The review highlighted the fact that 
only 38% of papers addressed the clinical significance of the QOL differences and 
there was a lack of consistency across the papers in how the QOL scores were 
interpreted. 
The main objective of the research was to build on the work of King et al and 
produce interpretation guidelines for the QLQ-C30 questionnaire. A literature search 
was carried out to identify all articles containing mean scores from the QLQ-C30 
questionnaire for a group of patients over time or between groups of patients. The 
identified papers then underwent a review by a panel of experts in order to group the 
QOL differences into large. medium. small or trivial categories for a meta-analysis. 
Chapter 4 details the full methods used to produce the interpretation guidelines and 
highlights improvements to the original methodology. Chapter 5 summarises the results 
of the literature search. 
Chapter 6 investigates the quality of the meta-analysis. The expert opinion was 
key to the development of the guidelines and since the methodology was new various 
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methods were used to ensure their quality, including qualitative and quantitative 
methods. Chapter 6 is divided into two parts. Part 1 reports on a qualitative study 
carried out with the expert review panellists and Part 2 uses a quantitative approach to 
assess the quality of the meta-analysis. 
Chapter 7 contains the main study results and interpretation guidelines. We have 
published the guidelines for comparisons between groups of patients in the Journal of 
Clinical Oncology( 4). 
Alongside the main study I carried out interviews with patients aimed at finding 
out how patients could contribute to and improve the methodology. The results from 
this qualitative study are reported in Chapter 8. 
Conclusions and a discussion of the overall findings can be found in Chapter 9. 
1.2 Quality of life (QOL) 
1.2.1 QOL definition and instruments to measure QOL 
The EORTC describes quality of life assessment in cancer clinical trials as 
providing "a more accurate evaluation of the well-being of individuals or groups of 
patients and of the benefits and side-effects that may result from medical 
intervention."(5) Various definitions of QOL have been proposed and no one concise 
definition has emerged as a standard. However, most definitions include one or more 
of the following concepts; health status, phYSical functioning, symptoms, psychological 
adjustment, well-being, and life satisfaction(6). Quality of life is defined by Ferrans(7) 
as "a person's sense of well-being that stems from satisfaction or dissatisfaction with 
the areas of life that are important to him/her". 
Patients' perception of their health and well-being, is an important aspect of 
health care. Quality of life can be measured using questionnaires which ask a series of 
questions regarding how the patient is functioning in various aspects of their life or any 
symptoms they are experiencing. Each question has a selection of possible answers to 
choose from, e.g. 'Not at all', 'A little', 'Sometimes', 'Very much'. These questionnaires 
are often used within clinical trials in order to gain experience of the effect of treatments 
on quality as well as quantity of life. This has become a vital part of cancer research in 
particular as treatments are often toxic, and the benefits, whether extended survival or 
palliation of symptoms, are often offset by adverse side effects. 
The answers to questions in the QOL questionnaire are used to generate a QOL 
score for that patient for the time period covered by the questionnaire. These scores 
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are designed to measure the patients' health and well-being. During 20 years of QOL 
research, a rigorous methodology has been developed to create the questions and a 
scoring system so the questionnaires measure QOL reliably and validly. However, like 
other clinical measurements, the meaning of scores is not clear until the questionnaires 
have been widely used in different patients in different circumstances. Familiarity with 
the questionnaire and its range of scores is required to start to understand the clinical 
significance of QOL scores. 
1.2.2 QOL measurement in Cancer 
Cancer and its treatment can affect many different aspects of QOL. Initially just 
the diagnosis can affect a person's life with the associated fear and anxiety it can 
cause. Then the anti-cancer treatments may have side effects such as nausea, fatigue, 
vomiting and hair loss. The disease and its treatment can also affect a person's ability 
to work and socialise as they normally would. 
There are two instruments which are commonly used to measure QOL in cancer 
patients; the EORTC QLQ-C30 and the FACT-G. These account for the majority of 
published trials of QOL in cancer and are the focus for the thesis. The FACT-G was 
developed in the USA(8) and the QLQ-C30 questionnaire(9) in Europe. 
FACT-G was released in 1993 after 5 years of development and testing(8). It was 
originally developed as a cancer-specific measure, but its scope was then broadened 
to chronic conditions generally. The FACT-G (see Figure 1) comprises 27 questions 
that assess four primary dimensions of QOL: physical (7 items), social and family (7 
items), emotional (6 items), and functional well-being (7 items). It uses 5-point Likert-
type response categories ranging from 0 = 'not at all' to 4 = 'very much'. The total 
FACT-G score is the summation of the four subscale scores and ranges from 0 to 108. 
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Figure 1 FACT-G quality of life questionnaire 
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The QLQ-C30 consists of 30 questions (Figure 2). The answers to these 
questions are then scored into 15 subscales measuring different aspects of QOL. The 
questionnaire is composed of both multi-item scales (i.e. more than one question 
contributes to an overall score for that scale) and single-item scales. There are five 
functional scales (cognitive (CF). physical (PF). emotional (EF). social (SF) and role 
functioning (RF)). three symptom scales (pain (PA). fatigue (FA). nausea and vomiting 
(NV)). a global health status / QOL scale (QL). and six single items (appetite loss (AP). 
constipation (CO). diarrhoea (01). dyspnoea (DY). sleep (SL) and financial impact (FI)). 
Each of the multi-item scales includes a different set of items and no item occurs in 
more than one scale. All of the scales and single-item measures range in score from 0 
to 1 00. A high score represents a higher response level. A high score for a functional 
scale represents a high/healthy level of functioning . a high score for the global health 
status/QOL represents a high QOL. but a high score for a symptom scale/item 
represents a high level of symptomatology/problems. 
Figure 2 EORTC QLQ-C30 quality of life questionnaire 
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1.3 Interpretation of QOL scores 
Although QOL questionnaires are now widely used in cancer research , their 
potential to impact on treatment practice cannot be fully realised until the scores and 
changes in these scores can be interpreted . Interpreting the clinical significance of 
effects observed on QOL scales is problematic because their units of measurement are 
unfamiliar to clinicians, policy makers and patients alike (10). For example, say a 
clinical trial found an average difference of 20 points between two treatment groups, 
indicating that Treatment A had better quality of life than Treatment B. However, 
Treatment B was found to improve survival by a small amount. In order to inform 
clinical practice, clinicians need to know if this size of change in QOL is meaningful to 
patients or worthy of clinical attention. Until the QOL scores can be interpreted it is not 
possible to weigh up the survival advantage versus the QOL disadvantage and make 
informed decisions. There is a pressing need to make the results of QOL assessments 
more clinically interpretable so they can be more informative in practice. 
QOL instruments undergo extensive testing to ensure their validity and 
responsiveness. For example, known-group comparisons( 11) test whether the 
questionnaire can distinguish between two groups known to be clinically different. 
Analyses to look at how responsive the questionnaire is over time may also be 
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conducted. As part of this validation process some limited data on interpretation of 
scores emerges but the process does not address what the smallest change in score is 
that would be meaningful to patients or clinicians. Meaningful changes may be those 
that lead to a change in a patient's daily life or that lead to a change in patient 
management and, importantly, the degree of change deemed 'meaningful' may differ 
with perspectives. Various methods for trying to interpret aOL scores have been 
explored and these are reviewed fully in Chapter 2. Several authors provide a 
comprehensive overview of existing interpretation strategies(12-15). 
1.3.1 Minimally important differences 
The interpretation of changes (or differences in scores) is frequently based on the 
minimally important difference (MID). Although the precise definitions of MID vary it is 
essentially the threshold that separates trivial differences from those that, although 
small, are important. King(16) cites the definition from Jaeschke et a/(17) as probably 
the most influential in the field. They defined the minimally clinically important 
difference (MCID) as "the smallest difference ... which patients perceive as beneficial 
and which would mandate, in the absence of troublesome side effects and excessive 
cost, a change in the patient's management". 
De Vet et a/(18) highlight the importance of also distinguishing between the 
minimally detectable difference (i.e. the smallest change the instrument can detect) and 
the minimally important difference as described above. Both are relevant to the 
interpretation of scores, particularly for individual patients (since it is important to know 
the MID and also if the instrument is capable of detecting a change as small as the 
MID). 
1.3.2 Methods of interpretation 
The approaches to interpretation are broadly categorised into distribution-based 
or anchor-based(10). Distribution-based methods use statistical parameters to 
establish meaningful differences based only on observed HRQOL results, while 
anchor-based methods compare, or anchor, QOL differences to other clinical 
differences whose interpretation is known or to patients' perception of change. Current 
recommendations(15;18) suggest that interpretation should be based on a combination 
of methods but that patient-based and clinical anchors are primary, since they address 
the importance of differences. 
King et a/ recently developed a novel method for developing evidence-based 
interpretation guidelines, and illustrated it using the FACT-G(1). An early version of this 
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method was also used to develop preliminary interpretations and evidence-based effect 
sizes for the EORTC QLQ-C30(19;20). This method aims to collect published data on 
scores from the questionnaire and use these to develop guidelines for interpretation. 
Since the QLQ-C30 and FACT-G have been in circulation for a number of years and 
are the most commonly used cancer-specific QOL instruments, they are good 
candidates for such a method, with an abundance of published data from many 
different kinds of studies. 
The strength of this methodology is that guidelines are developed specifically for 
a questionnaire using data from that questionnaire. Scores from groups of patients or 
from a group of patients over time are extracted from the literature. Expert opinion is 
then used to group them into large, medium, small and trivial differences to gain an 
estimate of the range of scores that represent a meaningful change in QOL. These 
estimates would then be published for each scale in the questionnaire as a guide to the 
difference in QOL scores that may be interpreted as small, medium or large. 
Interpretation guidelines of this kind are aimed at comparing groups of patients 
such as those produced in clinical trials and health services research rather than 
investigating individual patient changes. Distinguishing between the two types of 
changes is important since a meaningful change when considering a group of patients 
is likely to be smaller than for an individual(12). This is because a small change that 
looks insignificant for a patient may actually translate into an important improvement in 
the population when considering the same change as an average score instead of an 
individual score. Although some patients will have an even smaller change than the 
mean others will have better changes (and some of these may be substantially better 
than the mean) and this could be a clinically relevant result overall. 
The planned guidelines will therefore be of use in planning and interpreting 
clinical research about the effects of cancer and its treatment on patients' QOL. When 
planning a clinical trial, investigators require a priori knowledge of what constitutes a 
clinically important effect so that they can calculate the sample size required for the 
trial. This information is currently unavailable despite substantial experience with 
cancer QOL instruments. Methods currently used to plan sample size may be under- or 
over-estimating the required study size, as noted by King et al(1). When a study is 
complete, both investigators and end-users need to understand the clinical relevance, 
and hence policy relevance, of the outcomes. Thus the interpretation guidelines and 
the more general methodology for developing them will facilitate better research about 
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the QOL of cancer patients, and better understanding of the results and implications of 
such research. 
1.4 Objectives 
The main objectives for this thesis were:-
• To further develop and extend the methodology for producing 
interpretation guidelines using published literature; 
• Apply the methodology to create guidelines for interpreting the size of 
changes in QOL scores from the QLQ-C30. 
Chapter 4 describes the methods for this project in full, including the numerous 
methodological refinements and extensions to the prototype methodology developed 
by King et a/(1 ;2). In summary: we obtained expert opinion from a much larger panel of 
experts and targeted their reviews to the cancer types or treatments they specialised 
in; we used a different scale to collect the expert opinion which allowed for uncertainty 
in their judgments of the QOL changes; we tried to include as much of the identified 
literature in the expert review as possible then used statistical analysis to identify the 
'best' evidence to go forward into the meta-analysis. 
The resulting evidence-based interpretation guidelines can be found in Chapter 7, 
providing researchers for the first time with separate guidelines for each subscale in the 
QLQ-C30. Researchers can now more accurately calculate sample size according to 
the subscale of primary interest and interpret QOL differences using our guidelines, 
which distinguish between differences between groups of patients and differences 
observed over time. These guidelines should be more widely applicable than those 
currently available as they are based on a wide range of cancers and clinical situations. 
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2 Literature review 
2.1 Approaches to interpretation 
Several authors provide a comprehensive overview of existing interpretation 
strategies(12-15) and these show a number of different approaches have been used to 
try to interpret QOL scores by finding the MIO(15). However, we have shown through a 
systematic review of randomised controlled trials reporting data from the QLQ-C30, 
that no single method has emerged as a standard for interpretation(3). 
The approaches to interpretation are broadly categorised into anchor-based or 
distribution-based methods(10). Figure 3 shows a summary of the methods and they 
are described in detail in the following sections. 
Figure 3 Methods used to interpret QOL scores 
2.1.1 Anchor-based methods 
Anchor-based methods relate changes in QOL scores to clinical status. The idea 
being that an independent measure whose interpretation is well understood is used to 
anchor QOL scores whose interpretation is as yet unknown. These methods "require 
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an independent standard or anchor that is itself interpretable and at least moderately 
correlated with the instrument being explored ."(12). 
2.1.1.1 Cross-sectional anchors 
Wyrwich et a/(21) describe the use of 'population-based' anchors where 
differences are expressed in terms of their impact on populations. For example , Group 
A has a mean QOL score of 50 points compared to Group B with 70 points. The 
absolute difference of 20 points may be hard to interpret where the QOL scale is 
largely unknown. Therefore instead of using the 20 points to interpret the difference an 
anchor (with known meaning) is used. Physical function may be an example of a 
population-based anchor. If we knew that 30% of Group A patients had quite a bit of 
difficulty taking a short walk outside of the house compared to 20% of patients in Group 
B, then there is an absolute difference of 10% or a relative increase of 20% (10/50) 
with more difficulties in Group A. Figure 4 shows this example in a picture, with red 
people used to indicate those in the group with quite a bit of difficulty taking a short 
walk in the two groups. 
Figure 4 Population-based anchor example 
QOL=50 QOL=70 
The authors describe the strengths of these anchors as follows:- "they retain the 
underlying complexity of the QOL construct that they anchor by providing a probabilistic 
relationship to a concrete indicator of the underlying concept. Moreover, if multiple 
population-based anchors are provided for interpreting score changes within a 
population, individuals can choose the external standard of greatest relevance or base 
decision on the average of several. " So in the above example we could also look at the 
proportion of patients with the ability to work, proportion with severe pain and so on in 
order to build up a clearer picture of the meaning of the change in QOL score. 
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2.1.1.2 Anchors over time 
Anchors over time (longitudinal anchors) can also be used rather than anchoring 
between groups as described above. The global rating of change is the most common 
anchor used over time to determine the MID(17;22). The global rating of change is 
measured on a 7 point scale in either direction (Table 1). 
Table 1 Global rating of change 
Score Description 
-7 A very great deal worse 
-6 A great deal worse 
-5 A good deal worse 
-4 Moderately worse 
-3 Somewhat worse 
-2 A little worse 
-1 Almost the same, hardly any worse at all 
0 No change 
1 Almost the same, hardly any better at all 
2 A little better 
3 Somewhat better 
4 Moderately better 
5 A good deal better 
6 A great deal better 
7 A very great deal better 
Patients complete a QOL instrument over time and use the global rating of 
change alongside it to assess the degree of change they feel. The score on the global 
rating of change scale is then used to attach meaning to the QOL scores over the 
same time period. Scores of 0, 1 or -1 are considered as unchanged, scores of ±2 and 
±3 are considered the minimally important difference, scores of ±4 and ±5 are a 
moderate difference and ±6 and ± 7 are considered to be large changes on the QOL 
scale. 
There are however some discrepancies among authors over the size of change 
on the global rating scale to use as the smallest difference of interest and therefore the 
size of the MID varies. For example, a change of two to three on the scale in either 
- 34-
direction was used by Juniper et a/(22) as the MID group compared with a change of 
one to three used by Jaeschke et a/( 17). 
One criticism of these methods is that the global rating of change scale is a 
single, non-validated item. This is then being used to anchor QOL questionnaires which 
are usually multi-item and well-validated. Also, because individual patients complete 
the questionnaires over time, the MID is determined within a specific group of patients 
therefore it's applicability across disease areas and between groups of patients with 
different characteristics is questionable. 
The reliability of patients' estimates of previous health status is also an issue. The 
strengths and weaknesses of the global rating of change scale were reviewed by 
Kamper et a/(23}. They indicate that recall bias(24} and response shift(25} affects 
whether the ratings actually measure the transition between the two time points as 
intended. Studies have now found that actually the global rating of change relates more 
strongly to another patient-reported measure at the same time than to the change in 
that same measure over the time period in question(26;27). 
There is also literature on an adaptation of this method using between-patient 
ratings of change instead of within-patient ratings (17;28;29). The advantage of using 
between-patient ratings is that it avoids the issue of recall bias and response shift as 
patients are asked to compare themselves to others with the same disease rather than 
remembering changes in their own health over time. The MID results using the 
between-patient or the within-patient ratings actually resulted in similar MIDs. 
2.1.2 Distribution-based methods 
Methods in this category use the distribution of aOL scores to interpret 
meaningful change. The methods generally find the minimally detectable difference 
which is not the same as the minimally important difference(18}. The MID requires 
input from patients or clinicians. The distribution-based methods result in the change or 
difference being expressed as a standardised measure rather than trying to estimate 
the MID. The standardised measure can then be used to estimate the relative size of 
differences. Some work however has also been done to link the distribution-based 
estimates with MID or MCID(30}. 
Guyatt et al(12) provide a full description of the available distribution-based 
methods. The methods which have been used in the interpretation of QOL measures 
are described in more detail here. 
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2.1.2.1 Effect size (ES) 
One of the earliest distribution-based methods uses effect sizes. The effect size is 
calculated as:-
Mean change in QOL scores 
ES = Standard deviation at baseline 
Effect sizes from QOL measures are generally compared with those defined by 
Cohen(31) as representing small, moderate and large effects. Cohen proposed small, 
medium and large effect sizes as 0.2, 0.5 and 0.8, respectively. His intention was for 
these guidelines to better inform sample size calculations. The guidelines are now 
widely used, not only to calculate sample sizes, but also to estimate a difference or 
change that might be meaningful. However, Cohen described his guidelines as 
"arbitrary conventions ... recommended for use only when no better basis for estimating 
the effect size is available"(31). 
2.1.2.2 Half a standard deviation 
Others have commented that half a standard deviation seems to have a general 
universality about it and that Cohen's guidelines for 0.5 as a moderate effect were 
actually very intuitive. Norman et a/(32) conducted a review of the literature calculating 
MID for health-related QOL measures. They studied the magnitude of the MIDs found 
in 38 studies and concluded that they were all consistently close in size to half a 
standard deviation. This implies that, regardless of the instrument or disease, half a 
standard deviation could be considered as a rule of thumb to ascertain important 
changes. While the authors acknowledge that this should not be viewed as a fixed 
benchmark they do provide evidence based on psychological theory as to why half a 
standard deviation may be important. 
There are however some criticisms of this work(33;34). The studies compared 
used different definitions of MID so essentially they were measuring slightly different 
concepts. There were also some studies excluded from the review because the effect 
sizes were substantially different to those found in the other studies, therefore the claim 
that 0.5 standard deviations (SD) was found to be remarkably consistent across the 
studies is misleading. Although a simple universal rule is attractive for interpretation it 
seems unlikely that one definition of a meaningful difference exists across all types of 
diseases and HRQOL aspects. 
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2.1.2.3 Standard Error of Measurement (SEM) 
The SEM is described by Wyrwich (30) as follows, "If a single patient completes 
the same HROOL or health status measure repeatedly, with no change in HRaOL or 
health status taking place between testings and no memory of question and/or 
response effects, the standard error of measurement reflects the standard deviation of 
the distribution of his/her repeated questionnaire scores." 
The SEM takes into account the reliability (test-retest reliability measured using 
intra-class correlation coefficient) of the aOL measure as well as within-person 
variability(SD). It is calculated as follows: 
SEM = SD~l - reliability 
However, there is a lack of agreement on the threshold value for SEM that 
represents a meaningful difference, with papers showing anything from 1 (35) to 
2.77(30) as a significant change. There are also discrepancies on how to calculate the 
reliability of the OOL instrument for use in the calculation of SEM. 
Wyrwich et a/(35) showed that a one-SEM change broadly conformed with 
Cohen's definition of small, moderate and large effect sizes. The more reliable items 
had 1-SEM corresponding to Cohen's definition for small effect sizes and the more 
unreliable items had 1-SEM more similar to Cohen's moderate difference. The authors 
have also conducted further reviews(30) to try to establish the link between the SEM 
and the MID but one SEM was not consistently found to represent the MID, with some 
studies showing up to 2.3 SEMs were equivalent to the MID. 
2.1.3 Combined anchor and distribution-based approaches 
Anchor-based methods do not take into account the measurement precision of 
the instrument so cannot account for changes due to random variation alone. The 
distribution-based methods, however, use only the statistical properties of the sample 
or the instrument so there is then difficulty in defining what a meaningful change is to 
patients or clinicians. Therefore more recently attempts have been made to use a 
combined approach to the interpretation of aOL scores thus using the advantages of 
both of these approaches. 
An early method from Cella et a/(36) calculated both anchor-based and 
distribution-based estimates of meaningful change but did not attempt to produce a 
combined estimate. Jacobson et a/(37) improved on this method by requiring a change 
to meet both the criteria from the anchor-based and distribution-based methods before 
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it could be considered as an important change. Crosby et a/(38) were the first to try to 
integrate the methods by describing how to resolve any discrepancies between the 
estimates from the two methods and also accounting for the fact that MID varies 
according to the baseline value. Their approach was fairly simple though in that either 
the anchor-based or distribution-based cut-off was used depending on which was 
highest. Yost et a/(39) instead describe using the range of MIDs from different 
approaches as guidelines. 
A different approach to combining any number of anchor and distribution-based 
methods is through triangulation. Denzin(40) describes methodological triangulation, 
where multiple methods are used to examine social phenomenon. The rationale being 
that "the flaws of one method are often the strengths of another: and by combining 
methods, observers can achieve the best of each while overcoming their unique 
deficiencies". The MID estimates from global ratings of change, statistical distribution 
estimates and qualitative data from patients were combined in this way by Leidy and 
Wyrwich(41). Revicki et a/(42) describe triangulation as "examining multiple values 
from different approaches and converging on a small range of values". They suggest 
plotting the range of MIDs from the different methods on a graph in order to narrow 
these down to a smaller range or single MID point. They also recommend weighting the 
approaches though with clinical anchor methods taking precedence. 
In a more recent method the integration of the two methods has been more 
sophisticated. De Vet et a/(43) developed a visual method called the anchor-based 
minimally important change (MIC) distribution method. They classified patients into 
three groups using a clinical anchor; patients with an important improvement, no 
change or an important deterioration in QOL. The distribution of the change scores for 
each group were overlaid on a graph. Cut-offs between the size of changes were then 
decided using either ROC (receiving operator characteristics) optimal cut points or the 
95% limit of the distributions. The ROe cut-off is the point that minimises the incorrect 
classifications (e.g. where patients with no change would be classified as improved or 
vice versa). 
2.1.4 Reference Populations or Norms 
QOL data from a study sample can be compared with data from the general 
population in order to gauge the size of changes. Differences from the general 
population matched by age and gender or comparison of patients with percentiles from 
the general population could be used. Differences between reference data sets from 
different countries however have been found, highlighting the need for data from the 
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same country as the QOL data. Therefore, in order for these to be a useful 
interpretation tool data are needed from a large number of countries. The general 
population has problems in the same domains as those relevant to cancer patients, 
emphasising that reference population data does not provide a comparison with no 
symptoms or perfect health but reflects the chronic conditions of aging in a population. 
Also, this method of interpretation does not address the importance of changes on the 
QOL scale(44). Section 2.2 highlights the population-based reference values available 
for the QLQ-C30. 
2.2 Existing interpretation strategies for the QLQ-C30 
Various methods have been adopted to aid interpretation of the QLQ-C30 
specifically. King(20) used 14 studies to estimate effect sizes using clinical anchors and 
compared these to Cohen's guidelines. They found that the guidelines were 
approximately adequate for physical, role and symptom scales but not for global and 
psychosocial dimensions of the QLQ-C30, which resulted in smaller effect sizes. 
Population-based reference values have now been published for German(45), 
Danish(46), Norwegian(46;47) and Swedish(48) populations. 
Osoba et a/(49) published small, moderate and large changes in scores from the 
QLQ-C30 based on global ratings of change using the Subjective Significance 
Questionnaire (SSQ). The SSQ used a 7-point scale ranging from much worse through 
no change to much better. This aimed to address the importance of changes to 
patients. These differences were 5-10 for a small difference, 10-20 for a moderate 
difference and >20 for a large difference. However, the SSQ was not found to correlate 
well with the QLQ-C30 although there was a linear trend between QLQ-C30 scores and 
the SSQ. This study was carried out in breast cancer and lung cancer patients and it is 
not clear how the results may generalise for other patient populations. The study was 
also carried out for specific subscales of the QLQ-C30 (global, physical, emotional and 
social functioning) and therefore these differences may not be applicable to other 
subscales. The observations on size of change in score from this study were however 
similar to those from King et a/(20). 
Each of these methods used to aid interpretation of the QLQ-C30 suffers from 
shortfalls as highlighted, although they have encouraged clearer presentation of QLQ-
C30 results and taken important steps towards starting to interpret rather than simply 
report QOL results. 
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3 Background 
This chapter is published in the European Journal of Cancer. Kim Cocks, 
Madeleine T. King, Galina Velikova, Peter M. Fayers and Julia M. Brown (2008). 
Quality, interpretation and presentation of European Organisation for Research and 
Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled 
trials. European Journal of Cancer, Volume 44, Number 13, pages 1793-1798. 
The aim of this review was to look at the quality of the reporting of studies using 
the QLQ-C30 and investigate how widely the available methods for interpreting QOL 
scores were being used. 
3.1 Abstract 
Aim: To review reporting standard, presentation and interpretation for quality of 
life (QOL) outcomes in randomised controlled trials (RCTs) using the EORTC QLQ-
C30. 
Methods: Cancer RCTs reporting EORTC QLQ-C30 data were identified and 
reviewed against a reporting quality checklist. Interpretation/presentation methods for 
QOL data were also recorded. 
Results: Eighty-two papers were reviewed. 70% met criteria for high quality 
reporting; 94% reported mean scores; 84% presented results in tables/graphs; 80% 
reported p-values or statistical significance. Clinical significance was addressed in 
38%. Where clinical significance was not addressed, reliance was usually on statistical 
significance to interpret the results. 
Discussion: EORTC QLQ-C30 results are generally reported well, although it was 
common to rely on statistical significance alone for interpreting results. While 
interpretation in terms of clinical significance has improved in recent years, there is still 
a lack of robust clinical interpretation of QOL results even in papers reported to a high 
standard. 
3.2 Introduction 
While a considerable body of evidence about health-related QOL is accruing from 
cancer clinical trials, the extent of its impact on clinical practice is unclear. One of the 
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barriers is poor communication of the clinical relevance of the results(SO). Reviews of 
prostate cancer trials(S1), breast cancer trials(S2), and surgical oncology trials(S3), 
report that 11 %, 33% and 67% were able to inform clinical decision-making. Part of this 
variability in these estimates arose because of differences in how the ability to inform 
decision-making was measured. Regardless of this, it is clear that in order to inform 
clinical decision making, a QOL study needs to be designed robustly, reported 
adequately and interpreted appropriately. 
The CONSORT statement(S4;SS) provides a checklist for reporting RCTs. 
Efficace et a/.(S6) propose a checklist specifically for evaluating QOL outcomes, listing 
criteria for reporting QOL outcomes and identifying the essential issues to be 
addressed in order for a trial to have reliable QOL outcomes. The checklist comprises 
11 items grouped into four categories: conceptual, measurement, methodology and 
interpretation. The authors define a paper with high quality QOL outcomes as one that 
meets at least 8 out of the 11 criteria and these have to include three high-priority 
concerns ("baseline compliance reported", "psychometric properties reported" and 
"missing data documented"). 
Osoba et a/(S7) and GuyattlSchunemann(SO) recommend that the presentation of 
aOL data include proportions of patients reporting a QOL benefit. They argue that this 
provides results meaningful to clinicians and therefore the results are more likely to 
influence clinical decision-making. Osoba et a/(57) recommend 10% of the scale as the 
cut-off point to define improvement, with a stipulation that this degree of change should 
persist for a reasonable period. As an additional guide to interpretation Guyatt et 
a/(SO;S8) also show how to generate the number needed to treat for one patient to 
benefit from therapy. 
A number of different approaches have been used to develop interpretation for 
QOL scores. Some are entirely data driven and some use clinical anchors to interpret 
differences (over time or between groups). However, there are a number of shortfalls of 
the current methods and no single method has emerged as a standard for 
interpretation. Some are not specific to the QOL instrument being used and the validity 
of these is rarely tested for the specific instrument prior to relying on them for 
interpretation. It is also common to rely on statistical significance in order to interpret 
whether differences in scores are clinically significant. However, statistical significance 
does not necessarily imply a meaningful difference in a clinical context, particularly if 
the minimum clinically important difference in QOL was not determined a priori and 
used to determine the sample size for the trial. 
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Several authors provide a comprehensive overview of existing interpretation 
strategies(12-14;59). Various methods have been used to aid interpretation of the 
EORTC QLQ-C30 specifically, which are of interest for our review. King(20) used 14 
studies to estimate effect sizes (mean difference divided by standard deviation) using 
clinical anchors, and compared these to Cohen's guidelines(31) which propose small, 
medium and large effect sizes are 0.2, 0.5 and 0.8 respectively. King's estimates were 
about the same as Cohen's guidelines for physical, role and symptom scales, although 
for the global and pyschosocial dimensions of the QLQ-C30, the estimates were 
smaller. Osoba et a/(49) provided estimates for small, moderate and large changes in 
scores from the EORTC QLQ-C30 based on retrospective global ratings of change, an 
approach based on individual patient's rating the importance of changes in QOL. These 
were found to be 5-10 for a small difference, 10-20 for a moderate difference and >20 
for a large difference, similar to those yielded by King's analysis(19;20). This is the 
basis of Osoba et afs(49) recommendation of 10% of the scale as the cut-off point to 
define a clinically important change. 
This review summarises the quality of QOL reporting for cancer RCTs using the 
EORTC QLQ-C30 and looks at the methods used to present and interpret the QOL 
data, particularly in papers that score well on the quality checklist. The interpretation 
methods used across studies are reviewed to assess how widely used current methods 
are, the extent to which clinical significance is addressed and whether there is a need 
for additional interpretation guidelines for the EORTC QLQ-C30. A summary of the 
methods of presenting the data is used to assess whether it is reported clearly and in a 
way that may be utilised by clinicians. 
3.3 Methods 
I searched for potential sources of EORTC QLQ-C30 scores using Cinahl, 
Medline, Embase, Medline-in-process and Psychinfo concurrently via the Ovid 
interface. The search terms were qlq c30, quality of life questionnaire c 30, quality of 
life questionnaire c30, eortc qlq-c30, qlq c33, qlq c30+3. References from the EORTC 
bibliography(60) were also added. I removed duplicates in Ovid or subsequently in 
Reference Manager. 
I reviewed papers identified as cancer RCTs using the EORTC QLQ-C30 and 
classified them according to the minimum standard checklist for evaluating QOL 
outcomes(56). If more than one paper was identified reporting QOL results from the 
same study then the study report was included rather than a paper reporting any wider 
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issues, for example comparisons of statistical methods. Papers were defined as having 
high quality QOL outcomes if they met at least 8 out of the 11 criteria, including the 
three high-priority concerns ("baseline compliance reported", "psychometric properties 
reported" and "missing data documented"). If any items were evaluated as "not 
applicable" then these items were excluded in the evaluation of high quality. A second 
reviewer (Prof Brown) independently classified a sample of the papers. 
Methods used for presenting the data were recorded for all papers in terms of 
whether text, tables or graphs were used and the type of data presented (e.g. means, 
medians, effect size, p-values, proportion improved etc.). For papers addressing 
clinical significance, the method of interpretation was recorded. 
3.4 Results 
3.4.1 Identification of papers 
As of February 2006, 911 papers had been identified using the search strategy. 
Papers were included if they presented any data from the EORTC QLQ-C30, were 
cancer trials and were available in English. Ninety-two papers were identified as cancer 
RCTs reporting EORTC QLQ-C30 scores. 
Ten papers were subsequently excluded from the review. Nine used the data to 
investigate different statistical techniques, conducted extra analyses or reported long-
term follow up rather than reporting the results from the RCT and the checklist does not 
seem applicable. Four of these papers also had a trial report for the same study which 
was included. One paper was excluded as it was a pilot study with a randomised 
design exploring the feasibility of QOL assessment in a further RCT. Eighty-two RCTs 
were therefore included in this review. 
3.4.2 Study characteristics 
Table 2 shows the characteristics of the 82 studies. Sample sizes ranged from 31 
to 1491 patients, with a mean of 272. In total, the papers reported on more than 22000 
patients. The majority of studies involved patients with breast cancer (21%), mixed 
cancer sites (18%), lung cancer (17%) and colorectal cancer (11%). No other cancer 
sites represented more than 10% of the sample. Patients were from a wide range of 
countries, although the majority of studies were European (67%). 
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Table 2 RCT Study characteristics 
Number of studies (%) 
Design 
Phase II 7 (9%) 
Phase III 25 (30%) 
Not specified 50 (61%) 
QOL end point 
Primary 12 (14%) 
Secondary 67 (82%) 
Not specified 3 (4%) 
Number of patients 
Mean (standard deviation) 272 (239.1) 
Median (range) 208 (31-1491) 
Region/Country where study conducted 
Europe 
Multi-country 6 (7%) 
Austria 1 (1%) 
Belgium 1 (1%) 
Denmark 2 (2%) 
France 4 (5%) 
Germany 3 (4%) 
Italy 6 (7%) 
Netherlands 6 (7%) 
Norway 6 (7%) 
Spain 1 (1%) 
Sweden 8 (10%) 
UK 11 (13%) 
International 
Multi-country 10 (12%) 
Australia 2 (2%) 
US/Canada 15 (18%) 
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Number of studies (%) 
Cancer site 
Breast 17 (21%) 
Mixed sites 15 (18%) 
Lung 14 (17%) 
Colorectal 9 (11%) 
Leukaemia/Lymphoma 7 (9%) 
Prostate 7 (9%) 
Brain 3 (4%) 
Oesophageal/Stomach 3 (4%) 
Gastro-intestinal 2 (2%) 
Malignant melanoma 2 (2%) 
Head and neck 1 (1%) 
Ovarian 1 (1%) 
Testicular 1 (1%) 
3.4.3 Quality of reporting 
Table 3 shows the level of QOL reporting according to the checklist. As the 
EORTC OLQ-C30 is a generic instrument designed for all cancer patients and was 
previously validated in cancer patients, the measurement criteria in the checklist were 
satisfied for all papers. The main failings of studies were that there was no rationale for 
using the questionnaire, no details of the administration and not addressing clinical 
significance of results. The majority of papers (>90%) reported the hypothesis (or 
stated OOL as an end point), stated the timing of assessments and included some 
general presentation of the results. Fifty-seven (70%) papers met the criteria for high 
quality. Reporting was of slightly higher quality in the 41 papers whose primary 
end point was QOL or which reported QOL as the main purpose of the paper rather 
than reporting the overall results of the trial. Thirty-five (85%) of these papers met the 
criteria for high quality. However, despite QOL results being the main aim of these 
papers, still only 22 (54%) addressed clinical significance. 
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Table 3 Level of reporting according to the minimum standard checklist for 
evaluating QOL outcomes in cancer clinical trials 
QOL Issue All RCTs High quality QOLas 
N=82 N=57 primary 
outcomel 
aim 
N=41 
Conceptual 
A priori hypothesis stated 77 (96%) 57 (100% ) 40 (98%) 
Rationale for instrument reported 25 (30%) 19 (33%) 18 (44%) 
Measurement 
Psychometric properties reported 82 (100%) 57 (100%) 41 (100%) 
Cultural validity verified 82 (100%) 57 (100%) 41 (100%) 
Adequacy of domains covered 82 (100%) 57 (100%) 41 (100%) 
Methodology 
Instrument administration reported 39 (48%) 33 (58%) 29 (71%) 
Baseline compliance reported 62 (76%) 57 (100%) 36 (88%) 
Timing of assessments 82 (100%) 57 (100%) 41 (100%) 
documented 
Missing data documented 64 (78%) 57 (100%) 38 (93%) 
Interpretation 
Clinical significance addressed 31 (38%) 25 (44%) 22 (54%) 
Presentation of results in general 78 (95%) 56 (98%) 41 (100%) 
Not applicable for two studies 
3.4.4 Presentation of QOL data 
Thirty-two (39%) papers used a combination of tables and graphs to summarise 
the data. Thirteen (16%) used graphical summaries alone and 24 (29%) used tabular 
displays. Thirteen (16%) reported aOL results in the text with no graphical or tabular 
summary. A higher proportion of the papers meeting the standard of high quality 
reporting used both graphs and tables 27 (47%) to display the results. 
Fifteen (18%) of papers report the percentage of patients with improved aOL 
scores as recommended by Osoba et 8/(57) and Guyatt et 8/(58) and this percentage is 
similar in the subgroup of high quality papers (21%). The definition of 'improvement' 
varied between the reports however, with some papers using >10 points as an 
improvement (with or without a minimum length of time for this to be sustained) and 
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other papers regarding any increase in scores as an improvement. No papers reported 
the number of patients 'needed to treat' in order for one patient to benefit. 
The majority of papers reported the mean QOL scores (77 (94%» and 56 of these 
also indicated the variation around the mean (standard deviation, standard error or a 
confidence interval). Sixty-six (80%) papers reported p-values or an indication of the 
level of statistical significance of QOL differences. Eleven papers reported medians 
and six papers reported both means and medians. Three papers reported effect sizes. 
The summary measures used in the subgroup of high quality papers were very similar 
to the full set of papers. 
3.4.5 Clinical significance and interpretation of results 
Clinical significance was addressed in 31 (38%) papers (Table 3) and this was 
only marginally higher (44%) in the high quality papers. The most common method 
used was a change of >10 points to define a clinically relevant change (18 papers, 22% 
of all papers). This was usually referenced using Osoba et a/(49), in which a change of 
10-20 is "moderate". However, one paper referred to differences of 10 or more as 
large. Four other papers defined clinically meaningful change as any change from 
baseline, 5-10 points (not referenced), 8-10 points (Sloan(61» and 10-15 points (Lee et 
a/(62» respectively, while three further papers defined different sizes as clinically 
meaningful depending on the scale. Two of these use a method used for the Uppsala 
questionnaire(63) and the other uses King's(19) estimates based on evidence-based 
effect sizes. Other methods of interpretation used were reference populations or norms 
(three papers) and effect sizes as defined by Cohen(31) or Osoba(49) (three papers). 
Two papers defined some results as clinically meaningful without defining the criteria 
used. 
Clinical significance was not addressed in 51 (62%) papers; four of these papers 
contained no discussion of QOL differences and 47 (57% of all papers) relied mainly on 
statistical significance (or lack of statistical significance) in their discussion of whether 
there were changes in QOL (Table 4). These studies ranged in size from 48 to 791 
patients (median 205 patients) and it is likely that at least some of these, generally 
large, studies will have found statistical differences in QOL that were too small to be of 
clinical relevance. For example, the largest study found differences in scores as small 
as 2.1 (physical and social functioning subscales) were statistically significant. 
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Table 4 Methods of interpretation 
Clinical Methods used to assess size of QOL Number of 
significance differences between groups or changes over papers (% of 
addressed time total) 
Yes· 31 (38%) 
Use of specified difference in score as 
clinically relevant:-
> 10 points 18 (22%) 
5-10 pOints 1 (1%) 
8-10 points 1 (1%) 
1 0-15 points 1 (1%) 
Subscale-specific 3 (4%) 
Comparison with reference population/norms 3 (4%) 
Effect sizes «0.2 no change, 0.2-0.5 small, 3 (4%) 
0.5-0.8 moderate, >0.8 large) 
Criteria for clinical significance undefined 2 (2%) 
Stable or improved from baseline defined as 1 (1%) 
clinically relevant 
No 51 (62%) 
Statistical significance 47 (57%) 
No discussion of QOL differences 4(5%) 
*multlple methods used for 4 papers therefore numbers do not add to 31 
3.5 Conclusion/Discussion 
This review shows that RCTs using the EORTC QLQ-C30 report the QOL data to 
a high standard, with 70% meeting the criteria for high quality QOL outcomes. Similar 
reviews of aOL reporting in cancer trials have been carried out in prostate 
cancer(51 ;56}, advanced breast cancer(64}, colorectal cancer(65), non small-cell lung 
cancer(66} and, more recently, in complementary and alternative oncology 
medicine(67). These reviews generally show a lower standard of reporting, in particular 
the reporting of clinical significance ranged from 12% to 21 % compared to the 38% 
seen here. This may be due to the earlier time period of studies included in previous 
reviews. Also, as our review was limited to studies using the EORTC QLQ-C30, three 
of the criteria were automatically met as the questionnaire is well validated, with 
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psychometric properties and cultural validity reported, and a range of QOL domains 
covered. 
The main failings of the papers according to the checklist were not reporting the 
rationale for using the EORTC QLQ-C30 or the method of administration. These issues 
also arose in the previous reviews(51 ;56;64-67). In our review, this could be because 
the EORTC QLQ-C30 is well validated in cancer patients and authors referencing the 
validity of the questionnaire may regard this, implicitly, as their rationale for using it but 
without explicitly stating this they fail on this criterion. A more appropriate consideration 
regarding rationale for the chosen instrument may be whether QOL is relevant in the 
study at all, which QOL dimensions are important and therefore is the instrument 
chosen appropriate? The method of administration was only regarded as reported if the 
setting, e.g. questionnaires given in clinic or posted to patients at home, was reported. 
It was common to report that the questionnaire was self-reported but this was not 
considered sufficient to fulfil the criterion. An important aspect of administration is 
whether the assessments were before or after the clinical consultation, whether the 
results were confidential or whether they were used as part of the patient's 
management, which are details unlikely to be included in a paper. 
A further finding of this review is that, perhaps not surprisingly, the RCTs meeting 
more of the criteria on the checklist were those with QOL stated as the primary 
outcome or reporting QOL as the main purpose of the paper. Papers reporting the full 
results of a clinical trial with QOL as a secondary outcome will have far less space to 
report the results therefore are likely to fail on more of the criteria. Papers reporting 
QOL alongside the main trial results are important if QOL is to have an impact on 
clinical decisions and on the results of clinical trials. Therefore it is unfair to penalise 
these papers because of the level of reporting of the QOL data when space in the 
manuscript will be limited. It is possible that there is a need for an even more minimal 
checklist in order that QOL results can be reported to a high standard despite limited 
space in the manuscript, otherwise such checklists may encourage separate reporting 
of the QOL results from the main trial results and could ultimately limit the overall 
impact of QOL data. 
The majority of papers use a table or graph to display QOL results, which is 
encouraging as this is a good way of presenting QOL results from a number of 
subscales in a concise and clear way. Papers meeting the criteria for a high standard 
of reporting according to the checklist were more likely to use both tables and graphs to 
display the results. Surprisingly, three (5%) papers which met the criteria for high 
quality reporting used text alone to report QOL results. These papers reported p-values 
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for any significant results but little else. Although the checklist contains 'presentation of 
the results in general' as a criterion, this is based on whether the authors discuss the 
QOL outcomes giving any comments regardless of the results. This criterion can 
therefore be met by papers reporting very little QOL data resulting in them being 
classified as 'high quality' when they are clearly uninformative with regards to the QOL 
results. 18% of papers presented percentage of patients with 
improved/deteriorated/stable scores but the definition of an improvement varied. This is 
of concern, since papers which use any change in score as a 'clinically important 
change' and/or fail to specify a minimum time period will tend to overestimate the 
degree of change and therefore the impact of treatment. 
Less than half of the papers addressed the clinical significance of QOL results. It 
is of some concern that half of the papers relied on statistical significance, or lack of 
statistical significance, rather than interpreting the magnitude of change per se. Whilst 
the minimum standard checklist for evaluating QOL outcomes(56) classes papers 
according to the robustness of QOL outcomes it is deficient in that it does not assess 
the appropriateness of the statistical analysis which is key to the aOL results. Given 
the apparent reliance on statistical significance in order to interpret results it is 
important that complex issues such as multiple outcomes, missing data and 
longitudinal data are dealt with appropriately in the statistical analysis and reported in 
suitable detail. 
Where clinical interpretation was attempted, simple definitions were most 
common; generally >10 points was regarded as clinically significant. Osoba's work, 
however, was based on breast and lung cancer patients and the results may not be 
generalisable to other patient populations. The study was also carried out for specific 
subscales (global, physical, emotional and social functioning) and therefore these 
differences may not be applicable to other subscales. Although more detailed 
guidelines for interpretation are available for the EORTC QLQ-C30(19;31) a universal 
rule regardless of the subscale may be more attractive due to space limitations in 
manuscripts and the need for results to be easily understood, but if there are real 
differences in how to interpret the different subscales, then it is important to take this 
into account. A universal rule applied to all cancer sites and subscales may miss 
important differences in QOL or over-interpret differences that actually are of little 
clinical significance. 
This review has highlighted that there are a number of methods of presentation 
and interpretation of QOL data available for use but that these are being applied 
regardless of their relevance to the specific QOL instrument or scale and could 
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therefore be misleading. For accurate interpretation of QOL results, there is also a 
need to incorporate the adequacy of the statistical analyses in any assessment of the 
robustness of QOL outcomes. There is a need for further guidelines for the 
presentation and interpretation of results from the EORTC QLQ-C30 - and other QOL 
instruments - thus improving the ability of RCTs to influence treatment decisions. 
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4 Methods 
4.1 Methods overview 
Figure 5 shows an overview of the steps involved in producing the evidence-
based interpretation guidelines. The project followed three phases. The initial phase 
involved searching for articles containing mean scores from the QLQ-C30. The second 
phase was the expert review process used to group the contrasts into trivial, small, 
medium and large. The final phase was the meta-analysis and derivation of the final 
guidelines. Each step is described in detail in the subsequent sections. In practice a 
number of the steps were overlapping, e.g. the literature search was updated monthly 
and new papers identified while the expert review process was on-going. 
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Figure 5 Overview of study processes 
r-----------------------------------~ 
Literature search and check for duplicates 
Screening for relevance Reject 
Accept paper 
Paper retrieval Reject 
Accept paper 
Data entry and further check for duplicates Reject 
Accept paper 
Selection of contrasts 
Masking papers and creating coversheets 
Expert review and consensus process 
Calculation of expert size class 
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4.2 Identifying relevant published data 
4.2.1 Literature search and check for duplicates 
Potential sources of EORTC QLQ-C30 scores were identified by searching 
Cinahl, Medline, Embase, Medline-in-process and Psychinfo concurrently via the Ovid 
interface. The search strategy was developed from the EBES project(1). The search 
terms were qlq c30, quality of life questionnaire c30, quality of life questionnaire c30, 
eortc qlq-c30, qlq c33 and qlqc30+3. Fields searched were: ti - title, ab - abstract, kw-
keyword heading, kf - keyword heading word, sh - MeSH subject heading, ot - original 
title, hw - subject heading word, tw - textword, it - instrumentation. References from 
the EORTC bibliography(60) supplemented the search. They were imported into a 
Reference Manager® library and merged with the search results. Duplicates were 
removed in Ovid or subsequently in Reference Manager by myself and the research 
assistant. The literature search was run and updated monthly until December 2006. 
4.2.2 Screening for relevance 
The assessment for relevance was carried out initially using abstracts and then 
confirmed by retrieving the pdf files (see Section 4.2.3). Sources were considered 
relevant if they provided information about at least one informative contrast for at least 
one of the QLQ-C30 subscales. An informative contrast was one of the following:-
• Cross-sectional: The mean difference between two independent groups. 
• Longitudinal: The mean change within a group over time. 
However, for the contrast to be truly informative it had to be based on a known 
anchor. Recall an anchor is defined as "an independent standard or anchor that is itself 
interpretable and at least moderately correlated with the instrument being 
explored."( 12). Anchors were discussed in more detail in Section 2.1.1 and some 
specific examples of what we considered to be informative contrasts for the project 
follow in Table 5. Guyatt(12) stated that "the stronger the association, the more secure 
the inferences about interpretation of the target measure, and weak associations are 
liable to yield misleading results". I reviewed all anchors identified from the papers to 
ensure that the anchors we thought had the stronger and more well-known 
associations with QOL were prioritised for the review process. For example, we know 
there are small systematic effects of gender from the large reference population 
datasets and disease stage has been shown to separate groups of patients with 
respect to QOL during the validation of the QLQ-C30 questionnaire, therefore these 
were strong candidates for informative contrasts. 
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Table 5 Examples of informative contrasts and relevant anchors 
Type of contrast Anchor Description 
Cross-sectional Gender Males versus females 
Cross-sectional Treatment Laparoscopic versus open surgery 
Cross-sectional Disease stage Stage I versus Stage IV 
Longitudinal Time Baseline versus 3 months 
Longitudinal Time Diagnosis versus 1 year 
The research assistant screened the abstracts according to the exclusion criteria 
listed in Table 6. I then reviewed any abstracts highlighted for potential exclusion. If 
further information was required I then retrieved the pdf file of the article and reviewed 
in detail against the exclusion criteria. 
Table 6 Exclusion criteria 
Exclusion criteria 
Full paper unobtainable 
Non-English papers 
Reasoning 
Abstracts alone would not provide enough information for 
the project. 
Initially these papers were to be translated and included 
in the project where relevant. I developed a procedure for 
translations of non-English papers which involved an 
initial screening interview with the Research Assistant 
and translator in order to check through the exclusion 
criteria prior to full translation. The process was initiated 
but a larger number of papers requiring translations were 
identified than expected and the cost of translations was 
prohibitively high. This led to non-English papers being 
excluded. 
Use of EORTC QLQ-C30 in The EORTC QLQ-C30 questionnaire was developed 
diseases other than cancer specifically for cancer patients. There were however 
articles where the questionnaire was used in other 
disease areas. These were excluded as the 
questionnaire and the interpretation guidelines were 
aimed at cancer. 
No QLQ-C30 scores 
reported 
Articles such as narrative reviews and published 
protocols were identified in the literature search, which 
contained no actual data from the questionnaire. 
Exclusion criteria 
Mean EORTC QLQ-C30 
scores not reported 
Only reporting the mean 
score of one group at one 
time (uninformative) 
Overall sample size less 
than 10 or all contrasts 
contain a group with less 
than 10 patients 
Papers containing only 
contrasts of the following 
nature:-
- comparing questionnaire 
administration method, e.g. 
computer vs paper or 
patient vs proxy 
- comparing languages, 
e.g. as part of a cross-
cultural validation study 
- comparing cancer sites, 
e.g. breast vs lung, unless 
a comparison of cancer vs 
non-cancer/control. 
Only the 'financial 
difficulties' subscale is 
reported 
No patient numbers 
reported 
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Reasoning 
Papers reporting only medians or correlations with 
EORTC QLQ-C30 data were excluded. 
Papers had to contain at least one informative contrast 
(comparing across groups or within a group over time). 
Although meta-analytic techniques can account for small 
studies by weighting in the analysis it was decided that 
data from 1-9 patients would not contribute greatly to the 
review. Generally these would be case studies from a 
single clinician or centre. The volume of work required to 
process these papers and obtain expert review 
outweighed the small contribution they would make to 
the interpretation guidelines. Further, they were likely to 
yield unreliable estimates. 
These were excluded as they did not clearly represent a 
known clinical anchor on which to base estimates of size 
of difference. 
There is much debate over the inclusion of this subscale 
in a quality of life instrument and it was decided that 
papers which also had data from the other subscales 
should be prioritised. 
Required for the meta-analysis. 
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Exclusion criteria Reasoning 
Subscales not calculated The EORTC questionnaire has a validated system for 
according to EORTC scoring into subscale scores. If this system was not used 
scoring manual or use of or if the scores were transformed from the 0-100 scale 
an unknown score without explanation or details then they could not 
transformation contribute to the meta-analysis. 
I used Reference Manager® to manage the potential articles and wrote guidelines 
for the research assistant detailing the study processes described here. I wrote a 
specification for a Microsoft ACCESS database to store the data extracted for analysis 
and to track the progress of papers through the study. A programmer was used to build 
the database. 
4.2.3 Paper retrieval 
Following the initial screening the research assistant retrieved potential articles 
using on-line journals in the form of pdf files or photocopies from the library or 
document supply centre. The Reference Manager ID number was used as the link 
between the Microsoft ACCESS database, Reference Manager library and the paper or 
electronic copies of articles. I designed an EBIG Study Evaluation Sheet which was 
created for all papers (Figure 6). This contained the Reference Manager ID number 
along with the first author name, year, journal title and country. This sheet was 
produced for every article identified through the searches (except duplicates), including 
all rejected studies. 
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Figure 6 EBIG Study Evaluation Sheet 
First Author and Initials 
EndNote Ref No. 
------ ---
Year Journal Country 
./ 
Entered on Database? 
Accepted? 
------
--_.".-
Rejected? 
REJECTED 
./ REASON: ./ FROM: 
Abstract No QlQ Scores Presented 
PDF No mean scores presented 
Printed copy Uninformative 
I- -
KC confirmed Only Financial difficulties scale 
f-- - r------
Administration method 
Validation study 
---
Review 
Other 
Notes: 
Note that the full list of exclusion criteria in Table 6 was developed by coding the 
'Other' category from this summary sheet as the project progressed. The rejection 
criteria on the evaluation sheet were those specified prior to starting the literature 
search. Note also that Endnote Ref No. refers to the Reference Manager ID number 
(the initial searches were managed using Endnote and later transferred to Reference 
Manager). 
4.2.4 Data entry and further check for duplicates 
A specifically designed data entry form was used to enter the details from the 
EBIG Study Evaluation Sheet. Rejected papers had the reason for rejection recorded 
and then were not processed any further. Where more than one reason was applicable 
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a hierarchy was used with the first exclusion criteria met in the above table being 
recorded. 
Additional details were added to the database for papers accepted after this initial 
screening. These details included the type of study, source of the study sample, 
country of origin, language of QLQ-C30 questionnaire used, study name or number, 
type of primary cancer and extent of cancer. These fields were used to identify 
duplicate data, i.e. the same data reported in more than one source. Duplicate sources 
were identified by first looking at papers with authors in common. Papers reporting data 
from the same sample were still included in the project if they contrasted mean scores 
using different anchors. If papers reported on the same sample using the same anchor 
then the source providing the most detail about the sample and mean EORTC QLQ-
C30 scores was included. Duplicate papers were retained for the review process if they 
provided additional clinical details of the study. For example, a clinical trial may have 
been reported in detail in one paper and the QOL results published separately. 
Although the latter provides the most QOL information it is unlikely to describe the 
study in as much detail as the main trial publication. In this scenario the papers were 
attached together for the expert review so the experts had more information on the 
study. Papers reporting the same study but with different anchors were also batched 
together for review. 
Further basic data collection included details of the sample characteristics (age, 
sex, gender, disease site and disease stage), study design and study research 
question. 
4.2.5 Selection of contrasts 
Any QOL comparison from the paper (from a table, text or figure) was a potential 
contrast for the project. Therefore papers were likely to contain more than one 
informative contrast and the number could actually be quite high. For example, a single 
table reporting all 15 subscales of the QLQ-C30 for two treatment groups at baseline 
and one further time could lead to 60 contrasts (i.e baseline versus the second time 
within treatment group A, baseline versus the second time within treatment group e, 
comparison of treatment group A versus e at baseline and comparison of treatment 
group A versus e at the second time). Considering a paper may contain more than one 
table/graph containing QOL scores the number of contrasts could quickly become 
unmanageable and confusing to review. In order to avoid single papers dominating the 
project the number of contrasts was reduced according to defined rules. Contrasts 
were selected based on trying to obtain a dataset containing the full range of sizes of 
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QOL differences. i.e. we did not want to accidentally exclude very small or very large 
differences as all sizes were needed. If a number of points in time were reported then 
only three of them were taken forward (baseline. mid treatment and end of treatment or 
closest time to the end of treatment). If a number of cross-sectional contrasts were 
present various measures were used to reduce the number of possible comparisons. 
For example. if there were a number of treatment groups then one would be chosen as 
the 'control' group and only contrasts containing the control group used. If there were a 
large number of anchors then the strongest anchors were taken forward. i.e. those that 
are known to be closely linked to QOL. Papers with potentially large numbers of 
contrasts were discussed with the EBIG team for input. before I decided which 
contrasts to include on a case by case basis. 
4.3 Grouping contrasts using expert review 
In a traditional meta-analysis of randomised controlled trials (RCTs). studies may 
be grouped by dose level for example. in order to estimate the effect size within similar 
dose groups. Here we needed to group the contrasts into large. medium, small and 
trivial QOL differences in order to estimate effect sizes for each category. We sought to 
do this by using expert opinions on the appropriate size category for each contrast. 
Expert opinion was sought from a panel of professionals with experience of 
cancer and the EORTC QLQ-C30. Following the literature review papers were 
categorised into different cancer areas. Where a paper covered more than one cancer 
they were usually categorised into an area of expertise instead e.g. radiology. 
chemotherapy. palliative care and so on. The expert panel was recruited based on the 
requirement for experts in all of the identified areas. The majority of experts were 
approached through the EORTC Quality of Life Group and in the UK the National 
Cancer Research Institute Clinical Studies Groups. The aim was to have at least three 
opinions for each paper so more reviewers were sought for disease areas with a large 
number of papers in order to reduce the workload for the project. 
When a potential expert was identified they were sent an initial invitation letter. If 
they were willing to participate they returned details of their background and areas of 
expertise. Reviewers were then sent a manual containing an explanation of the project 
and the format of the review. The full expert review manual can be found at 
www.ctru.leeds.ac.uk/ebig(68} and the following sections describe the process in more 
detail. They were asked to return a practice example before reviewing any papers for 
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the project. Any issues with how the example was completed were raised by myself 
with the individual before they could commence reviewing. 
The only papers excluded from the expert review were those that only contained 
a randomised contrast at the baseline time. These contrasts were assigned to the 
'trivial' category automatically as randomised differences at baseline should be due to 
chance alone. 
4.3.1 Masking papers and creation of coversheets 
The aim was to obtain an assessment (blinded to the OOL results) of how experts 
believed the EORTC OLO-C30 subscales would behave in each clinical situation 
defined in the contrast. We wanted a review from three experts for each paper in order 
to use an average opinion to group the contrasts in the meta-analysis. Experts were 
sent a copy of the paper along with a coversheet which showed the contrasts selected 
for review. 
The reasoning behind obtaining a blinded assessment was to ensure that experts 
did not use pre-conceived ideas of the size of OOL differences to influence their 
ratings. For example, if an expert was familiar with Osoba's work(49) and regarded a 
difference of 10 points as a medium difference they could then use this as a 
benchmark if they could see the actual OOL scores in the original article. By blinding 
the experts to the OOL results they had to rely on their knowledge of the contrast and 
clinical setting and of using the OLO-C30 to make a judgement on the likely size of 
OOL difference. Tables, graphs and text that contained OOL results (from both the 
OLO-C30 and any other OOL questionnaire) were blacked out, or "masked". Also any 
interpretation of OOL results in the text was masked. Additional results from other QOL 
or patient-reported outcome (PRO) instruments were removed as these could give an 
indication of the OLO-C30 results if they assessed similar aspects of OOL. The expert 
could therefore read about the type of study and setting, sample size, other results 
from the study, treatment details and adverse events if applicable. 
The reviewer was asked to make a judgement on each contrast from the paper as 
to the relative size of differences (trivial, small, medium or large) they expected the 
domains in the QLQ-C30 to indicate for the chosen contrasts. If experts were familiar 
with the study they were asked not to try to recall the actual results from the study, but 
to judge what they might expect if they were conducting a similar study. If they felt they 
knew a study too well they could opt to return the paper without reviewing. They were 
asked to judge whether the OOL difference within a contrast would be a little, 
moderately or much better/worse. Definitions of large, medium, small and trivial were 
- 61 -
provided in the manual as described in Table 7. The categories were given numbers; 0 
for trivial, 1 for small, 2 for medium and 3 for large. A direction was also assigned to the 
scale so the experts were using a seven-point scale from -3 to 3. 
Table 7 Definition of large, medium, small and trivial size categories 
Size Description 
category 
Large When circumstances have obvious and unequivocal clinical relevance 
(e.g. the contrast of patients with asymptomatic, early stage disease 
versus those with end-stage disease, or a treatment that is known to 
markedly improve the health state of most patients treated), group-level 
HRQOL is expected to be much better or worse, and large effects are 
expected. 
Medium When circumstances are likely to have clinical relevance, but to a lesser 
extent (e.g. for patients with metastatic disease, the contrast of those who 
respond to treatment compared those who do not respond, or a treatment 
that is known to be effective for a half of patients treated), group-level 
HRQOL is expected to be moderately better or worse, and moderate 
effects are expected. 
Small When effects are expected to be subtle but nevertheless clinically 
relevant (eg, the contrast of patients with regionally advanced cancer 
versus those with newly diagnosed metastatic disease, or a treatment that 
is known to improve the health state of only a small proportion of patients 
treated), group-level HRQOL is expected to be a little better or worse, and 
small effects are expected. 
Trivial When circumstances are unlikely to have any clinical relevance, group-
level HRQOL is not expected to be any better or worse, and at best "trivial" 
effects are expected (including differences that may occur by chance). 
We use the phrase "much the same" for this size class. 
A copy of the QLQ-C30 subscales and questions were also provided in the 
manual and experts were asked to keep these in mind while making their judgements, 
in order to consider what difference they expected clinically together with the difference 
the QLQ-C30 questions might detect. 
Please refer to Appendix I for an example of a coversheet from the project. The 
coversheet gave brief details of the paper and the comparisons that they were being 
asked to make a judgement on. The brief details on the coversheet were intended to 
- 62-
summarise some key details of the paper, eg disease, disease extent, number of 
patients, type of study etc. and of the anchors used to contrast two groups of patients 
or a group over time. A blank summary table of the contrasts was then provided for 
experts to fill in with their ratings. The comparisons were divided into cross-sectional 
and longitudinal. Experts were advised to read the coversheet and then read the 
masked paper in order to understand the patient group and clinical setting for the 
comparisons. The tables only contained those subscales reported in the paper for each 
anchor. The numbers of patients in each group were included in the tables to give 
reviewers information regarding attrition in the study. 
Preparing coversheets for the review was a time-consuming process which was 
open to human error in the transcription of information from the papers onto the 
coversheets. Initially the research assistant prepared the coversheets and then these 
were checked by myself or Prof Brown. In order to increase the efficiency of the 
process I wrote programs using SAS® software which could use the information directly 
from the Microsoft ACCESS database in order to populate the coversheets with the 
basic summary information from the study and also produce blank tables for the 
reviewers to fill in. This was output into Microsoft Word. Therefore the Research 
Assistant could simply enter the study details and contrast information into the 
database and then automatically produce the coversheet using the SAS® program. 
Although I still checked a proportion of the coversheets, the automation eliminated any 
possible error due to transcribing alone. Separate quality control checks were carried 
out on the database to check the information had been entered correctly so this also 
directly reduced any errors in the coversheets. 
4.3.2 Expert review and consensus 
4.3.2.1 Review process 
Papers were allocated to relevant experts in batches, for example a single expert 
would be responsible for reviewing up to five papers in any four week period. Further 
papers were not sent to an expert until they had returned the previous batch of papers. 
Allocation was according to the area of expertise required and the availability of the 
individual. For some cancer sites there was a pool of experts to choose from, while for 
others (e.g. brain cancer) there were only two or three experts on the expert panel. The 
number of papers assigned to each reviewer was therefore determined by the number 
of papers identified in their area, their rate of returning papers after review and the 
length of time they were on the expert panel over the period of three years the review 
process was carried out. 
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4.3.2.2 Review format 
Reviewers were asked to judge on a scale of -3 to 3 where 3 represented a large 
difference, 2 a medium difference, 1 a small difference and zero a trivial difference 
(Table 8). The negative or positive scale indicated the direction they thought the 
change would be in. For longitudinal contrasts a positive difference indicated an 
improvement in QOL scores over time and a negative difference represented a 
deterioration in QOL over time. For cross-sectional contrasts the direction simply 
referred to whether Group A was better than Group B or vice versa (see Section 
4.4.1.2.2 for more details). 
Reviewers were asked to use a percentage scale to indicate the certainty of their 
judgement. They could choose either one category or to spread their expectation over 
a few of the categories, with 0% representing completely uncertain, 100% representing 
completely certain. Reviewers also had the option of striking a line through, or returning 
a whole review, if they felt unable to make an assessment in that situation. 
In the example in Table 8 the reviewer expected a small difference in physical 
functioning in favour of the younger group. They are not as certain for the cognitive 
functioning but indicate the difference could be trivial to small in favour of the younger 
group, with more emphasis on the small difference category. They are less sure again 
for the social functioning subscale, but indicate the difference should be trivial to small. 
Table 8 Example of recording an expert reviewer's expectation 
Anchor: Age Group 1 worse post Group 1 better post 
Group 1: <60 years chemotherapy chemotherapy 
Group 2: >60 years -3 -2 -1 0 1 2 3 
Physical Functioning 100% 
Cognitive functioning 25% 75% 
Social functioning 50% 50% 
4.3.2.3 Consensus 
In the original EBES methodology(1 ;2) the experts chose one of the three size 
classes. Therefore it was clear to see where there were disagreements between the 
reviewers and initiate a consensus process. Because here reviewers could assign 
percentages to their ratings and rate in more than one of the size classes it was not as 
easy to see where major discrepancies lay. For that reason the only papers sent back 
to reviewers for querying were those where there was a discrepancy between 
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reviewers in the direction of the difference. The papers were returned to all reviewers 
for that paper to see if the direction had been confused when making their ratings. 
Reviewers were asked to check that their ratings were as intended for the specific 
contrasts where there was an issue. Reviewers either returned the coversheets after 
checking with any changes marked on (noting their reason for changing) or confirmed 
they were happy with the direction as originally marked. They did not enter into any 
discussions with the other experts, nor were they aware of the other experts' 
judgments. 
4.3.3 Calculation of expert size class 
Only papers with at least two reviews were taken forward for the analysis. For 
each reviewer, on each contrast, their weighted average was calculated using their 
percentage certainty as weights. So in the earlier example (Table 8) the weighted 
average for Cognitive Functioning from this reviewer would be (O.25xO)+(O.75x1)=O.75. 
This is referred to as an "individual opinion" on a contrast. The mean of these weighted 
averages from each reviewer on a contrast was then calculated, referred to as the 
"overall opinion" for that contrast. The overall opinion was then categorised into the 
small, medium and large categories for analysis using rounding, referred to as the 
"expert size class". i.e. if the overall opinion was 0.5 or greater but less than 1.5 then 
the expert size class was deemed to be 'small', greater than 1.5 but less than 2.5 
would lead to a 'medium' size class and so on. The expert size class was used to 
group the contrasts in the meta-analysis in order to estimate the effect within each of 
the size groups. See Section 4.4.2 for the detailed meta-analysis methods. 
4.4 Meta-analysis methods 
4.4.1 Data extraction 
4.4.1.1 Standard deviation extraction/derivation 
I used standard deviations directly from the paper where possible. Where 
standard deviations were not provided, I calculated or estimated them using other 
information in the article where possible. If no information was available to estimate the 
standard deviation then I used imputation. 
Derivation of standard deviations were based on the recommendations in the 
Cochrane handbook(69) and Follman(70), which are summarised in Table 9. For cross-
sectional comparisons the pooled standard deviation was calculated where possible or 
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imputed. For longitudinal comparisons the standard deviation of the baseline time and 
the standard deviation of the change was calculated or imputed. 
Table 9 Derivation of standard deviation (SO) 
Data given 
Means and 
standard errors 
for each group 
Mean 
differences 
between groups 
and standard 
errors· 
Means and 
confidence 
intervals for 
each group 
Mean 
differences 
between groups 
and 95% 
confidence 
intervals· 
SO calculation 
SD= SEx~ 
Where SE is the standard error and SO is the standard deviation for 
each group. 
SD = SE of difference in means 
~ V;;I +~ 
NB Confidence intervals had to be symmetric around the mean in 
order to estimate SO 
SD = ~ x (upper limit - lower limit)/ t 
Where t is the appropriate t-value for the significance level of the 
confidence interval and sample size (determined using Excel or t-
tables). 
SE = (upper limit -lowerlimit)/3.92 
SD = SE of difference in means 
J 1 +~l 
nl n2 
Data given 
Means for each 
group or 
difference 
between the 
means and p-
value from t-
test* 
Means/mean 
differences 
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SO calculation 
SE = difference in means 
t 
SD = SE of difference in means 
rt:I V~+~ 
Where t was determined from the p-value using Excel or t-tables. For 
boundary p-values (e.g. p<0.05) the upper limit of the boundary was 
used in order to down-weight trials without full information. SO could 
not be estimated where a lower boundary alone was given (e.g. 
p>0.05). 
NB SO could only be estimated for large sample sizes (>60) with an 
approximate Normal distribution. SO could not be estimated for small 
between groups sample sizes or for skewed distributions. 
and 
interquartile 
ranges 
Differences in 
change from 
baseline scores 
and SO from 
individual times 
Effect sizes 
(ES) 
Means/Mean 
differences 
between groups 
and ranges 
SD - Q75-Q25/ 
- /1.35 
Where Q75 and Q25 are the upper and lower quartiles. 
Where confidence intervals of change, t-values or p-values were 
also available then the above methods were applied. In the absence 
of any other information the SO had to be imputed instead. 
SD = difference in means 
ES 
Could not be estimated. 
Means for each SOpooled could be estimated from SO of whole group(71) 
group and SO 
for whole group 
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*In these situations there is insufficient information to derive the SO for each group or 
time. The calculated SO is the average of the two groups rather than the SO for each 
group. Using these derivations therefore assumes equal variances for the two groups. 
If there was insufficient data available in the paper then I imputed standard 
deviations. Imputation was carried out assuming a common change variance(70) 
across contrasts for the same subscale, i.e. a weighted average of the reported change 
variances was used to impute for each subscale. This method of using other studies in 
the meta-analysis for imputation has previously been shown to provide accurate meta-
analysis results(72). The level of imputation required in the dataset is summarised in 
Chapter 5. 
4.4.1.2 Calculation of summary statistics for each contrast 
I conducted separate analyses using two different outcome variables: mean 
differences and effect sizes. Mean differences were appropriate for the meta-analysis 
methods because all of the measurements from the papers were on the same 
scale(69), i.e. 0-100 as scored using the EORTC OLO-C30 scoring manual(73). The 
standardized mean difference (or 'effect size') "is used as a summary statistic in meta-
analysis when the studies all assess the same outcome but measure it in a variety of 
ways"(69), therefore is not necessary here where all studies are using the same 
outcome measure. The analysis of cross-sectional contrasts was however repeated 
using effect sizes as the outcome measure in order to compare our results to other 
guidelines for interpretation of OOL which commonly use effect size. Effect size was 
calculated as the mean difference divided by the best available estimate of between-
person standard deviation. 
Cross-sectional and longitudinal contrasts were analysed separately as they may 
be fundamentally different and warrant individual guidelines. Note that also the 
calculation of standardised mean differences (effect sizes) are fundamentally different 
for the between group comparisons and for comparisons over time (see Table 10 and 
Table 11). Standardised mean differences over time need to take into account 
correlation between observations on the same patients(71). 
I weighted the contrasts in the meta-analysis using the inverse variance method. 
This has been shown to be the optimal way to combine estimates in a meta-analysis 
while accounting for the reliability of the estimates(74). If estimates were not weighted 
then contrasts with a small number of patients would be given equal weight to those 
with a large number of patients. The inverse variance method uses the sample size 
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and standard error to weight the contrasts in the analysis so larger studies are given 
more weighting. 
4.4.1.2.1 Longitudinal contrasts 
I calculated the mean differences for longitudinal contrasts so a positive 
difference indicated an improvement in aOL scores over time and a negative 
difference represented a deterioration in aOL over time for both symptom and function 
subscales. Since symptom subscales have a low score representing better aOL and 
function subscales have a high score representing the better aOL the calculations 
were reversed in order to achieve consistency in improvement or deteriorations over 
time across all contrasts. Table 10 details the calculations depending on which data 
were presented in the paper. Experts were asked to allocate a positive score if they 
thought the second time would be better than the first and a negative score if vice 
versa. They also did this regardless of the type of subscale so the calculation of mean 
difference and expert ratings were in the same direction. The standard errors (SE) 
presented in the table were used for weighting the contrasts in the analysis (see 
Section 4.4.2 for full details of the meta-analysis methods). 
The notation used in Table 10 is as follows:-
i Tl = Mean score for baseline time 
iT2 = Mean score for follow up time 
SOT1 = Standard deviation of baseline scores 
SOT2 = Standard deviation of follow up scores 
SDpooled = Pooled standard deviation 
i T2 - Tl = Mean change scores 
SOchange = Standard deviation of the change over time 
r = correlation between between baseline and follow up times, estimated at 0.5 if not 
given in the paper(75) 
n1= Number of patients at baseline time 
n2=Number of patients at follow up time 
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Table 10 Calculation of summary statistics and standard errors for longitudinal contrasts 
Data available from paper or Mean Definition of SDpooled ** Standard error of MD Effect size Standard error of 
imputation difference (ES)*** ES 
(MD) 
Means and sd for individual XTZ -XTl SDf,l + SDf,z 2SD~ooled(1 - r) 2(1 - r) ESz 
times where the subset of 2 XTZ -XTl +-
"\j n --.J n 2n 
those with time 1 (T1) and time SDpooled Where n is the common 
2 (T2) are reported (i.e. n1=n2) 
sample size at time 1 and 
time 2 
Means and sd for individual XTZ -Xn (nl - l)SDi + (nz - 1)SDi 2SD~ooled(1 - r) 2(1- r) ESz 
XTZ -Xn +-times where all patients with T1 
"\j nl + nz - 2 'J n ~ n 2n 
and all patients with T2 are SDpooled Where n is the average of 
reported (ie n1 *- n2) the sample size at time 1 
and time 2 
Mean change and sd of change XTZ - Tl SDchange SD~hange XTZ - Tl 2(1- r) ESz 
.J2(1- r) SDpooled +-
"\j n --.J n 2n 
--- -- - ----
-_._-
--
NB These calculations are for the functional subscales. For symptom subscales, a multiplier of -1 was used. Calculations were sourced from Lipsey and Wilson(75), 
Follman(76) and The Cochrane Handbook(77). Some specific scenarios were derived. 
**May also be derived using Table 9 where needed. 
***This effect size estimate has been shown to be upwardly biased, particularly for small sample sizes(78), therefore as recommended by Lipsey and Wilson(75) I 
have subsequently applied a correction of [1 - _3_], where N is the total sample size for the contrast, to each effect size. 
4N-9 
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4.4.1.2.2 Cross-sectional contrasts 
For cross-sectional contrasts a negative or positive mean difference had less 
meaning. The order of the two groups for comparison was chosen as consistently as 
possible, for example, Group 1 was always the control group in a treatment study, the 
lowest age group, the less advanced disease stage etc. This attached similar meaning 
or 'direction' to similar contrasts within the same anchor. However, for some cross-
sectional contrasts there was not an obvious choice of 'control' group, for example 
outpatient versus inpatient contrasts or a comparison of two commonly used therapies. 
In these cases the direction of the difference was more arbitrary and the groups were 
allocated in the order they appeared in the original article. 
As for the longitudinal contrasts the calculation was reversed for the symptom 
subscales so that a positive difference on a function subscale had the same meaning 
as on a symptom subscale. Experts were asked to give a positive score if they thought 
Group 2 would be better than Group 1 and negative if they thought Group 2 would be 
worse than Group 1. The mean differences were calculated as shown in Table 11 in 
order to match the direction the experts were judging in. The calculations are shown for 
functional subscales. The calculations for symptom subscales were the same with a 
multiplier of -1. The standard errors (SE) presented in the table were used for weighting 
the contrasts in' the analysis (see Section 4.4.2 for more detail). Note that some papers 
presented change from baseline scores rather than mean scores for the groups 
therefore the difference between groups was the difference in these change scores. 
The notation used in Table 11 is as follows:-
Xl = Mean score for Group 1 (or Phase 1 for a cross-over study) 
X2 = Mean score for Group 2 (or Phase 2 for a cross-over study) 
n1 = Number of patients in Group 1 (or Phase 1 for a cross-over study) 
nz = Number of patients in Group 2 (or Phase 2 for a cross-over study) 
N = Number of patients in the cross-over trial 
SDpooled = Pooled standard deviation 
XAB = Mean score for Group A at time B 
SDchange = Standard deviation of the difference between two measurements on an 
individual 
r = Correlation between phase 1 and phase 2 scores (for cross-over studies) or 
between time 1 and time 2 (for change from baseline), estimated at 0.5 if not given in 
the paper(75} 
MD= Mean Difference 
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Table 11 Calculation of summary statistics and standard errors for cross-sectional analysis 
Data available from paper Mean Definition of SDpooled ** Standard error of MD Effect size Standard error of ES 
or imputation difference (ES)*** 
(MD) 
Means and standard X2 -Xl (n1 - 1)SDi + (n2 - 1)SDi JR; MD; n1 + n2 ES2 SDpooled - + - SDpooled + deviations for each group 
'l n1 + n2 - 2 n1 n2 'l n1n2 2(n1 + n2) 
Mean change from baseline (X22 - X21 ) SDchange JR; MD; n1 + n2 ES2 ,/2(1- r) SDchange -+- SDpooled + for each group and standard - (.\'12 - .\'11) n1 n2 ~ nln2 2(nl + n2) 
deviation of the change 
Means and standard X2 -Xl SOpooled is the SO of a single 
SD'hang, fi MD; SDpooled ~ deviations for each phase measurement or pooled SO N+ 2N (cross-over study) from phase 1 and phase 2 if 
where x ,/2(1- r) 
cannot assume both are 
SDchange 
equal. i.e. 
= J2 X (SDpooled)2(1 - r) (nl - 1)SDi + (n2 - 1)SDi 
V n1 +n2 - 2 
--_ .. _---
------ ----- -
-
--
-_ .. - _L 
-
NB These calculations are for the functional subscales. For symptom subscales, a multiplier of -1 was used. Calculations were derived from a 
combination of those given in Lipsey and Wilson(71), Follman(70) and The Cochrane Handbook(77) 
**May also be derived using Table 9 where needed. 
***This effect size estimate has been shown to be upwardly biased, particularly for small sample sizes(78), therefore as recommended by Lipsey and 
Wilson(71) I have subsequently applied a correction of [1 - _3_], where N is the total sample size for the contrast, to each effect size. 
4N-9 
I 
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4.4.2 Estimating large, medium, small and trivial effects using meta-
analysis 
4.4.2.1 Meta-analysis approach 
The meta-analysis was carried out using SAS® Software. I wrote macros to 
implement the analysis by adapting those written by Wang and Bushman(79). I 
conducted meta-analyses for each subscale separately in order to create guidelines for 
specific subscales. Hence with 15 subscales and two outcome variables (mean 
difference and effect size) there were 30 models constructed to combine the cross-
sectional contrasts and 30 for the longitudinal contrasts . The contrasts were grouped in 
the meta-analysis by the expert size class in order to obtain an estimate for large, 
medium, small and trivial effects. This is akin to a standard meta-analysis of RCTs 
where studies may be grouped by dose, for example, in order to estimate the effect 
size within each group of studies using similar doses. The following Forest plot (Figure 
7) is used to illustrate how the analysis estimated an effect size for trivial, small, 
medium and large differences. Note that plots of this nature have not been used to 
display the actual results due to the large number of contrasts that would be required in 
each figure . 
Figure 7 Forest plot to illustrate meta-analysis methods 
Random effects mean 
difference t 95% confidence Average 
Paper/Contrast number: Anchor: Contrast (A vs B) interval expert opinion 
211 : Randomised treatment: 25mg vs 100mg 
13/1 : Age: 60-64 vs 55-59 
776/3: Primary disease: Breast vs Colon 
Subtotal (Trivial)· 
77612: Disease stage: III vs I 
496/3: Comorbidity: Comorbidities vs None 
20/1 : Disease stage: Recurrence vs no recurrence 
Subtotal (Small)· 
169/3: Performance status: Deteriorated vs Improved 
169/4: Weight loss: >10% vs none 
261/4: Performance status: Kamofsky 40-60 vs 90-100 
Subtotal (Medium)· 
( 
A better 
I ) 
5 10 15 
No diff B better 
Trivial 
Trivial 
Trivial 
Small 
Small 
Small 
Medium 
Medium 
Medium 
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4.4.2.2 Fixed effect models, tests for heterogeneity and meta-regression 
Initially I planned to carry out the analysis using a fixed effect model (weighting 
contrasts using the inverse variance method). This was the method used for the EBES 
project. A fixed effect model for meta-analysis assumes that each observed effect 
estimates an overall population effect (with a random error only due to chance). Here 
this meant assuming that within each subscale and for each size class the observed 
effect for the contrast was the common effect plus a within-contrast error, i.e. 
Yijk = Po + Yijk 
Where Yijl< is the mean difference or effect size for the fh contrast in size class j 
and subscale k, f30 is the population effect for that subscale and size class and a;ijk is 
the variance due to sampling error for the fh contrast. 
The weighted mean (Yijk ) within each expert size class 0) and for each subscale 
(k) was calculated using the inverse-variance as weights:-
- r. Cijk/SEi~k 
Yijk = r. l/SEi~k 
Where Cijk = the effect estimate (mean difference or standardised mean 
difference) for the fh contrast in size class j and subscale k and SEijk was the standard 
error for that estimate. These were extracted from the data as described in Table 10 
and Table 11. 
Fixed effect meta-analysis ignores between-contrast variation. As a result, 
parameter estimates are biased if between-contrast variation cannot be ignored. In a 
traditional meta-analysis very similar studies are usually combined, to compare Drug A 
vs Drug B for example, and this assumption may therefore be appropriate. However, 
here, the contrasts being combined were not only from different studies across different 
cancers but they also covered a wide range of anchors. Further, even within an anchor 
the contrasts could vary greatly in what they were comparing. Therefore I carried out 
tests for heterogeneity(77) to indicate if the fixed effects models were appropriate in 
this situation. The Q-statistic (a weighted sum of squared deviations from the mean) 
was calculated, 
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The Q-statistic has a chi-square distribution with degrees of freedom n-1 where n 
is the number of contrasts for that subscale and size class. If the value of Q is larger 
than would be expected from the chi-square distribution then the hypothesis of a single 
population mean would be rejected. 
The tests for heterogeneity were highly significant for all models here indicating 
that the variation between contrasts was greater than would be expected by chance 
alone. I then used meta-regression to explore if the extra variation could be explained 
by characteristics of the studies/contrasts. I identified a group of potential factors for the 
meta-regression that could explain the heterogeneity between the contrasts. These 
were discussed and agreed with the rest of the team prior to any analysis. Table 12 
shows the list of factors explored. 
Table 12 Factors for meta-regression 
Applicable Paper or Factor Description 
to which contrast 
contrasts level 
factor 
Both cross- Contrast Expert size Trivial, Small, Medium, Large 
sectional class 
and 
longitudinal 
Both cross- Paper Design Cohort, Multiple (contains multiple studies), 
sectional Non-randomised phase I, Non-randomised 
and phase 11, RCT Phase 11, RCT Phase Ill, RCT 
longitudinal (phase not specified). 
Both cross- Paper Disease Brain, Breast, Colorectal, Gastro-Intestinal, 
sectional Gynaecological, Haematological, Head and 
and neck, Lung, Mixed, Prostate, Testicular, 
longitudinal Urology/Kidney 
Cross- Contrast Anchor Disease related, 
sectional T reatmenVI ntervention/ Assessment related, 
Patient characteristics related, Physical 
function related, Symptom/Emotional related, 
Time related, Survival related 
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Applicable Paper or Factor Description 
to which contrast 
contrasts level 
factor 
Cross- Contrast Timing of Baseline, Other, Not specified 
sectional the contrast 
Longitudinal Contrast Timing of Time in months if known 
second 
assessment 
Longitudinal Contrast Dropout Proportion of patients dropping out from 
Time 1 to Time 2 for each contrast. Note this 
is zero if the subset of patients with both 
times is presented. NB this does not 
necessarily represent attrition across the 
study more generally. 
Initially the expert size class was added to the model as the grouping variable in 
order to show whether accounting for the expert size class alone explained the 
heterogeneity between the contrasts. Then each of the other factors was added 
individually to see if heterogeneity remained after accounting for the expert size class 
and one extra factor. Multivariate meta-regression analyses were not carried out due to 
the probable collinearity between the proposed factors. The meta-regression model 
can be written as follows:-
Where Yik is the mean difference or effect size for the Ih contrast in subscale k, f30 
is the population effect for that subscale, Xl represents the size class (with coefficient 
~l) and X2 is one of the factors from Table 12 (with a coefficient of ~2) and U;lk is the 
variance due to sampling error for the Ih contrast. 
None of the factors adequately explained the heterogeneity. Following the advice 
in Wang and Bushman(79) I concluded that a random effects model was more 
appropriate since the variation in contrast effects could not be explained by the expert 
size class and anyone additional factor. 
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The guidelines were therefore derived from random effects models. The results 
from the fixed effect models are not reported in the thesis as the model was clearly 
inadequate for the wide range of contrasts being combined. 
4.4.2.3 Random effects model 
A random effects model assumes the population effect to be estimated is actually 
a distribution rather than a single value. The size of the effect has its own mean and 
variance. This assumption behind the random effects model seemed reasonable for the 
kinds of contrasts being combined here. We assumed that within the size classes the 
contrasts lead to similar but not identical effect sizes. The basic model for the random 
effects model is as follows:-
Where Yijk is the mean difference or effect size for the Ih contrast in size class j 
and subscale k, {3i is the local population effect for that subscale and size class and 
(Jiijk is the variance due to sampling error for the Ih contrast. 
Models fitted the expert size class as a fixed effect and contrasts nested within 
papers as a random effect. Contrasts were nested within papers in order to account for 
multiple contrasts from each paper. Expert size class was used in the model to group 
the contrasts in order to estimate effects for trivial, small, medium and large separately. 
The effect size for each contrast was weighted by the inverse of the variance of the 
estimate for that contrast plus an estimate of the additional random variation between 
contrasts in that size class, 
Where SEj2 was the estimator of the variance of the outcome variable (either 
mean difference or effect size) from the ith contrast within the size class and 8~ was the 
estimator of the random effects variance for that size class. The random effects model 
variances were estimated using the residual (restricted) maximum likelihood (REML) 
method. 
4.4.3 Quality assessment 
4.4.3.1 Background 
4.4.3.1.1 Quality assessment in standard meta-analyses 
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In the standard application of meta-analysis, quality assessment means 
investigating criteria that may affect the validity of the meta-analysis results, i.e. looking 
at each study and assessing the extent to which a study's design and conduct are likely 
to prevent systematic errors or bias(69). A number of scales or checklists have 
emerged that assess the methodological quality of clinical trials(80), largely focussing 
on whether a trial is randomised or conducted in a blinded fashion. Once a quality 
assessment has been carried out there are a number of options for incorporating 
quality assessment into the meta-analysis(69;81); from ignoring quality, weighting 
according to quality through to excluding poor quality studies. Each approach and 
problems with the approaches are discussed below:-
• Ignore the variation in quality. The reasoning behind this approach is that 
the quality assessment is subjective and a meta-analysis should be 
objective. However, when you consider an individual study the degree to 
which you believe in the results comes from an assessment of the study 
and its conduct. So when considering a meta-analysis it would seem at 
odds to disregard any indication of study quality. 
• Use exclusion criteria to exclude studies with a high risk of bias. This 
effectively then ignores any variation in quality of the included studies and 
the cut-off point for inclusion is arbitrary. 
• Use measures of validity or quality to explore the data via subgroup 
analyses or sensitivity analyses. For example, arranging meta-analysis 
plots of results in order of validity in order to show where the differences 
lie or analysing subgroups above and below cut-points for validity. This 
gives more insight as to how validity effects the outcome measure but 
does not make a decision on how to treat the different subgroups in the 
analysis. 
• Use quality assessment to weight studies in the analysis or to explore the 
magnitude of effects across studies using meta-regression. Weighting is 
generally not recommended as it is fairly arbitrary as to how to convert 
quality scores into weights. The Cochrane Collaboration strongly 
discourage the use of quality weighting scales(77) 
In practice a combination of these methods is useful rather than considering one 
approach to the issue of quality. 
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4.4.3.1.2 Meaning of quality for EBIG 
This was not a standard application of meta-analytic techniques and the meaning 
of quality for this analysis was likely to differ from that in standard meta-analyses. The 
units being combined were not studies, which have a widely accepted hierarchy for the 
quality of their design and reporting (see for example www.ebmpyramid.org(82)}.This 
pyramid treats systematic reviews as the highest, or best, level of evidence and 
randomised controlled trials as the best evidence from individual studies. However, 
here the units being combined are contrasts rather than studies. Although study design 
may have a bearing on the quality of the resulting contrasts from that study it is not 
clear that all contrasts from the same study would thus be of the same quality. 
The standard quality criteria were derived with treatment comparisons in mind. 
The RCT would therefore provide the gold standard of evidence because the 
randomisation should ensure the characteristics of the treatment groups were very 
similar, in terms of both observed and unobserved characteristics. A cohort study does 
not have the bias protection of randomisation, and therefore would be considered 
evidence of a lower quality. While the notion that study designs have a certain 
hierarchy of evidence may apply directly to the contrasts in our meta-analysis which 
compare treatments, this makes up only a small proportion of the contrasts included in 
the analysis. 
For other contrasts the standard measures of quality may not be relevant. Say we 
were combining a contrast comparing males versus females from a RCT with the same 
contrast from a cohort study. The groups of males and females are a product of the 
sample in the study and not affected by whether the study is randomised. Therefore it 
is not as clear that the RCT provides a higher standard of evidence for our meta-
analysiS. In fact, the RCT may have a study population more refined by other inclusion 
and exclusion criteria than the standard population of cancer patients. This may make 
decisions on the size of possible QOL differences more difficult for an expert to predict 
than if the contrast was from a cohort study with a population more like they are used 
to seeing through the clinics. 
Despite the differences between our analysis and standard meta-analyses the 
aim of investigating quality however was the same; to explore factors that could affect 
the validity of the meta-analysis results. The aim of quality assessment was to look for 
factors that modified the effect size in some way. In our methodology we considered 
that there were two areas which could affect the quality of the resulting interpretation 
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guidelines; the quality of the studies (paper level factors such as study design and 
attrition) and the quality of the expert reviews (contrast level factors). The quality of the 
study could affect the size of the QOL differences observed in the study, therefore 
directly impacting on the effect size for analysis. The quality of the experts' reviews 
could also impact the effect size since if the expert size class was incorrect then the 
contrasts would be pooled inappropriately and the resulting size class estimates would 
be incorrect. 
The size class which grouped the contrasts for analysis was obtained using the 
average expert judgement. Factors that could affect the reliability of the average score 
from experts were therefore important. Firstly, there was the issue of agreement 
between reviewers and how this affected the average review score. If a contrast had 
two reviewers who disagreed in their judgements then taking the average would place 
the contrast in a size class that was not actually intended by either reviewer. Secondly 
we considered the uncertainty around the expert ratings. If there was a large amount of 
uncertainty in where the reviewers placed their judgments then using the average to 
define size class may also be fairly meaningless. 
We also considered that there may be factors that made it harder for experts to 
predict the QOL differences. The contrasts the experts found hard to judge may not be 
as useful for deriving the guidelines. Qualitative interviews with the experts (described 
in Section 4.4.3.2) were used to identify any possible factors making their review more 
difficult so these could be explored in relation to quality. 
4.4.3.1.3 Approach to incorporating quality assessment in EBIG 
Since the factors which may affect quality were largely unknown in this 
application of meta-analysis I considered that weighting the analysis by a derived 
quality score would be inappropriate. This method is already criticised as being too 
arbitrary and here it would have been even harder to attach a score to the various 
factors we identified as possibly affecting quality. 
In a traditional meta-analysis it is important to include all of the available evidence 
to avoid bias. Here we have an added level of complexity in that the grouping variable, 
the expert size class, is a subjective measure. The expert size class was also derived 
in an experimental way so we could not be sure of its accuracy and reliability up front 
for each contrast. Rather than trying to synthesize all of the available evidence I 
considered it more appropriate to identify the contrasts where the expert size class was 
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most likely to be accurate and then exclude the contrasts of a poor quality when 
deriving the guidelines. That way only the 'best' evidence contributed to deriving the 
guidelines and more faith could be put in the results. 
4.4.3.2 Interviews with experts 
All members of the expert panel were invited to take part in a short telephone 
interview in order to provide feedback on the review process and to obtain details of 
their approach to the reviews. Interviews were conducted when reviewers had 
completed the review of some papers but. where possible. were still involved in the 
review process. Full details of the interview questions are provided alongside the 
results in Chapter 6. 
The expert review process was a new approach developed from the original 
methods used for the EBES project. The EBES expert panel consisted of only three 
experts (clinical oncologists) who reviewed all papers regardless of the disease area. 
For our project papers were allocated to different reviewers from a larger panel of 
reviewers. according to either the disease area or the specific treatment or other 
specialist area if papers contained a mixture of disease areas. Although the instruction 
manual(68) was written to try to ensure a consistent approach between reviewers it 
was unknown whether a larger panel. with different backgrounds. would approach the 
reviews consistently. 
The quality of the interpretation guidelines directly relies on the quality of the 
expert reviews. since the estimates from the meta-analysis are grouped using the 
expert opinion. Interviews with the experts were used to identify factors that could 
affect the quality of the reviews. such as aspects the experts found difficult and how 
they approached the task. These factors were then explored quantitatively by 
investigating their effect on the experts' uncertainty and concordance between the 
expert reviews. described in the following sections. 
4.4.3.3 Meta-analysis quality 
4.4.3.3.1 Exclusion of small studies and contrasts 
We made a decision at the start of the project to exclude any studies containing 
less than ten patients. These were likely to be the poorer quality studies and would 
provide unreliable estimates of mean change due to the small sample size. During the 
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project it also became apparent that. due to the same arguments, individual contrasts 
with any group containing less than ten patients should also be excluded. 
4.4.3.3.2 Data checking and cleaning 
In order to ensure the best quality data there were a number of data checking 
processes used during the project. A proportion of the data entered on the database 
(both mean differences from the original papers and expert review scores) was 
reviewed by myself and Prof Brown to check for data entry errors. Initially 100% of the 
data entered was checked and once the error rate was sufficiently low only a proportion 
were subsequently checked. I also wrote a data cleaning program in SAS® to highlight 
any reviews where the reviewers weighted average disagreed by more than two size 
classes. This was run monthly by the research assistant. Where discrepancies were 
found the data entry of the reviewers scores were checked first and then, assuming 
there were no errors in the data entry, the paper and coversheets were sent back to 
each reviewer on that paper to check the review was as they had intended. The 
contrast with a discrepancy was highlighted so the reviewers only had to check the 
contrast in question. However, the reviewers still had no knowledge of the nature of the 
discrepancy or of the other reviewers' scores. 
4.4.3.4 Expert review quality 
The following three sections explain the methods used to measure correlation 
between the experts and the observed aOL differences, concordance between the 
reviewers and uncertainty in their ratings. These analyses were only relevant for the 
subset of contrasts that underwent the expert review. Therefore the contrasts we 
assigned to trivial (as they were baseline contrasts between randomised groups) were 
excluded from these analyses. 
4.4.3.4.1 Correlation with mean differences in original paper 
Correlation was used to assess the degree to which reviewers judgements were 
reflecting the actual score differences in the papers. Non-parametric (Spearman's rank) 
and parametric (Pearson's) measures of correlation were both calculated along with p-
values at the 5% level to test the null hypothesis for each reviewer that their correlation 
was equal to zero, i.e. no correlation between their ratings and the observed scores. 
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4.4.3.4.2 Concordance between reviewers 
The 'agreement' or 'concordance' between different reviewers for the same 
contrast was difficult to define because experts could assign percentages across the 7-
point scale to represent their view of the size in QOL change. Although measures of 
agreement have been developed for ordinal scales similar to our rating scale, the 
measures I found through searching the literature all assume that raters were placing 
their ratings in only one of the categories, rather than potentially across a number of 
categories. Because there was a lack of a standard measure for this particular type of 
data I explored a number of possible measures. 
Two measures were used which required each reviewer's weighted average on a 
contrast to be rounded up or down to the closest size class. The first measure looked 
at the distance between the reviewers in terms of number of size classes apart( 1) and 
the second method used a consensus measure derived using information theory which 
gives a score between 0 (complete disagreement) and 1 (complete agreement) (83). 
Although these provide simple summaries there is a loss of information when rounding 
the weighted averages up or down. For example, a contrast with two reviews with 
weighted averages of 1.4 and 1.6 would have the same agreement as a contrast with 
two reviews further apart such as 1.0 and 2.0. Two further measures were therefore 
used which were based on the continuous weighted average measure rather than 
requiring any rounding into categories; Intra-Cluster Correlation (ICC) coefficients(84) 
and the between-reviewer standard deviation. The details for these four methods are 
as follows. 
1) After rounding each reviewer's weighted average back onto the original scale 
(-3 to 3 as described in Section 4.3.1) the maximum distance between 
reviewers on the same contrast was calculated. The proportion of contrasts 
with exact agreement, a distance of one category apart, two categories apart 
and so on were calculated. These are displayed in pie chart and provide an 
easy visual summary of how closely the experts agreed. 
2) The consensus measure (Cns) was calculated for each contrast as 
follows(83); 
~ (IX.-JlI) Cns(X) = 1 + 61. Pi lo92 1 - I d
x 
x 
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Where X represents the scale used by the reviewers (-3, -2, -1, 0, 1, 2, 3), Xi is 
the ith member of that scale, Pi is the proportion of reviewers with their rounded 
weighted average in the ith category for that contrast, dx is the width of the scale 
(Le. 7) and iJx is the mean score. The calculation is illustrated for a range of 
consensus values in Table 13. 
Table 13 Calculation of consensus between reviewers 
Contrast Reviewers Number of reviewers in each Mean Cns 
(Paperid: weighted category after rounding (iJx) 
Contrast: averages -3 -2 -1 0 1 2 3 
Subscale) 
13:5:PA -3,1.8 1 0 0 0 0 1 0 -0.50 0.36 
785:2:PF -1.5,-3.0,2.5 1 1 0 0 0 0 1 -0.67 0.35 
13:12:AP 0.4,2.5 0 0 0 1 0 0 1 1.50 0.65 
916:2:EF 0,1.5,0 0 0 0 2 0 1 0 0.67 0.80 
23:1:QL -2,-1.9,-1 0 2 1 0 0 0 0 -1.67 0.90 
17:2:PF 0.8,1.0,0.5 0 0 0 0 3 0 0 1.00 1.00 
3) The ICC measured the degree of clustering between the weighted average of 
each reviewer on the same contrast. The ICC was calculated for each 
subscale and for longitudinal and cross-sectional contrasts separately. If Xij = 
iJ + Sj + Wij , where Xij is the ith rating (weighted average for each reviewer) on 
the r contrast. Mu is the overall population mean of the ratings, Sj is the 
difference from iJ of the jth contrasts 'true score' (Le. the mean across 
repeated ratings on the r contrast) and Wij is the residual component 
(containing inseparable effects of the reviewer, reviewer by target interaction 
and error term). If the residual variance is Or and the variance of Sj is Ob then 
the ICC is defined as Ot/(Ob+Or) or, in words, the proportion of between 
variance in total. The meaning of ICCs and how sensitive they would be to 
differences between reviewers however was unclear, since the original scale 
used by the reviewers was a 7 -point categorical scale and the calculated 
weighted average was then used as the outcome variable. As a rule of thumb 
ICCs of <0.4 were defined as poor agreement, 0.4 to 0.75 as fair to good 
agreement and >0.75 as excellent agreement(85). 
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4) The standard deviation between the weighted means from reviewers judging 
the same contrast was calculated as an alternative measure of concordance. 
The standard deviation (SDbetween) was calculated for each contrast using the 
distance of the weighted mean for each reviewer from the overall mean of the 
two or three reviewers. For example, for a single contrast with r reviewers and 
a mean weighted average score of ji, 
SDbetween = 
4.4.3.4.3 Uncertainty in reviewers scores 
r 
_1_~ (Jl' - ji)2 
r-1L I 
i=l 
Uncertainty within a reviewer's judgment could also be defined in a number of 
ways. Simplistically it could just be the number of categories each reviewer places their 
percentages in, i.e. if a reviewer rated 100% in one category they are certain of their 
judgement whereas if they marked percentages across three categories they are less 
certain. However, this would rate uncertainty as the same for a reviewer with 
judgements in two categories split 90%: 1 0% compared with a review split 50%:50% 
from a different reviewer. It is clear therefore that the weight in each category is 
important as well as the number of categories used. Summaries of the average number 
of categories used for a contrast and the average peak (highest weight) used are easy 
to interpret and therefore were used as simple summaries of the uncertainty. 
A different approach to uncertainty was used for the purpose of exploring factors 
affecting uncertainty. Uncertainty was defined by calculating the standard deviation for 
each review from its weighted mean. If W1 to W7 were the weights assigned by a 
reviewer to each of the categories on the -3 to 3 scale (divided by 100 so they add to 1) 
the weighted mean for that review was calculated as 
J.l = [(w1 x-3)+(W2 X-2)+(W3 x-I)+(w4 xO)+(w5 xl)+(w6 x2)+(w7 x3)] 
The standard deviation within a review was calculated using the formula for 
calculating the standard deviation of a weighted mean. 
(~Wi(Xi - p)' J 
a weighted = (N -l)Lw; IN 
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where the Xi are the -3 to 3 on the rating scale, N is the number of non-zero 
weights. 
Since the sum of our weights equates to 1 this is equivalent to 
sd = J~x" w(x, - 11)2 
1\' N _ 1 L.J I I r 
I 
This is referred to as the within-reviewer standard deviation. The average of the 
within-reviewer standard deviations for each contrast was used as the measure of 
uncertainty. 
4.4.3.4.4 Investigation of factors possibly affecting the quality of expert reviews 
Factors related to overall study quality and other factors highlighted from the 
expert interviews as potential issues with the review process were investigated to see 
which influenced the quality of the expert review. The standard deviation measures of 
concordance and uncertainty defined above were the outcome measures and I used 
mixed models to fit each factor individually. Multivariate analyses were not carried out 
as a number of the factors would be inter-related and we were interested in exploring 
the influence of each factor on quality, rather than only retaining the strongest 
characteristics in a multivariate model. Categorical variables were fitted using dummy 
variables. The dummy variables were a series of dichotomous variables (taking the 
value 0 or 1). When modelling, I chose one of the categories as the reference value 
and all of the other dichotomous variables were fitted in the model to compare the 
effect on the outcome variable compared with the reference category. 
The list of factors (Table 14) were discussed and finalised by the project team. 
The factors were not always applicable (or defined in the same way) for both cross-
sectional and longitudinal contrasts, therefore separate models were conducted for the 
two types of contrast. Some were factors investigated as they are known to affect study 
quality (as defined for standard meta-analyses), e.g. study design. Some factors were 
derived during discussions in the project team (anchor, disease, time of cross-sectional 
contrast and timing of second assessment for longitudinal contrasts). 
A couple of factors arose during the expert interviews (Chapter 6). The experts 
mentioned that if a contrast contained a heterogeneous group of patients it made the 
review more difficult. In order to investigate this we decided that patients with different 
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stages of disease best represented the issue of heterogeneity and used this as a 
measure of heterogeneity for the cross-sectional contrasts. 
The experts also raised the issue of anchors not clearly relating to QOL making 
the reviews hard (Section 6.1.3.3). Although we tried not to include any anchors we felt 
were unrelated to QOL, the anchors we did include contained a mixture of anchors well 
known to influence QOL and some lesser known anchors, which although we felt would 
influence QOL they may not have been well known to all of the experts. Strength of 
anchor (or familiarity of the anchor(15» was therefore used as a possible factor 
affecting the expert review quality. This was based on the team's expert opinion 
through experience of trials and quality of life research. The categories were defined by 
Prof Velikova and confirmed by the rest of the project team. This was aimed at 
identifying anchors that we thought were strongly related to QOL compared to those 
that although may be related could be largely unfamiliar to the experts. 
Dropout or attrition as a potential factor was the subject of much discussion. For 
standard meta-analyses one may consider studies with a high degree of attrition to be 
biased. However, here we were looking at cancer studies and some were very long 
term studies therefore attrition, and high levels of it, would be inevitable. Plus, the 
interpretation guidelines would ultimately be used for studies of the same nature, i.e. 
with possibly high levels of attrition. We therefore did not feel these studies should be 
excluded but it is possible that contrasts with high attrition may have been hard for the 
experts to judge (since it would require considering the types of patients remaining in 
the study at that point in time). However, attrition levels for the whole study may be 
completely irrelevant for some contrasts (e.g. contrasts at baseline or early on in the 
study) so a different approach to including attrition in the modelling was used. For the 
cross-sectional contrasts I used the timing of the contrast as an indication of whether 
this was influencing the concordance or uncertainty (broadly assuming that the later 
contrasts are more likely to suffer with attrition). For the longitudinal contrasts the 
definition was easier. I used the timing of the second assessment as one indicator (with 
similar reasoning as for the cross-sectional factor) but also investigated a more specific 
measure using the proportion of patients at time 2 compared with that at time 1 in the 
contrast. 
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Table 14 Factors possibly affecting expert review quality 
Applicable Factor Levels Description Key for 
to which plots 
contrasts 
Both Design 6 Cohort Coh 
Multiple Mul 
Non-randomised phase I NRI 
Non-randomised phase 11 NRII 
RCT Phase 11 RCTII 
RCT Phase Ill/Not specified RCTIII 
Both Disease 13 Brain Bra 
Breast Bre 
Colorectal Col 
Gastro-Intestinal GI 
Gynaecological Gy 
Haematological Hae 
Head and neck H&N 
Lung Lun 
Mixed Mix 
Prostate Pro 
Testicular Tes 
Urology/Kidney Uro 
Cross- Anchor 7 Disease related Disease 
sectional Treatment/Intervention/ Tmt 
Assessment related 
Patient characteristics related Pat 
Physical function related Phys 
Symptom/Emotional related Symp 
Time related Time 
Survival related Surv 
Cross- Strength 3 Well understood Known 
sectional of anchor Unfamiliar Unknown 
Variable (familiar to some) Variable 
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Applicable Factor Levels Description Key for 
to which plots 
contrasts 
Cross- Time 3 Baseline Baseline 
sectional (timing of Post-baseline Other 
the cross- Not specified NS 
sectional 
contrast) 
Cross- Disease 3 Early Early 
sectional stage Late Late 
Mixed Mixed 
Longitudinal Timing of Continuous Time in months if known 
second 
assess-
ment 
Longitudinal Dropout Continuous Proportion of patients 
dropping out from Time 1 to 
Time 2 for each contrast. 
Note this is zero if the subset 
of patients with both times is 
presented. NB this does not 
necessarily represent attrition 
across the study more 
generally. 
4.4.4 Definition of analysis dataset 
The quality assessment described in Section 4.4.3 was used to make decisions 
on which contrasts represented poor quality evidence and should be excluded from the 
analysis. The term "full dataset" was used to describe the set of papers/contrasts for 
which we obtained at least two expert reviews. The "analysis dataset" refers to the 
subset of these which were deemed good quality evidence and subsequently used in 
the derivation of the evidence-based guidelines. The analysis dataset consisted of 
contrasts with:-
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• at least two expert reviews (or baseline contrasts between randomised 
groups) 
and; 
• for small, medium and large differences; average expert opinion and the 
actual aOL difference in the same direction or 
• for trivial differences; agreement between reviewers, i.e. weighted 
averages for each reviewer categorised into zero size class. 
4.4.5 Patient review methods 
Opinions from patients were sought to develop a method for eliciting informed 
opinions on aOL differences from patients and to seek to validate the use of experts on 
our review panel. The full methods and results for this pilot sub-study can be found in 
Chapter 8. 
4.4.6 Sensitivity analyses 
Sensitivity analyses were used to test the robustness of the meta-analysis results 
and subsequent guidelines to variations in the methodology used. The analyses 
included sensitivity around the imputation methods, the exclusion of poor quality 
contrasts and the method used for obtaining the random effects variance. 
4.5 Evidence-based interpretation guidelines 
The meta-analyses were used to estimate an average effect within each size 
class. Guidelines were then determined using the midpoint between these estimates 
for each size class. For example, if the estimate for a small effect was 5 points and the 
estimate for a medium effect was 9 points then the guidelines would recommend a 
minimum medium effect of 7 points for sample size calculations and interpretation. 
4.6 Summary tables and display of results 
Chapter 5 contains a summary of the literature search results and details of the 
studies meeting the inclusion criteria. A flow diagram is used to record the flow of 
identified articles through the study, including details of reasons for rejection or 
exclusion at any stage. Summary tables are used to show the characteristics of articles 
meeting the inclusion criteria with respect to study design, country where carried out, 
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research question, types of cancer studied as well as a summary of their aOL results 
overall. Observed mean differences in actual reported aOL scores are summarised to 
show the range of differences found in the literature. The proportion of contrasts are 
reported which meet the most commonly used criteria of 10 points for a moderate 
difference. The subset of randomised treatment comparisons are summarised as these 
may be informative when considering sample size calculations for RCTs. The Chapter 
also contains details of the contrasts included in the analysis dataset and a summary of 
the expert review panel. 
Chapter 6 contains the results from the quality assessment including the final 
definition of the analysis dataset. 
The main results (Le. estimates of trivial, small, medium and large effects from 
the random effects models) are summarised in Chapter 7. Estimates are displayed as 
the weighted mean differences (and weighted effect sizes) with 95% confidence 
intervals as calculated by the random effects models. A summary table and box and 
whisker plots are used to show the estimates and 95% confidence intervals for trivial, 
small, medium and large for each subscale. 
4.7 Improvements to the original methodology 
The methodology for this project built on the EBES project by King et a/(1). They 
used published mean scores from the FACT-G questionnaire and, using meta-analysis 
techniques, combined these with expert opinion on the size of differences. A number of 
key improvements were made to the methodology for the purposes of this project. 
4.7.1 Exclusion of papers 
The EBES project excluded papers with high levels of attrition (>20%) in case of 
bias. However, since cancer studies, particularly those with long term follow up or for 
certain types of cancer, suffer from high levels of attrition due to death I felt it may be 
important to be able to include these studies. They may still be high quality studies and 
we wanted to include all stages of cancer and as many cancer sites as possible. 
Attrition bias arises where there is differential attrition across contrast groups (e.g. a 
higher rate of attrition for one treatment group compared to another) rather than studies 
with high attrition per se. Since the meta-analysis involves many different contrasts (Le. 
not just comparisons of different treatment groups) I felt it was likely that attrition would 
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not be as much of a concern as it may be for standard applications of meta-analysis. 
Therefore, instead of excluding studies with high attrition I aimed to include all studies 
and then investigate attrition as a possible source of heterogeneity. 
4.7.2 Expert panel 
The EBES project used only three medical oncology experts. who were 
responsible for the review of papers from a wide variety of cancers and treatments. 
This had the advantage of the expert panel working very closely with the research team 
and a consensus process where the individual expert reviews were in clear 
disagreement was possible. The experts also saw each paper and therefore gained a 
lot of experience in carrying out the reviews. 
I felt that it could improve the quality of the expert reviews if we targeted the 
review of papers according to the specific area of expertise required for that paper. 
Therefore the same experts would not review each paper. The panel would include a 
wider range of expertise such as nurses. radiographers and psychologists rather than 
just clinicians. This required a much larger panel of experts in order to cover the wide 
range of cancers and treatments studied in the papers. While a smaller panel has the 
advantage of the experts being very well trained in the methodology and a consensus 
process easier to manage there are other advantages to our approach. I hoped that by 
using a wider range of experts the reviews could be based on an in-depth knowledge in 
that field and therefore lead to good quality opinions on the appropriate size class for 
the contrasts. 
4.7.3 Quality of the expert reviews 
I have incorporated in-depth investigations into the quality of the expert reviews 
from this project. Using both qualitative and quantitative analysis methods I aimed to 
explore the process being carried out by the experts to find out what affects the quality 
of the reviews (and indeed what defines quality in the process). The EBES project used 
the distance between expert reviews as the lone measure of quality. 
4.7.4 Review scale 
In the EBES project experts had to judge each contrast by deciding if it would 
lead to either a trivial. small. medium or large difference in the relevant aOL subscale. 
In reality. it is likely that when judging a group of patients even an expert would have 
some uncertainty as to the likely size of the effect. I therefore amended the scale 
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experts used for their reviews. I allowed the experts to attach a certainty to the 
judgments. Experts could either decide that the contrast would definitely lead to 
differences of a particular size or they could spread their expectation across a few of 
the size classes. 
4.7.5 Meta-analysis 
The EBES project used basic fixed effect models to combine the contrasts in a 
meta-analysis. Since there were a wide variety of contrasts being combined (from 
different cancer sites and based on different clinical anchors) I investigated whether 
there was heterogeneity before combining the contrasts and then investigated possible 
sources of the heterogeneity. This is more akin to the method used in standard meta-
analyses of studies comparing randomised treatment groups. If heterogeneity is 
present then the fixed effects models are inappropriate and the random effects model 
is the best approach to combining the contrasts. 
The EBES project had fairly small numbers of contrasts for the longitudinal 
analyses and therefore any improvements over time were analysed together with 
deteriorations in time. There is however evidence(86) that relevant differences may 
vary depending on whether the score is improving or deteriorating. Therefore I felt it 
was important to try and estimate the size of effect for improvements and deteriorations 
separately if numbers allowed. 
4.7.6 Patient opinions 
The EBES project did not use the opinions of patients in the development of the 
interpretation guidelines. This project addresses, for the first time, how patients could 
contribute to the development of interpretation guidelines. The methodology to obtain 
patient opinions was developed and piloted as part of this project. 
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5 Data Extraction and Summaries 
5.1 Study flow diagram 
The literature search was updated until December 2006. The flow diagram 
(Figure 8) shows that of an initial 911 papers identified, 330 met the inclusion criteria. 
The main reasons for rejecting papers were that no scores from the EORTC QLQ-C30 
were reported (30%) or, if they were reported, the means of the scores were not 
available (21 %). 287 papers were reviewed by at least one expert or were not sent for 
review as they only contained randomised contrasts at baseline. The expert review 
process was conducted from June 2006 to July 2008. 
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Figure 8 Flow diagram accounting for papers through the project 
581 papers excluded :-
174 No QLQ-C30 scores presented 
121 No mean scores reported 
71 Uninformative contrasts only 
49 English translation unavailable 
46 No useful anchor 
32 Unable to extract data/numbers 
28 Not actually the QLQ-C30 
23 Not a study in cancer 
22 Duplicate data 
14 Sample size too small 
1 Unobtainable paper 
43 papers excluded:-
39 No expert reviews available 
(no expertise on panel/end of 
study period) 
4 Reviewers unable to review 
64 papers excluded:-
60 Only one expert opinion 
4 Errors found on coversheets (mis-
interpretation of data in paper by 
central office) 
I 4389 contrasts excluded (not meeting 
agreement criteria*):-
2224 cross-sectional 
2165 longitudinal contrasts 
~ ~L. ~ __ I l~ -4(J'" It '" .". ... If J ~ > ,_ r 
. ~ '\ 
, . 
'* Agreement criteria : 1) For trivial contrasts; all experts in agreement. 2) For small . 
medium or large contrasts ; direction of expert opinions in agreement with the observed direction 
in the paper (e,g, experts and paper both indicate Group A better than Group B), 
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5.2 Expert reviewers 
There were 34 expert reviewers involved over the lifetime of the project who 
reviewed at least one paper. The review panel consisted of oncologists, nurses, 
surgeons and psychologists. Table 15 shows a summary of the number of papers 
reviewed by each person (ranging from 1 to 98). Figure 9 shows that less than 60% of 
the panel were oncologists but the panel also contained surgeons, haematologists, 
nurses, palliative care specialists, a psychologist, a respiratory physician and a 
researcher. There were 87 unique combinations of the reviewers (data not shown). The 
most papers reviewed by anyone set of the two/three reviewers was 16. 
Table 15 Number of papers reviewed by each reviewer 
Mean 
'Median 
- -
~andard Deviation 
t--=-Standard Error 
t-
Max 
I--
Min 
--
N 
Figure 9 Expert panel specialities 
Number of papers reviewed 
18.8 
12.0 
20.4 
3.5 
98.0 
1.0 
34 
• Oncology 
• Surgery 
• Haematology 
• Nursing 
• Palliative Care 
Psychology 
• Respiratory 
Research 
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5.3 Characteristics of eligible papers 
Table 16 summarises characteristics of the 330 papers meeting the search 
criteria. The majority of the 330 papers were cohort or descriptive studies 236 (72%). 
Randomised controlled trials accounted for another 69 (21 %) of the included studies. 
The remaining papers were reports from multiple studies (17 (5%» and non-
randomised phase 1/11 studies (8(2%». The majority of the studies were European (227 
(69%». The research questions addressed by the papers were usually to describe the 
effects of disease or treatment on QOL (267(81%», with other research questions such 
as validation of QOL questionnaires and long term follow up of survivors accounting for 
less than 5% of the papers each. A wide variety of cancer sites were included in the 
330 papers, papers in breast (46(14%», head and neck (46(14%» and lung (37(11%» 
were the most common disease areas, other areas account for less than 10% of the 
sample each. In addition to these papers looking at a single cancer site there were 78 
(24%) of the papers reporting on multiple cancer sites. 
Patients from the 330 studies ranged from age 31-84, with a median age of 61 
years. 26 (8%) of studies contained males only, 58 (18%) contained women only and 
225 (68%) contained both males and females (these data were missing from the 
remaining studies). 
Table 16 Summary of paper characteristics 
RESEARCH QUESTION 
~----~-=--~~----~~~~~--~~~--------------~ Describe effect of disease &/or treatment on HRQOL 
Long-term FU of survivors 
Develop &for validate OLO core module 
Comparison of HROOL instruments 
N % 
267 80.9 
14 4.2 
12 3.6 
10 3.0 
6 1.8 
-----------------~~--~~---------------------------~-+---~ 
Develop &for validate QLQ core & disease specific module 
r- Relationship between HROOL & other variables (e.g. age, sex, survival) 5 1.5 
--
Psychosocial interventions (e.g. nursing, education, counselling 
programmes) 5 1.5 
--Develop &/or-validate another HROCIquesUonnaire-----·· --.. --- --- ----f.-----4 1.2 
1-- - -------------------- -------.. ------1------1--------1 
Cross-cultural validation of the OLO-C30 3 0.9 
-Ref-e--re-n--ce--d-a-ta--f-o-r -O-L--ccO---,C-30-·-----·---·-------- 1 53 
----Clinical gU--idelines(eg-. -d-eveloping cliniea--fgu-id-e-lin-e-s f ----.---.--------~ -Q.3 
---- ---- - -------------- ---- ~- ---- ------
Cultural issues in HROOL & health care 
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-Economic evaluation - - ------ - --- --- - - - -- - - - - - --+-~~--o~ 
ST-UDYDESIGN-- -------- ------------ -- ---------------I---t-~ 
Cohort/descriptive study- ------------------ -------=1236 71.5 
RCTphase not s-pecified --- ------ -- - --- ------- I 46 13.9 
-----------------------+--+--
--------:-
5.2 Multiple studies 17 
---- - ------~------------- ------------------1---+-----1 
RCT Phase III 17 5.2 
RCT Phase 11 6 1.8 
----------:---=--:------c-:------- --------------------+--+-___ --c-I 
Non-randomised Phase II 1.8 6 
--------- -- - ------------------------4----+---1 
Non-randomised Phase I 2 0.6 
REGION 
----------------------------+ 
------ ----------------------------- -- ----------1 
Europe 227 68.8 
1---------------
Rest of World 56 -17.0 -------------------------------+---::-+-
------------------------------------------+--+---4 
USA/Canada 47 14.2 
--~ ------------- ---------------
CANCER SITES 
--------------+--+ 
Multiple 78 23.6 
Head and neck 46 13.9 
Breast 46 13.9 
Lung 37 11.2 
Haematological 28 8.5 
Colorectal 26 7.9 
GI I 24 7.3 
Prostate 22 6.7 
Urology/Kidney 7 2.1 
Gynaecological 7 2.1 
Brain 4 1.2 
Testicular 3 0.9 
Malignant melanoma 2 0.6 
Total 330 100.0 
From the 330 eligible papers, 10682 contrasts were selected for expert review. 
57% of the contrasts were cross-sectional and 43% longitudinal. 
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5.4 Full dataset 
The full dataset included any of the eligible papers that had at least two expert 
reviews by the end of the study period. Of the 330 papers meeting the inclusion criteria 
223 remained in the full dataset after the review process. 60 (18%) papers were 
excluded as they only had one reviewer and 39 (12%) excluded as they had no 
reviews. Eight further papers had to be excluded during the review process for other 
reasons. Four papers (1 %) were rejected by the reviewers and four (1 %) had errors on 
the coversheets sent to reviewers (Figure 8). The papers rejected by reviewers were 
due to the wide range of patients in the sample which reviewers felt made it impossible 
to judge what the aOL differences might be. 
The full dataset had very similar paper and patient characteristics to the 330 
eligible papers described above (data not shown). There were 7833 contrasts (57% 
cross-sectional, 43% longitudinal). 
5.5 Analysis dataset 
The analysis dataset is defined in Section 4.4.4. Once the criteria for good quality 
contrasts had been applied there were 152 papers contributing 2212 cross-sectional 
contrasts and 118 papers contributing a total of 1232 longitudinal contrasts for analysis 
(Figure 8). A total of 7238 contrasts were excluded (68% of the 10682 original eligible 
contrasts). Table 17 shows a breakdown of the reasons for excluding contrasts from 
the analysis dataset. Exclusion criterion 1 refers to the trivial difference size class, 
where a contrast was excluded if reviewers did not all rate the contrasts as trivial. 
Exclusion criterion 2 refers to the exclusion of contrasts from the small, medium and 
large size classes (where there was disagreement between the direction of the expert 
overall opinion and the actual aOL scores). 
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Table 17 Reasons for exclusions from analysis subset 
Number of Reason for exclusion Total Remaining 
contrasts Insufficient Exclusion Exclusion excluded in 
excluded (% 
number of criterion 1 criterion 2 analysis 
of those in 
expert dataset 
eligible reviews 
data set) 
Cross- 1653 1436 788 3877 2212 
sectional (27%) (24%) (13%) (64%) (36%) 
(from 6089 
eligible) 
Longitudinal 1196 1557 608 3361 1232 
(from 4593 (26%) (34%) (13%) (73%) (27%) 
eligible) 
Total 2849 2993 1396 7238 3444 
excluded (27%) (28%) (13%) (68%) (32%) 
(from 10682 
eligible) 
Table 18 summarises characteristics of papers in the analysis dataset. The 
characteristics were very similar to those of the 330 eligible papers described in 
Section 5.3. The majority of the 211 papers were cohort or descriptive studies 149 
(71%). Randomised controlled trials accounted for another 51 (24%) of the included 
studies. The remaining papers were reports from multiple studies (7 (3%» and non-
randomised phase 1111 studies (4 (2%». The majority of the studies were European (150 
(71%)). The research questions addressed by the papers were usually to describe the 
effects of disease or treatment on QOL (175 (83%». with other research questions 
such as validation of QOL questionnaires and long term follow up of survivors 
accounting for a maximum of 5% of the papers each. A wide variety of cancer sites are 
included in the analysis dataset. papers in breast (42 (20%». lung (35 (17%». head 
and neck (28 (13%» and colorectal (22 (10%)) were the most common disease areas. 
Other areas accounted for less than 10% of the sample each. In addition to these 
papers looking at a single cancer site there were 24 (11 %) of the papers reporting on 
multiple cancer sites. 
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Patients from the 211 studies ranged from age 31-74, with a median age of 62 
years. 21 (10%) of studies contained males only, 45 (22%) contained women only and 
136 (67%) contained both males and females (these data were missing from the 
remaining studies). 
Table 18 Summary of paper characteristics (analysis dataset) 
N % 
---
--- ---
--
RESEARCH QUESTION 
---- - - --
--
--- ------- -----
Describe effect of disease &Ior treatment on HRaOl 175 82.9 
--
--------------------
long-term FU of survivors 11 5.2 
--- -- - - - - -- -----
--Develop &Ior validate alQ core module 8 3.8 
-------- -- _._--
Comparison of HRaOl instruments 
I 
5 2.4 
- - --~----
Psychosocial interventions (e.g. nursing, education, counselling I 
programmes) I 4 1.9 
----- -----
Develop &for validate ala core & disease specific module 3 1.4 
-Oevelop&forvalidate another HRaOl questionnaire 2 0.9 
f--- -- ------------ ---
Cross-cultural validation of the QlQ-C30 2 0.9 
--_._-- -------------------------~------------_ .. _--- c------
Cultural issues in HRaOl & health care 1 0.5 
--
-- ---------
--------------
--
STUDY DESIGN 
----------------------
----------------
Cohort/descriptive study 149 70.6 
I- - --- --------- ---
RCT Phase not specified 30 14.2 
-- -~---.- - -------- -- ---
RCT Phase III 15 7.1 
f--------- --
Multiple studies 7 3.3 
1-----------------
RCT Phase II 5 2.4 
---_._----- -
Non-randomised Phase 11 3 1.4 
----------
RCT Phase III crossover 1 0.5 
-- ---------
-
--_ .. ---- -'-
Non-randomised Phase I 1 0.5 
i-= ------------
REGION 
I- --- - -- ----- - --- --------
Europe 150 71.1 
-
--------_. --------_._---- ----
Rest of World t34 16.1 -- --_.--_._-USA/Canada 27 12.8 -- - --------- .. _--- ------ ----- - ------- ------------ ---- ------
-CANCER SITES 
Breast 42 19.9 
lung i 35 16.6 
Head and neck I 28i 13.3 
Multiple I 24\ 11.4 
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~% - - ~- - - --- - - ------- - - ------------------.-~ 
Colorectal ---- 22 10.4 
Haematological 19 9.0 
Prostate 18 8.5 
GI I 10 4.7 
Urology/Kidney 5 2.4 
Brain 4 1.9 
Testicular 3 1.4 
Gynaecological 
I 
1 0.5 
Total 211 100.0 
Thirty-two percent of the papers had two reviews and 68% had three reviews 
(Table 19). The number of contrasts ranged from 1 to 24 per paper with a median of 2. 
The sample size of the included papers ranged from 10 to 2640 patients with a median 
of 133 patients. The global quality of life scale was the most frequently reported 
subscale (Table 20). The financial difficulties subscale was often omitted from the 
results. 
Table 19 Number of papers/contrasts with at least two reviewers (analysis 
data set) 
'I Contrasts 11 % of all contrasts Papers % of all papers 
Number of reviewers i , 
I I 
------ --------l I 1372\ Two 39.8 67 31.8 
r---=: i 20721 
~~--I---~-
Three 
I 
60.2 144 68.2 
1 3444 1 -ill 1--Total I 
I 
Table 20 Number of contrasts by subscale (analysis dataset) 
_
lcross.sectional LOngitud.inal 
Subscale L ~ ---r N % N
i
_ % 
Appetite Loss (AP) 1 134 6 76 I 6 
Cognitive-Functioning (CF) I 1631~-- 71 -~--6ii 5 
-Constipation(CO) -~-----t---128l·· r- 701-6 
?-ia~~h~e_~_ ~ D!~~_--=-~~- -~ --I-~~ ___ 1_~:~~-6- __ ~_7~1=_ ~~ 
Dyspneoa (DY) i 112 i 5 i 581 5 ~- ----~--- ~_~ __________ 1 __ ---+-i----+--
Emotional Functioning (EF) i 1821 81 116 ! 9 
__ _ _______ " ___ 0 ________ • _ ---1 _______ ---~-~ ______ .L _ 
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Subscale l:r_o_ss-~~~t~~~~11 L_o_ngitu~!_n~ 
______________ ~ N __ % I----~l u~ 
Fatigue (FA) i 150 7 t- 102 1 8 ~:~~a~~:p:n1~9(NV} i 1:1: F~ :: 1- ~ 
------- -- ----- -- -r- -'l--~--+--~a!~PA~---- _ ' 148i 71 92~~ 
Physical Functioning (PF) I 1881 8 91 I 7 
Global QOl (Ql) I 195 9 118 10 
~~~_o_m_n_ia __ ( __ S __ l __ )_ -------t-I ---=--::-=-=+------t-
~I I 
-"--
--
171 8 89 7 
182 8 97 8 
111 ! 51 655 
I -~----
2212[ 
I 
1232i i 
Role Functionfng (RF) I 
--::c----------- I 
Social Functioning (SF) 
I initially coded the contrasts under 50 individual anchors, using descriptions for 
the anchors from the source papers. I then collated these using seven broad categories 
for the description of the anchor (Table 21). Time-related and treatment-related 
anchors were the most common. 
Table 21 Frequency of anchors (analysis dataset) 
Anchor (categorised) Examples of individual anchors or Number Number 
contrasts of of 
papers contrasts 
T reatmentll nterventionl Graft versus host disease, Previous 87 875 
Assessment related chemotherapy, Responsibility for 
follow up, Treatment (non-rand), 
Treatment (rand), Type of surgical 
technique, Use of pain killers, Use of 
psychosocial support 
Time related Cross-sectional: <1yr post BMT vs 123 1275 
>1yr post BMT, active treatment 
group versus follow up group 
longitudinal: Baseline vs 2nd cycle, 
Pre vs post treatment, Baseline vs 
6mths follow up 
Disease related Clinical phase of disease, Co- 54 628 
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Anchor (categorised) Examples of individual anchors or Number Number 
contrasts of of 
papers contrasts 
morbidity, Disease stage, Presence 
of metastases, Presence of stoma, 
Primary disease, Response status, 
Time since diagnosis, Tumour site 
Patient characteristics Age, Gender, Marital Status 24 239 
related 
Physical function Arm problems, Performance status, 16 317 
related Erectile dysfunction, Anal function, 
Urinary continence, Dysphasia, 
Motor deficit 
Symptom/Emotional Anxiety, Confusion, Pain, Weight 9 92 
related loss, Insomnia, Neurological status, 
Symptom reporting 
Survival related All patients vs completers, Baseline 2 18 
comparisons of survivors at 3 
months vs non-survivors at 3 months 
5.6 Data extraction/Imputation 
Standard deviations could be directly extracted from the paper or calculated from 
the information provided for 57% of the cross-sectional contrasts and 50% of the 
longitudinal contrasts in the analysis dataset (Table 22). 
Table 22 Level of imputation required for analysis dataset 
SO available SO imputed 
Cross-sectional 1273 (58%) 939 (42%) 
Longitudinal 613 (50%) 619 (50%) 
The impact of imputation on the analysis results was investigated later via 
sensitivity analyses, see Section 7.3.1 for details. 
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5.7 Summary of QOL data from papers 
The QOL data was summarised for the analysis dataset in order to show the 
range of QLQ-C30 scores from the contrasts in the final analysis. Mean differences for 
cross-sectional comparisons (Table 23) ranged from 0 to 64 points with a median of 5.8 
points. Across subscales the medians ranged from 3.0 (01 and NV subscale) to 9.7 (RF 
subscale). For longitudinal comparisons (Table 24) the difference score ranged from -
54 (a deterioration in the 01 subscale) to 50 points (an improvement in the PA 
subscale), with a median of 1. Across subscales the medians range from -4 (PF 
subscales) to 6 (EF subscale). Overall 30% and 27% of the contrasts had QOL 
differences of more than 10 pOints for cross-sectional and longitudinal contrasts 
respectively (Figure 10 and Figure 11). 
The RF subscale had the highest proportion of QOL scores of 10 or more for both 
cross-sectional and longitudinal contrasts. There were some subscales with scores 
which deteriorated over time on average (FA, NV, PF and RF) and some which 
improved over time on average (EF, PA and SL). EF in particular had a higher average 
QOL difference when compared with the other subscales, with an average mean 
difference of 6 points (effect size 0.27) compared to the average over all subscales of 1 
(effect size 0.04). 
Baseline scores for the longitudinal comparisons are summarised in Table 25. 
This shows that some subscales had an average score at baseline which represents a 
particularly low level of symptoms (NV, 01 and CO) or a high level of functioning (CF, 
PF and SF) which actually leaves little room for improvements over time. 
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Table 23 Analysis dataset: Cross-sectional mean differences and effect sizes 
Mean difference I Effect size 
1 Standard Standard 1- I - : Standard : Standard , , 
subscales . I i I: :. !! ~ Mean j Medi_an :~~i~t~~n Erro~_ l'~aximunl ;.I~inimum t Mean Median; Deviation \1 Error Maximum 1 Minimum ; N 
AP 8.8
1 
5.9 1 8.6 0.8, 37.71 0.0 i 0.36 0.25: 0.36 0.03 1.86 i O.OO! 134 
~~~;~~--=-;:~t-- --::! -.-~ __ ~, ~ --=~; t = ___ ~~ i _ ~::~I- ~:~~ j 3:: I· ~:~: -~~~: L _~~~ I~:~ 
0,', ,,4·~t _, ~~~i-. ___ ~~2 , __ , _0~4f __ . _ 22A ___ .0'_,0) __ 0,.20] ._,_0 .. ~5~, ,0.19, 0.02 0.90 1 __ 0:00] _135 ~~~_ _ --L--!~~L--:'~1---~-~---~1-----=~~i---~.~ __ ~.2~ ____ ~·~~I ______ ~:2_2+ ________ -+-_ 
0.31 0.22 0.31 0.02 
All 
--- --- ----- ~---------
0.0 I 0.42 0.32 0.38 
1 --+-- 1 1 -- -- --- -- ----- - ----------
0.0 0.22 0.18 0.19 
0.03 
5.1 0.6 26.3 0.02 
J. -------:_ ------,- --------- -------:-t----------+--
6.8 0.6 38.0 0.0 0.31 0.20 0.34 0.03 
PA 1--9.71 7.01 9.5 O.B 49.0 0:0'---6.37 -, 0.27 0.35f-----Omj----T75t-' 0.00t--148 
----~----
11.2 0.8 60.0 0.0 0.51 0.36 0.55 0.04 
~L --= __ t _8.5 r 5.5 c 7.7 0.6 35.0 O-:o~ 0.37 0.25 0.33-' 0.02 1.6~J 0.00 195 ~ _____ t _~~.4 9.7 12.7, 1.0 64.0 0.1 t-- 0.48 0.29 0.71 0.05 5.921 0.00 171 
I-~F -____ ~ __ ~~2 1 ,~-~~t- 8.1 0.6
1 
50.0 0.0 0.34 0.29 0.30 0.02 1.83f 0.00, 182 
::----------t- _ 6.B!__ 5.0 6.2 0.6 29.3 0:2 0.25 0.17 0.31 0.03 2.13 1 0.01 111 
All i 8.5 i 5.8 8.7 0.2 64.0, 0.0 0.35 1 0.24 0.39 [ 0.01 5.92 1 0.00 I 2212 
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Table 24 Analysis dataset: Longitudinal contrasts mean differences and effect sizes 
AP 
, Mean difference I Effect size 
, , 
r--" . --,- _."-- .... __ .. ---·'r ._--_. .-. ," -- + 
: Standard I Standard I I i 'Standard Standard, 
subscales ! : 1 : I " 
Mean ,Median I Deviation I Error I Maximum I Minimum : Mean ! Median Deviation Error 'Maximum Minimum' N 
-_=O~~ ~_ _ ~.~ ~ ~~~~_~~ 1~-=-1.5 t ----- 30.S) -- -~_1~0 t -0.02; 0.03 0.47 0~05! 1.41 -1.34 76 
-0.76 66 
All 
70 
----L L _____ L -- j ,-- 1 .1 -, ---- -~ -
1.1 
~; ----+-~~:~t-~~:~l-. ~F ~:: --~~~-~!:~-~~~~-IEr- --~~~;r ·-~~~I-~- ::;;J ... :~:~:1-1~: 
, 5.81 -1.0 12.7 _14.91-u-----+-----~l 
C-PA--1-~-i~~ ::~l :~::[ ::~ :;:! ::::1:~::: -:~::~ ~::~' ~:~:I- _2~~'~ -1.1 5 1 92 
!~ ________ L---4.11 ----~2- 9.7 1.0 13.8 -45.0 _--=-0.1!. __ -0.15 0.41 0.04 0.57 r' -1.80 1 91 
QL i -0.11 2.8 9.6 0.9 22.0 -36.3 0.01 0.12 0.43 0.04 1.17 -1.531 118 
--~-.----+--
~~~ __ ~--J -3.2 -3.0 13.5 1.4 I 20.1 -50.0 -0.11 -0.09 0.45 0.05 0.64 -1.50 I 89 
SF ! -1.4 -1.0 , 9.5 , 1.0 16.1 -33.4 -0.05 -0.03 ~0.36_ 0.04 0.59, -1.18/ 97 
~~~-~~-_~T~~--3~71-----4.~ , 8.6 1.1 I 17.5 -28.2 ~-O.13 - 0.13 0.30 0.04 I O])~-------1:~ 65 
All I -0.4r 1·~L 10.2 0.31 50.3 -54.01 ~ 0:~.42 0.01 1 2.61, -2.49] 1232 
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Figure 10 Analysis dataset: Cross-sectional contrasts - proportion with QOL 
differences of 10 or more points 
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Figure 11 Analysis dataset: Longitudinal contrasts - proportion with QOL 
differences of 10 or more points 
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Table 25 Analysis dataset: Baseline scores for the longitudinal contrasts 
Mean Mean Median SD SE Max Min Number 
baseline (overall) of 
scores for contrasts 
each with mean 
contrast baseline 
score 
provided 
CF 81.2 83.5 10.3 1.4 96.7 42.7 57 
c EF 69.2 70.0 9.0 1.0 89.9 44.0 88 
0 PF 77.8 78.9 11.0 1.3 96.3 46.0 75 :;:::; (,) 
QL 62.8 63.0 8.2 0.8 83.1 40.0 99 c 
::J 
u. RF 71.3 73.4 13.2 1.6 95.7 34.0 70 
SF 77.1 78.2 9.1 1.0 94.7 51.0 76 
AP 22.7 17.0 16.7 2.1 87.6 3.2 61 
CO 19.8 15.5 15.4 2.0 80.5 0.0 57 
DI 13.8 8.7 17.2 2.2 91.0 0.4 62 
E DV 24.6 17.3 18.3 2.7 72.0 7.0 46 0 
.... 
34.6 33.0 12.5 1.4 81.0 a. FA 6.5 83 E FI 18.4 13.9 14.1 2.7 53.3 1.2 27 >. Cl) 
NV 9.0 7.0 7.4 0.9 36.0 2.0 67 
PA 27.3 25.4 14.4 1.7 88.1 5.0 73 
SL 29.2 28.0 6.8 0.9 46.0 12.0 55 
5.7.1 Randomised treatment contrasts 
The subset of contrasts from randomised controlled trials in the analysis dataset 
were also summarised separately from the other cross-sectional contrasts. The mean 
differences arising from these randomised treatment comparisons could be very 
informative when planning sample sizes for new studies. 
Table 26 shows a summary of the differences arising from randomised treatment 
comparisons (excluding any randomised treatment contrasts at baseline). There were 
297 contrasts from 29 papers which compared two randomised treatments. Note that 
the number of contrasts was high compared to the number of papers as treatments 
could be compared at multiple points in time and more than two treatments could be in 
the randomisation. 
Figure 12 shows the proportion of contrasts for each subscale with the larger 
improvements (10 or more points difference between the treatment groups). Overall 
there were 12% of the RCT treatment contrasts achieving 10 or more pOints difference. 
The PA and SF subscales were the most likely to show the larger differences. 
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Table 26 Analysis dataset: Randomised treatment comparisons 
I Mean difference ' Effect size 
AII,-- - -- ------- T- -- --T ' - T 
'!I Standard I Standard I r ~ , i Standard Standard 1 
subscales ! ':! i I r i 
IN, Mean Median Deviation, Error I Maximum I Minimum: Mean I Median i Deviation Error i Maximum Minimum 
Apr~34i- 66 4.2-=-105 i--____ O.9t-=--3Ut -14:01 0.281 0~2ijl 043,- ~ 004) 1.136 -041 
~:-~t~:~I--;1~·~ ... -1::: ~:I=-~:::;j~~~~:i-~~~~l3~~:j- ~ _ ~:~l--~:~l- _~:!~tn~ __ :~::: 
DI .. ___ I _13!2.31 ... 1.5 _----=-5 __ ~.~ __ 22.0 _ ~1~.0 j 0.111 . 0.~91_ 0.2~ i- _O.O! ___ ~.90_1____ _ -0!6 
FI I 82, 2.4 1.6 7.2 
NV------ f-13rr---~ 2.9 7.8 0.7 
~~- ----t 1481-8.51 6.8 10.6 0.9 49fr_- -2, ~_:~i _~~~~~ 0.25i ___ ~~~~I,1.751 -0.75 
+-18~1_~~C 8.0 11.9 0.9 60.0 __ --=-1_~:~T-~~~i--~~~41 0.58 1 0.04t 4.21! ___ -O.:~ 
QL 1 195[ 7.81 5.2 8.4 0.6 35.01 -11.9 0.34 1 0.2~ 0.371 0.01 1.67] -0.66 
:~_=~~~:=,-~::: 12.il-g.ot 14.1 1.1 64.0~i~::j-~~-0~~7t---~~41 _~~~~,=- 5.9~,,: __ -0.67 
SF _l __ ~8~+ __ ~~~~-6.9 9.3 0.7 50.0 -15.6
1 
0.30 1 0.26
1 
0.35 0.03~____ 1.83
1 
___ -=?7~ 
SL _____ --+ __ ~~J_ 4.81 4.0 7.8 0.7 29.3 -13.0+ 0.181 0.121 0.35 0.03! 2:13 -0.44 
All I 2212/ 6.81 5.0 10.0 0.2 64.~ -25.11 0.28 1 0.20 I 0.45 0.01 1 5.92 i -1.04 
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Figure 12 Analysis dataset: Randomised treatment comparisons - proportion 
with QOL differences of 10 or more points 
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5.8 Summary and conclusions 
Not all papers identified in the literature search were appropriate for the project. 
The majority of papers which were excluded were due to the exclusion criteria we 
defined a priori. A smaller proportion of the papers were subsequently excluded during 
or after the expert review process. Although we had a large expert panel with a wide 
range of expertise, we could not identify appropriate experts for some of the papers. 
Following the review process, more than half of the reviewed contrasts violated 
the criteria for the analysis subset and were subsequently excluded from the analysis. 
The criteria for inclusion in the analysis subset were defined post hoc which is not ideal 
(full details and discussion follow in Chapter 6) but they were derived with the aim of 
only including the best quality contrasts in the analysis. Despite the large proportion of 
exclusions the papers included in the final analysis had very similar characteristics (e.g. 
study design, research question, cancer sites and so on) to the complete set of eligible 
papers. 
In common with other meta-analyses, variance data could not be extracted for all 
of the contributing contrasts. Standard methods were employed to impute these data 
and the possible impact of imputation was later investigated using sensitivity analyses. 
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Around 30% of the contrasts in our analysis met Osoba's definition of a moderate 
difference (10 or more points). When the contrasts were limited to just the treatment 
comparisons from RCTs this proportion was considerably lower, with only 12% of the 
contrasts achieving differences of this size. Some subscales were more likely than 
others to yield the larger differences (eg role functioning, physical functioning and 
fatigue when comparing between groups; pain, social functioning and physical 
functioning when assessing change over time). 
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6 Quality assessment 
Chapter 6 is divided into two parts; part 1 reporting the qualitative interviews with 
the experts and part 2 reporting the quantitative analysis used to define the contrasts 
for the analysis dataset. 
6.1 Part 1: Expert interviews 
6.1.1 Aims 
The aims of the interviews were: 
a) To find out how reviewers had approached the task 
b) To explore any possible issues with reviewing certain papers or subscales 
c) To generate possible factors affecting the quality of the judgements and use 
them in subsequent quantitative assessment of quality. 
6.1.2 Methods 
6.1.2.1 Interview 
A telephone interview with each expert on the panel was planned. The interview 
consisted of 12 questions (Table 27). 
Table 27 Expert interview questions 
1. Before starting this project did you already have an idea of what difference in 
OLO-C30 scores would be clinically relevant? 
If yes:-
a) What is it and what is this based on? 
b) Is it the same for all subscales? 
2. Were there particular study designs or types of papers that you found hard to 
make a judgement on or that you were less sure of your answers on? 
3. Were there particular clinical anchors that you found hard to make a judgement 
on or that you were less sure of your answers on? 
4. Did you find it easier to think about the cross-sectional comparisons or those over 
time? Why? 
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5. Were there particular subscales of the QLQ-C30 that were hard to make 
judgements on or you were less sure of your answers on? 
6. Can you describe your approach to the task? i.e. what process did you go 
through with each paper? 
7. Which aspects of the paper that you could see did you use most to help you fill in 
the tables? 
8. How long would you say on average each paper took you to review? 
9. Do you feel that experience of using the QLQ-C30 in cancer patients is enough to 
predict the size of difference in QOL scores in this way? 
10. Do you think there is a minimal level of experience that would make this task 
possible? 
11. Do you think it is possible to use published data at all to inform clinical 
interpretation of QOL scores? If so do you think there is an alternative way of 
utilising the published data? 
12. Additional comments 
The first question was designed to find out if reviewers were familiar with any of 
the literature on how to interpret QOL scores. We wanted to see if their judgements for 
this project might be based on work already done in the area of interpretation of 
EORTC QLQ-C30 scores specifically or QOL scores more generally. We were keen to 
avoid reviewers trying to guess what the quality of life scores might be in the papers 
and then making their judgements using a pre-conceived idea of what difference was 
clinically relevant, for example 10 points. We felt that if reviewers were approaching the 
task in this way it could compromise the aim of this project which is to look at a new 
approach to interpretation. 
Questions 2-5 were designed to highlight if there were any particular types of 
study, comparison or subscales which reviewers found hard to make a judgement on. 
These questions were included in order to identify factors that may indicate poor quality 
contrasts and to inform future projects of this nature by helping to screen papers for 
inclusion and highlight subscales that may not be as familiar to the reviewers and 
therefore not appropriate for this type of review. We felt the answers to these questions 
could also help to explain disagreements in the reviewers' judgements and aid 
interpretation of the main analysis. 
Reviewers were asked to read a handbook(68) which explained the aim of the 
reviews and included instructions on how to fill in the coversheets. However it was 
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anticipated that different reviewers may approach the task in different ways. Two 
questions (6/7) were designed to explore this and to see if there were specific sections 
from the papers that reviewers were using. 
Questions 8-11 were included to obtain the expert panels views on the project 
and methodology behind it as well as inform future studies using the same 
methodology on how the criteria for an expert may be defined. 
6.1.2.2 Sample and timing of the interview 
Interviews were conducted when reviewers had completed the review of some 
papers but, where possible, were still involved in the review process. All reviewers 
were invited to participate but a minimum of two reviewed papers was preferred prior to 
the interview. 
6.1.2.3 Data collection and analysis 
For each interview the reviewer's gender, area of expertise, the type and number 
of papers reviewed for the project were recorded along with dateltime and duration of 
the interview. Telephone interviews were recorded and transcribed verbatim. The 
interviews were carried out by myself and the research assistant. 
I used thematic content analysis (87) to organise the data from each question and 
group extracts of text. This involved forming a table for each question containing all the 
answers. I then extracted themes from the text. Results for some questions were also 
summarised quantitatively. 
6.1.3 Results 
6.1.3.1 Sample 
Thirteen reviewers were interviewed out of the 29 returning at least two papers 
(45%), representing 38% of the 34 experts involved over the lifetime of the project. 
Nine were interviewed by telephone as planned and four by returning a questionnaire 
(as a suitable interview time could not be arranged). Interviews were between 15 and 
26 minutes long, with the majority taking 15 minutes. The characteristics of the 
interviewed reviewers are summarised in Table 28. 
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Table 28 Interviewee characteristics 
Sex (M:F) 54%:46% 
Background 
Psychology 2 (15%) 
Respiratory medicine 2 (15%) 
Oncology 2 (15%) 
Neuro-oncology 1 (8%) 
Surgery 1 (8%) 
Radiotherapy 1 (8%) 
Haematology 1 (8%) 
Research fellow 1 (8%) 
Research coordinator 1 (8%) 
Public Health 1 (8%) 
Categories of papers reviewed (more than one area may have Number of 
been reviewed per reviewer) interviewees (%) 
Brain 1 (8%) 
Breast 5 (38%) 
Colorectal 2 (8%) 
Complementary therapy 1 (8%) 
Gastro-I ntestinal 1 (8%) 
Gynaecology 2 (15%) 
Haematology 1 (8%) 
Lung 5 (38%) 
Pain management 1 (8%) 
Palliative Care 2 (15%) 
Prostate 1 (8%) 
Psychosocial oncology 2 (15%) 
Testicular 1 (8%) 
6.1.3.2 Pre-conceived ideas of clinically relevant differences 
9/13 reviewers answered yes, indicating they had some idea of what a clinically 
relevant difference in scores would be. Four of these reviewers referred to Osoba's 
work(49), although none gave specific details in terms of the number of points deemed 
to be clinically relevant. One also mentioned Cohen's work(31). One reviewer used a 
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10% change as significant based on their previous work (although this was not 
specifically based on the EORTC QLQ-C30). The remaining four reviewers had their 
own idea of a clinically relevant difference based on their previous clinical or trials 
experience. 
Four reviewers with an idea of clinical relevance prior to starting the project said 
this was not the same for all subscales, two reviewers used the same measure of 
clinical relevance regardless of subscale, one reviewer was unsure if it should be the 
same for all subscales and two reviewers were non-responders for this question. 
~.1.3.3 Feedback on the types of papers and comparisons reviewed 
There were seven main themes emerging from question 2, these are summarised 
in Table 29 along with quotes from the interviews. 
Table 29 Study designs or papers hard to make a judgement on 
Theme (number of interviews Quotes 
extracted from) 
Unfamiliar I was more confident with studies that had 
treatments/i nterventions(3) radiotherapy being looked at as that's what I 
clinically deal with every day, so I am a lot more 
familiar with radiotherapy. REVIEWER15 
Because I am a psychologist. .. I am not familiar with 
the intricacies of each type of treatment as for 
example a medical doctor would be. So I found that 
quite difficult, and unless for some reason I was 
actually familiar with that through my work it would 
just be through the course of the work and not like, 
for example, a medical oncologist would be. I 
tended to email back and email that it was out of my 
expertise ... So it had nothing to do with the study 
design, but more the types of treatments - whether 
they were medically based treatments that I had no 
familiarity with. REVIEWER36 
Heterogeneous patient Papers that had a homogenous population were 
populations (2) easiest. .. The most difficult were those with 
populations that included subjects with both localised 
& metastatic disease. REVIEWER24 
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Theme (number of interviews Quotes 
extracted from) 
Complex trials, e.g. trials with I found the questionnaire very useful in randomised 
several stages (2) controlled trials, I found it much more difficult in trials 
which had several stages to them for example if they 
are comparing a run-in period and then a treatment 
period. REVIEWER38 
Not really. Most of the studies I had were all very 
similar. Most had a primary outcome that were 
looking at treatment. All relatively simple 
comparative studies. REVIEWER21 
High attrition rate (2) Another thing which is difficult, and which is a 
problem with all these questionnaires is when you're 
looking at very sick people particularly studies that 
looked at patients receiving best supportive care 
versus no treatment, or best supportive care versus 
a single treatment because the attrition rate is so 
very high. Therefore all these COL questionnaires 
select out the better patients because the poorer 
patients are too unwell to answer. REVIEWER38 
Studies where patients could '" for example patients with Iymphedema following 
move in and out of groups over surgery who some years didn't have this symptom 
time (1) and vice versa. In my mind there is some degree of 
cancelling out in papers like this. REVIEWER30 
Poorly designed studies and If it's been badly designed in terms of the research 
small sample sizes (1) question, then that messes up the quality of life 
scores. REVIEWER12 
All hard (2) All hard, only have history with patients and they 
don't tell everything to docs REVIEWER05 
Table 30 shows the results from question 3. 5/13 reviewers did not consider any 
anchors harder to judge than others. Two found all were difficult, although one of these 
only reviewed two papers. Anchors highlighted as difficult were time, side effects, those 
(in the reviewers opinion) with little or no relationship to QOL and contrasts comparing 
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groups fairly close together (e.g. next to each other on a scale, such as ECOG 0 
versus ECOG 1, rather than comparison of groups at opposite ends of the scale). 
Table 30 Difficulty of different anchors 
Theme (number of Quotes 
interviews extracted 
from) 
No difference in Not really. The anchors were all relatively clear. None 
difficulty (5) harder than others. REVIEWER21 
All difficult (2) All difficult. Side effects particularly variable and patient 
degree of well-being after treatment also variable 
REVIEWER05 
Time anchors hard (1 ) The time ones were most difficult. REVIEWER30 
Side effects (1 ) Side effects from drugs, particularly fatigue are very variable 
and degree of well-being a patient may have after treatment 
also varies. REVIEWER05 
Anchors with no Easy were age, sex, disease stage, disease type and 
relationship to QOL treatment. Hard ones were silly things like some biological 
hard (1) marker that would have no impact on QOL. REVIEWER12 
Anchors with closely ... obviously it is easier to make a determination between 
defined groups hard and ECOG1* and ECOG4* patient, but sometimes the 
(1 ) difference between ECOG2* and 3* were more difficult. 
And .,. it was a lot easier thinking about a 40 year old and 
an 80 year old, but trying to think about 40-50 year old 
compared to 50-60 year old I found that I was more 
indecisive. REVIEWER15 
*referring to ECOG performance status stages 
Table 31 summarises results from question 4, indicating whether longitudinal or 
cross-sectional contrasts were more difficult to judge. 3/13 reviewers had no 
preference, four found the time comparisons easier and four found the cross-sectional 
comparisons were easier. One answer was ambiguous and one reviewer could not 
remember. 
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Table 31 Preference for cross-sectional or longitudinal comparisons 
Theme (number Quotes 
of interviews 
extracted from) 
Longitudinal Time comparisons were easier than cross-sectional comparisons 
easier (4) as we follow up patients over a period of time. REVIEWER05 
Over time was easier. Helped to think of the QlQ scales in terms 
of clinical changes over time. Over time you can estimate what 
these might be - getting better or getting worse. Harder to think 
how groups might be different cross-sectionally. REVIEWER21 
I thought the ones over time were much easier than the cross 
sectional but that was maybe related to the study design of the 
papers, because some of the papers contain very heterogeneous 
groups, and to do a cross-sectional analysis of very 
heterogeneous populations I think it's flawed with all sorts of 
hazard. You're often looking at a mean value of heterogeneous 
groups and there is a great risk that they don't really relate to the 
group as a whole. Longitudinal easier, but again, the attrition rate 
is a huge influence. REVIEWER38 
Those over time. I suppose again it comes back to the treatment 
thing, I had to think very very hard on some papers about the 
treatment, and so over time you're making a more general 
assumption on what is happening to a person's Quality of Life and 
so there are general assumptions that I suppose apply across all 
treatments, and that's why I found the time thing easier as 
opposed to comparing two different groups. This relates back to 
my lack of familiarity of the treatment types (as cross sectional 
comparisons are based on treatments generally). REVIEWER36 
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Theme (number Quotes 
of interviews 
extracted from) 
Cross-sectional The time ones were difficult. When I went back to check my 
easier (4) consistency, I found on the time ones this was where I was making 
mistakes. Time ones are not intuitive. The cross-sectional ones I 
knew what the differences should be. Time ones I had to really 
think what am I comparing with what? REVIEWER30 
Cross-sectional easier, as a direct comparison between groups. 
Longitudinal more difficult, as (i) need to consider QOL effects of 
both toxicity & relief of cancer symptoms (see #2), and because of 
adaptation which will reduce sensitivity to detect changes in QOL. 
REVIEWER24 
I think the cross-sectional ones were easier because it was to 
consider the sample characteristics and clinical scenario at a 
single time point REVIEWER06 
Cross sectional. I was more confident with these than longitudinal. 
I think this was simply because I am more familiar within a clinical 
setting. When we're talking to patients, we tend to talk about those 
differences at one time point rather than talking about how they 
feel now and how they may feel in 2 years' time. Generally we're 
talking about comparing one treatment to another or no treatment 
to another rather than discussing with patients a prediction of how 
they'll feel over the next 2-3 years, so I am not as familiar with 
doing that. Most of these studies work prospectively, and the 
patients' memory and the way they're thinking about the Quality of 
Life may affect the outcome. REVIEWER15 
No preference (3) Didn't bother me which. REVIEWER12 
Table 32 summarises results from question 5, indicating whether any of the 
subscales were harder to judge. 3/13 reviewers said no. The other reviewers 
highlighted that generally subscales describing symptoms were found the least difficult. 
Subscales felt to be related to the disease or treatment were found easier and in 
particular contrasts which were specific to the disease rather than more general made 
it easier. 
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Table 32 Difficulty of different subscales 
Theme (number of Sub-theme Quotes 
interviews extracted 
from) 
Some subscales Financial difficulties Yes, financial difficulty, constipation, 
harder (9) hard to judge (4) diarrhoea, dyspnoea. Most patients 
were covered by health insurance, 
but cancer treatment may also cause 
some financial difficulties, so I am not 
sure how much. REVIEWER37 
In general I focused on the things 
that were clinical or disease related 
like cough or pain. Things like 
Financial might be the same and 
you'd 20% in all of the boxes 
because you haven't got a clue what 
might happen ... REVIEWER21 
Social functioning The psychosocial functioning was 
hard to judge (3) particularly difficult as we rarely 
question patients on this aspect of 
their life. REVIEWER05 
Role functioning I always had to think about the 'role' 
hard to judge (3) subscale because I feel that it is such 
an interpretation of the person 
answering it. So I always got stuck 
on that and was never confident 
about it.REVIEWER15 
Cognitive functioning The ones that were very difficult were 
hard to judge (3) financial status and cognitive 
functioning. REVIEWER38 
Emotional Cognitive -emotional- social more 
functioning hard to difficult & unpredictable 
judge (1) REVIEWER24 
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Theme (number of Sub-theme Quotes 
interviews extracted 
from) 
Constipation, Yes, financial difficulty, constipation, 
diarrhoea, dyspnoea diarrhoea, dyspnoea .... For the 
hard to judge (1 ) symptoms mentioned above, it is 
hard to determine whether they were 
from psychological stress or physical 
illness. REVIEWER37 
Global health status ... global health status is also difficult 
hard to judge (1 ) as relatively insensitive. 
REVIEWER24 
No difference in I feel very familiar with the QLQ-C30 
difficulty (3) and how it works, so no. 
REVIEWER12 
Some subscales Clinical/disease The easier ones are all the 
easier (4) related symptoms symptoms. Fatigue, nausea and 
easier (4) vomiting etc. REVIEWER38 
Fatigue In general I focused on the things 
Nausea/vomiting that were clinical or disease related 
Cough like cough or pain. REVIEWER21 
Pain It may be easier to make a 
judgement regarding say a specific 
treatment end emesis on say the 
nausea and vomiting scale in some 
studies. REVIEWER06 
the more defined areas like nausea 
and vomiting which are clearly 
related to an intervention 
REVIEWER38 
Global health status Some like Global health status and 
(1 ) fatigue were easier. REVIEWER38 
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6.1.3.4 Consistency of approach to reviews 
Reviewers generally described very similar approaches to the task. They either 
read the paper first and then the coversheet to determine what comparisons were 
being judged followed by re-reading the paper or some looked at the coversheet first 
and then read the paper with the comparisons required already in mind. Most reviewers 
described going back over their score sheets to check them once they had filled them 
in, some commenting on how confusing this part was and how carefully it needed 
completing with the direction and magnitude of expected change. Reviewers reported 
drawing on their knowledge of patients undergoing similar treatments and 
consideration of what the QOL scales would show. 
Specific sections of the paper mentioned by reviewers as the most useful were 
research question, patient characteristics, eligibility criteria, description of treatment, 
methodology, schedule and compliance with QOL forms, primary endpoint results and 
toxicity (Table 33). 
Table 33 Approach to reviews and information used (questions 617) 
Theme (number of Sub·theme Quotes 
interviews extracted 
from) 
Approach to task Read paper before I read the paper a few times first and 
described in detail looking at questions tried to get an idea of what it was 
(10) (7) looking at and so on, and then went 
step by step thought the questions. 
REVIEWER36 
Read questions I tended to read the tables for the 
before looking at answers just to get an idea of what 
paper (3) groups we were looking at, then I 
would read the paper and then I'd go 
back and do the tables. 
REVIEWER15 
Checked their Then fill in the tables and then go 
answers (4) back to check not got it wrong. 
REVIEWER12 
Specified information Patient Descriptive and demographic details 
used from paper (12) characteristics (8) of the sample. REVIEWER12 
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Theme (number of Sub-theme Quotes 
interviews extracted 
from) 
Methods/description The details about patients' clinical 
of treatments (8) condition and the therapy they 
underwent were most helpful and 
useful. REVIEWER37 
Primary/clinical .. primary results (RRlDFS/OS), .. 
results (3) REVIEWER24 
Research question I looked at the study design and 
(2) whether the question they asked was 
a question that was likely to give a lot 
of Quality of Life change. 
REVIEWER38 
Toxicity (1 ) toxicity if available REVIEWER24 
Other information Experience of Then, I go back to my own studies 
used to inform patients/studies (2) and memories of patient care. 
decisions (5) REVIEWER37 
Thought about the knowledge of sensitivity of QLQ-C30 
scale (2) to these effects REVIEWER24 
Drug adverse events Sometimes I go to the database or 
database (1 ) information centre for drug adverse 
effects, etc. of our hospital to collect 
updated knowledge to help me make 
decisions. REVIEWER37 
Recognised the I tried to recognise it which I did for a 
study (1) couple, and that was interesting 
because I had prejudged opinions for 
the <name of author> paper as I was 
familiar with the work. REVIEWER36 
6.1.3.5 Time taken to complete the reviews 
Averages were reported to be from 10 to 60 minutes. Most reviewers averaged 
between 15 and 30 minutes per paper. 
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6.1.3.6 Opinions on experience necessary in order to do the reviews 
The answers from questions 9/10 have been combined as there was substantial 
overlap in the comments (Table 34). Knowledge of cancer and quality of life 
measurement was required in order to be a reviewer for this project but no minimum 
level of experience was specified in the invitation letter to reviewers. Seven reviewers 
agreed that having experience of using the QLQ-C30 in cancer patients was sufficient 
to do the reviews, while 4 disagreed. A number of the comments received indicate that 
reviewers feel that both clinical and research experiencelinterest in the QLQ-C30 is 
useful and the more experience you have the better able you are to predict. There was 
a feeling that you needed to know some of the background to the instrument and be 
familiar with the scores through knowledge of published results or using it in clinical 
trials as well as using it day to day clinically. 
Table 34 Level of experience required to review papers 
Theme (number of Quotes 
interviews extracted 
from) 
The more experience More experience the more realistic the results. REVIEWER05 
the better the reviews 
will be (5) 
Need more in depth Think you need to go off and do a bit more reading around the 
knowledge of QLQ- subject to understand what the pitfalls might be. I don't think 
C30 and changes (4) clinicians using the QLQ-C30 every day would automatically be 
able to do this. You need to understand some of the 
background of the instrument. REVIEWER30 
I feel it would have been more helpful to have more knowledge 
of QLQ-C30 about the way patients answer and score various 
aspects of their treatment. REVIEWER05 
Used QLQ-C30 in a Someone who is used to using the instrument in say a clinical 
disease area (4) trial will have experience of the sizes of difference. 
REVIEWER06 
Clinical and research It might be that people who use the QLQ-C30 in their research 
experience of QLQ- have a better handle on it. REVIEWER21 
C30 useful (3) I think that you need more, you need both the clinical 
experience judging patients not necessarily using the QLQ-C30 
as well as experience with QLQ-C30 research REVIEWER36 
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Theme (number of Quotes 
interviews extracted 
from) 
Used QLQ-C30 in a yes, at least participating in cross-sectional studies for two 
study/studies (3) different cancers, one for each, better follow-up studies or 
clinical trials for more cancers. REVIEWER37 
6.1.3.7 Opinions on using published QOL data to inform clinical 
interpretation 
10 reviewers thought it was possible to use published data to inform interpretation 
of QOL scores, 1 was uncertain and 2 did not provide an answer. There was general 
agreement that published data should be able to be utilised but that it was difficult to do 
so. Three reviewers suggested improvements/additions to the EBIG methodology and 
two suggested alternative ways of utilising published data. The themes extracted from 
answers to this question (question 11) can be found in Table 35. 
Table 35 Using published data to inform interpretation 
Themes Sub-themes Quotes 
(number of 
interviews 
extracted 
from) 
Ideas to Patient I wonder if it would be interesting to involve 
improve the involvement (2) patient groups in the review of results involving 
EBIG method both patients and relatives. Also, it would be 
(3) useful to find out if the scores for the Quality of 
Life surveys agreed with the experience of 
patient helplines REVIEWER05 
I was also thinking of ways to get patients 
involved. REVIEWER15 
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Themes Sub-themes Quotes 
(number of 
interviews 
extracted 
from) 
Show reviewers I wonder if you would have got more useful 
the direction and information if some of the blacked out results 
just get opinions were given. Not the number or scores, but say if 
on size (1) emotional function was improved by treatment, 
then ask us how significant the change was. 
Because I think that particularly in longitudinal, 
when there might have been 4 or 5 time spots, 
and I know things can go up and down all over 
the place, the information may not have been 
useful from this. So sometimes knowing which 
way it was going it may have got more useful 
information. REVIEWER15 
Only use high First, if you're using published data, you're in the 
quality studies (1) hands of whoever did the study to how well it 
was done and how honestly it was done. I would 
only accept published data if the group was 
reputable and I was really confident that they 
had put in the manuscript exactly how they had 
gone about obtaining the Quality of Life data, for 
example many people failed to complete the 
forms. I think the longer the study goes on 
Quality of Life changes become less valuable. 
REVIEWER38 
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Themes Sub-themes Quotes 
(number of 
interviews 
extracted 
from) 
Other ideas for Reference values Yes, as a reference value. E.g. for a certain 
utilising (2) treatment of a certain cancer, how much a 
published data certain scale will change or differ. Physicians or 
(2) nurses can take these references for their own 
care plans and even care quality evaluation. 
REVIEWER37 
It must be possible to use data to inform clinical 
interpretation, but it is a matter of presenting that 
data in a way a clinician will understand. I guess 
the whole point of the project is to get a yard 
stick from which to work from. I think the only 
way to do that is to relate it to some other yard 
stick that a clinician would understand such as 
the Karnofsky performance score, e.g. the 
difference in QlQ between KPS (Karnofsky 
Performance Status Scale) 100 and KPS 80 is 
x. Then clinicians could identify the size of QOl 
difference related to something. REVIEWER21 
Use the Tricky but, yes. You could look at just the 
discussion from discussions and pick out the narrative and 
the paper to contextual description of the impact on QOl, if 
interpret changes the clinicians who have written papers have put 
(1 ) into words exactly what the results really mean. 
REVIEWER12 
General Should be able to If you can't use published data though, what's 
comments (5) utilise it but the point of it being published at all? You must 
unsure how (3) be able to utilise it somehow, but I don't think we 
yet know the best way to utilise it. REVIEWER30 
Uncertain if it can Hard to tell, based on guessing, very uncertain 
be utilised (1) way of doing it. REVIEWER04 
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Themes Sub-themes Quotes 
(number of 
interviews 
extracted 
from) 
Useful for group I suppose it depends on what you want to be 
interpretation not able to do though. If you are wanting to feed it 
individual (2) back to patients, or to help an individual patient, 
or if you have results of a clinical trial and you 
want to know whether it is a meaningful result as 
the result of the trial. REVIEWER30 
The trouble is that published data is derived from 
group data, and the individual ones are 
individual. But yes, I think there has to be a 
starting point, but you may have to refine it. 
REVIEWER22 
EBIG a good idea I think that the idea is great and that it does work 
that works (1 ) REVIEWER15 
6.1.3.8 Additional comments 
A number of reviewers commented on how useful and interesting they had found 
the project (see Table 36). There was interest in seeing how other reviewers had 
approached the task and in seeing the results. Reviewers also remarked on how 
educational the task had been as it had made them read around the subject more and 
think more about patient perspectives. 
One reviewer in a disease area with very few papers pointed out that all the 
published papers were using the same treatment therefore results may not be very 
generalisable in that disease area. They also pointed out that these papers were very 
well known to them. They also felt that the QLQ-C30 in that disease area may not be 
detailed enough to measure the QOL of these patients. 
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Table 36 Additional comments 
Themes (number of interviews Quotes 
extracted from) 
Interesting to do (4) This was interesting to do and it made me think 
about the patient perspective on treatment etc. 
REVIEWER05 
Possible issues with experts who I am not familiar with the intricacies of each 
are not medical doctors (2) type of treatment as for example a medical 
doctor would be. So I found that quite difficult 
REVIEWER36 
Possible influence of Cultural difference or misunderstanding due to 
language/cultural differences (1) language difference may also affect my guess. 
REVIEWER37 
Issues specific to brain cancer (1 ) For brain as so few papers and all are based 
on a single drug, in many ways it is limited. 
Very well tolerated drug. For the brain part this 
may not be a very representative/generalisable 
method. REVIEWER04 
Guessing (1) Sometimes I felt the review was like a 'guess'. 
If I can have more information, my 'guess' will 
be more accurate. REVIEWER37 
Direction of difference confusing ... found the way the cover sheets were written 
on judging scale (1 ) counterintuitive, where I could have just written 
this shows x, y, or z, I found filling in whether it 
was minus 3 or plus 3 very difficult, and I was 
worried I'd got it wrong and gone the wrong 
way. REVIEWER12 
6.1.4 Conclusions 
Feedback was not received from all the reviewers so it is important to note that 
this may be a biased sample, consisting only of those reviewers who were willing to 
spend time taking part in a telephone interview or who requested the questions via mail 
instead. 
One of our concerns about the project was that reviewers may already have clear 
ideas of a clinically relevant difference based on previous work, e.g. 10 pOints, and that 
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the EBIG reviews would be based on these rather than familiarity with the scores. 
Although reviewers may have had an idea of clinical relevance it is encouraging to note 
that there is no indication that their reviews involved guessing what the scores might be 
and then using existing estimates of clinical relevance to make their judgements. 
Reviewers generally approached the reviews in a similar way indicating that the 
guidelines provided for reviewers were adequate in the description of the task. 
The interviews with the experts were also useful in identifying how, if this 
methodology was to be repeated for other QOL measures, experts should be defined. 
As this was the first time a panel of this nature had been convened the definition of an 
expert was left rather vague. Since we required experts for a wide range of cancer 
types and contrasts we only specified that an expert should have experience of cancer 
and its treatment as well as the EORTC QLQ-C30. These interviews have highlighted 
that experience of the EORTC QLQ-C30 in just a research setting or just a clinical 
setting may be too narrow for a reviewer to judge papers from both settings. It may be 
that experts who have research experience with the QOL instrument as well as clinical 
experience can conduct the reviews more easily and accurately. Experts' familiarity 
with treatments is important in their perceived ability to judge the papers. Reviewers 
with narrow experience appeared to find the task more difficult. If repeated the 
recommendation would be to match the papers more closely to the experience of the 
experts, in terms of the setting (research/clinical) and according to familiarity of 
treatments/interventions in each setting. However, this may not be feasible as it would 
mean an even larger panel of reviewers was required and each reviewer would 
undergo training in order to then review only a very small number of papers. A better 
solution may be for papers containing relatively unfamiliar treatments/interventions to 
be excluded. Stricter criteria may be required for experts conducting these reviews to 
ensure that they do not judge papers containing unfamiliar treatments or clinical 
settings. Although it was an option for reviewers to return any papers without 
judgement if they felt unable to comment it may be that some experts chose to guess 
instead which may create more variation in the results and could be a cause for 
discrepancies between reviewers of the same papers. 
Instead of obtaining expert opinion on the size and direction of the difference in 
QOL we could have given the reviewers an indication of the direction of the change in 
order to concentrate the reviews on size only. This was suggested in one of the 
interviews. One advantage of this over the review process adopted would be that 
discrepancies between reviewers assuming different directions in QOL change would 
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have been eliminated and with only the magnitude being considered the review 
process would be simplified for the reviewers. We undertook a data cleaning exercise 
for papers where reviewers' opinions were in opposing directions but a number of 
discrepancies remained. One disadvantage of indicating direction is that the 'no 
difference' category may be under-used as an indication of direction points to some 
change in QOL scores. The major advantage of masking the direction as well as 
magnitude (as carried out in this project) is that comparisons where experts cannot 
agree on the direction of their judgements are highlighted as potentially comparisons 
that are not familiar enough to the experts or the anchor is not closely related enough 
to COL to be used to inform clinical interpretation of COL scores. 
Two reviewers quite rightly suggested patient involvement would be useful in 
production of the interpretation guidelines and the results from our patient pilot study 
can be found in Chapter 8. 
Two reviewers suggested an alternative way of using published data was as 
reference values. The main issue in trying to use the published data in this way would 
be the availability of data from a number of papers on the same anchor. It is unlikely 
that enough data is published at the level of specific treatments within cancers but it is 
likely that this is possible for other widely used anchors, e.g. ECOG performance 
status. If there are a number of papers reporting QOL scores for particular anchors and 
it appears reasonable from the analysis that results can be pooled over cancer types 
then reference values can be published in these interpretation guidelines alongside the 
more general guidance. 
One reviewer suggested a different way of utilising published data for 
interpretation would be to just use the discussion and interpretation from the paper on 
the meaning of the COL changes. Following a review of the RCTs identified in the 
literature search for this project only 38% of studies include a clinical interpretation of 
the QOL scores (3) so this method would only be able utilise some of the published 
data. Our review found that there was generally an over-reliance on statistical results 
rather than clinical interpretation of differences in QOL. 
One reviewer highlighted that the quality of the reviews is reliant on the quality of 
the underlying paper and how the study was conducted. This is a key issue with using 
published data to produce the interpretation guidelines and the second part of this 
Chapter investigates what constitutes a 'good quality' paper for this meta-analysis and 
how to weight the papers according to quality in the analysis. 
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Some of the reviewers' comments highlight areas that may affect the quality of 
the review:-
a) study design and complexity 
b) heterogeneity in patient population 
c) attrition rate 
d) anchors unrelated to QOL 
e) certain subscales which were harder to judge 
All these factors are considered further in Part 2 of this chapter investigating the 
quality of the expert reviews and the possible effect of quality on the overall study 
results. 
6.1.5 Discussion 
One aim of the interviews was to find out how experts approached the task and to 
see how consistent the panel of experts were. We found that despite having a large 
panel of reviewers working independently, the interviews revealed that the reviewers 
generally took a consistent approach to the reviews (Table 33). Reviewers highlighted 
patient characteristics and the methods or treatment descriptions as the main sources 
of information from the masked papers to inform their reviews. 
Although experts were generally familiar with different literature on the size of 
meaningful QOL differences it was encouraging to also note that there was no 
indication that this dominated the approach to the reviews. 
The interviews also sought to highlight any issues with particular papers, 
subscales or comparisons which more generally may affect the quality of the expert 
reviews and subsequently the results. A number of points were raised which were 
useful in guiding sensitivity analyses and investigations of quality in the meta-analysis. 
Contrasts with unfamiliar treatments/interventions, heterogeneous patient groups, high 
attrition rate and complex trials (e.g. multi-stage trials) were generally harder for 
experts to judge. Anchors highlighted as difficult were time, side effects, those which 
the reviewer felt had little relationship to QOL and contrasts comparing groups fairly 
close together (e.g. ECOG 0 versus ECOG 1 compared with ECOG 0 versus ECOG 4). 
These may be factors that could affect the quality of the reviews in terms of the 
concordance between reviewers' opinions or agreement between the reviewers' 
opinions and the study results. These contrasts may also be the ones with the most 
uncertainty in reviewers' opinions (i.e. percentages spread across the possible 
categories). Using a weighted average of reviewers' opinions in these cases may lead 
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to more variation in the pooled results. This is investigated quantitatively in Part 2 of 
this chapter. 
There was no indication that either longitudinal or cross-sectional contrasts were 
easier for experts to judge. 
Financial difficulties, social, role and cognitive functioning were harder for experts 
to judge than subscales which are more symptom-related. 
The definition of an expert for the project may have been too non-specific. A wide 
range of experience (e.g. clinical and research experience) with the EORTC QLQ-C30 
may be necessary in order to be familiar enough with how the scores behave in 
different situations. It may be that experts from different backgrounds or with 
experience only in the clinic or in research had different opinions on the likely size of 
difference, leading to discordance between experts. However, this could also be a 
strength of our choice of panel in that a wider range of views was sought and an 
average of these was then used to class the contrasts. 
These qualitative interviews were valuable in identifying factors that may 
influence how an expert judges the size of a difference in QOL. A number of these 
factors would not have been hypothesised without undertaking the interviews. These 
factors are used in the next chapter to explore concordance between reviewers on the 
same contrast and uncertainty in expert judgements quantitatively. This was with the 
aim of understanding the quality of the expert opinions and how the results from the 
project may be affected by including papers or contrasts the reviewers found hard to 
judge. 
At the start of the project we aimed to train the experts and provided a 
manual(68) to ensure they approached the reviews in the same way and these 
interviews are reassuring in that they show this appears to have been successful. 
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6.2 Part 2: Meta-analysis quality assessment 
6.2.1 Correlation between reviewers scores and actual QOL 
changes 
6.2.1.1 Cross-sectional versus longitudinal contrasts 
Different measures for measuring correlation (parametric and non-parametric) 
gave almost identical results therefore Pearson's correlation coefficients are used here 
for simplicity. Correlation between the reviewers' and actual QOL scores was 0.31 for 
the cross-sectional contrasts (Figure 13) and 0.21 for the longitudinal contrasts (Figure 
14). Note the graphs show individual reviewers' weighted averages (individual opinion) 
at this point rather than the average for a contrast (overall opinion) so this contains 
multiple observations on the same contrast. Note also that the randomised 
comparisons at baseline which were not sent for review were excluded here in order to 
get a picture of how well the experts were correlating with the actual scores rather than 
looking at the dataset as a whole. Although there is an overall positive trend for both 
types of contrasts (Le. showing a positive relationship between the reviewers' weighted 
averages and the scores from the original article) the scatterplots show there is a lot of 
variation. There are a number of sizeable mean differences falling in the trivial to small 
range and, at the other ends of the scale, a number of very small mean differences in 
the medium to large range. 
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Figure 13 Correlation between reviewers' scores and actual QOL scores - cross-
sectional contrasts 
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Figure 14 Correlation between reviewers' scores and actual QOL scores -
longitudinal contrasts 
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I also looked at the relationship between the overall weighted averages (Le. on a 
contrast level rather than on an individual review level) and the actual mean scores as 
this is more relevant as a measure of correlation between the grouping variable we 
used in the analysis and the paper scores. Since we are now looking at the relationship 
overall between the size classes and actual QOL scores the contrasts not sent for 
review are now included. The negative and positive reviews were also combined here 
as they were for the analysis (Le. contrasts with a negative review have the expert 
scores and mean differences multiplied by minus 1). 
Figure 15 shows the correlation between the mean difference and overall opinion 
for the cross-sectional contrasts. The Pearson's correlation coefficient is 0.32 
(p<0.0001), which is similar to that when considering the individual opinion (0.31). 
Figure 15 Relationship between overall opinion and actual QOL scores (cross-
sectional contrasts) 
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For the longitudinal contrasts (Figure 16) the correlation is 0.28 (p<0.0001), 
although the majority of contrasts are around the trivial and small categories (-1 to 1) 
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the positive relationship between the average expert score and actual OOL difference 
can still be seen. 
Figure 16 Relationship between overall opinion and actual QOL scores 
(longitudinal contrasts) 
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6.2.1.2 Individual subscales 
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The scatter plots in Appendix II show the overall opinion against the mean 
difference from the paper for each subscale. The correlations are summarised in Table 
37. Longitudinal and cross-sectional contrasts are combined in these analyses. Across 
subscales the correlations ranged from -0.05 to 0.47. PF and FA had correlations of 
>0.4. The subscales showing very little correlation «0.2) between the overall opinion 
and the paper mean difference were SL, DY, EF and FI. 
Table 37 Correlation of reviewers' scores with actual QOL differences (by 
subscale) 
Subscale : Pearson's correlation Number of contrasts: 
PF 0.47 6361 
; I 
r-- FA r -----~--·-·~~-O:42- ----~--------5781 
-------NV -r--- ----------0.39 ----------------4ial 
--------------c- -- --.~---... --- . --..J 
0.38 606 i 
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Subscale; Pearson's correlation Number of contrasts 
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6.2.1.3 Individual reviewers 
Plots of the relationship between reviewers' weighted averages and actual QOL 
differences can be found in Appendix Ill. Plots were produced for each reviewer in 
order to see if there were particular reviewers that stood out as outliers from the rest. 
For individual reviewers correlations range between -0.24 and 0.64 (Table 38). 
Correlations are highlighted using italics in the table below where the p-value indicates 
the correlation is not significantly different from zero or where a significant negative 
correlation exists between the reviewer and actual scores (as this indicates the 
reviewer tended to judge in the opposite direction to the paper). P<0.01 for all other 
reviewers indicating a significant correlation between their judgements and the QOL 
differences in the paper. Reviewers 4, 6, 8, 10, 16, 20 and 36 are highlighted as those 
with poor correlation of their judgments with QOL differences in the paper. These 
reviewers all reviewed a small number of papers (five or less papers each), with the 
exception of reviewer 36 who reviewed 12 papers in total but still had a correlation of 
close to zero. 
Table 38 Correlation of reviewers' scores with actual QOL differences 
Reviewer ! Number of I Number of Pearson's 
ID i papers I contrasts correlation 
------+---- ---------~--~- ---- ---~ I----~---
21 2L 21 0.64 0.002 
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Reviewer • Number of I Number of I Pearson's P-value 
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6.2.1.4 Subset of trivial contrasts not sent to reviewers 
The comparisons between randomised treatment groups but at the baseline time 
we thought should be automatically assigned to the trivial size class. These were not 
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sent for expert review therefore I have also summarised here the actual sizes of QOL 
differences that arose from these contrasts. They had a mean difference of 3.1 points 
(median 2.0) and a range from 0 to 14. 97% of the values were less than 10 points 
(Figure 17). The outlying points with mean differences above 10 points were all 
checked for data entry errors and were found to be genuine differences at baseline. 
Figure 17 Distribution of actual mean differences for contrasts not sent to 
reviewers 
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6.2.2 Concordance between reviewers on the same contrasts 
6.2.2.1 Distance between reviewers 
Seventy-six percent of the cross-sectional contrasts had a maximum distance 
between reviewers of up to one size class (Figure 18). This was lower for the 
longitudinal contrasts (63%), Figure 19. For the cross-sectional contrasts there were 
35% in exact agreement. There were less in complete agreement for the longitudinal 
contrasts (21 %). There were very few contrasts a distance of three or more size 
classes apart (8%). 
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Figure 18 Distance between reviewers for cross-sectional contrasts 
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Figure 19 Distance between reviewers for longitudinal contrasts 
6.2.2.2 Consensus measure 
• Exact 
. 1 category 
• 2 categories 
. 3 categories 
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• 6 categories 
The average consensus score was 0.90 for the cross-sectional contrasts and 
0.87 for the longitudinal contrasts (Table 39). The examples I showed in the Methods 
chapter (Table 13) show that a value of around 0.9 is achieved when the reviewers 
weighted averages are in adjacent categories. Summarising across expert size classes 
(Table 40) shows that the highest agreement is for cross-sectional contrasts is for the 
trivial differences (even removing those not actually sent for review). For the 
longitudinal contrasts the consensus is similar regardless of the expert size class 
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(Table 41). The consensus scores were also summarised by subscale (data not 
shown) but there were no noticeable differences across subscales. 
Table 39 Consensus score by contrast type 
Cross-sectional Longitudinal 
Mean 0.90 0.87 
Median 0.90 0.89 
Standard Deviation 0.09 0.10 
Standard Error 0.00 0.00 
Max 1.00 1.00 
Min 0.35 0.43 
N 4215 3397 
Table 40 Consensus score by expert size class (cross-sectional contrasts) 
Trivial Small Medium Large 
Mean 0.94 0.86 0.89 0.93 
Median 1.00 0.89 0.89 0.90 
Standard Deviation 0.08 0.10 0.08 0.05 
Standard Error 0.00 0.00 0.00 0.01 
Max 1.00 1.00 1.00 1.00 
Min 0.36 0.35 0.65 0.89 
N 2034 1696 450 35 
Table 41 Consensus score by expert size class (longitudinal contrasts) 
Deterioration Improvement 
Large Medium Small Trivial Small Medium Large 
Mean 0.90 0.86 0.87 0.89 0.86 0.85 0.89 
Median 0.90 0.89 0.89 0.90 0.89 0.89 0.89 
Standard Deviation 0.00 0.08 0.09 0.10 0.09 0.10 
Standard Error 0.00 0.01 0.00 0.00 0.00 0.01 
Max 0.90 1.00 1.00 1.00 1.00 1.00 0.89 
Min 0.90 0.57 0.43 0.51 0.51 0.65 0.89 
N 2 148 543 1774 850 79 1 
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6.2.2.3 Between-reviewer SO 
The average between-reviewer standard deviation was 0.5 (Table 42) for the 
cross-sectional contrasts and 0.7 for the longitudinal contrasts (Table 43). The 
distribution of the between-reviewer SO was positively skewed for both types of 
contrast (Figure 20 and Figure 21), i.e. the bulk of the values lie to the left of the mean, 
towards zero. Note the proportion of contrasts with zero SO will not be the same as the 
proportion with zero distance between reviewers shown in 6.2.2.1, since the former 
rounds the weighted averages to the nearest size class. 
Table 42 Between-reviewer standard deviation - cross-sectional contrasts 
Subscale 
Mean Median SO SE Max Min N 
AP 0.48 0.36 0.49 0.03 3.04 0.00 249 
CF 0.48 0.35 0.46 0.03 2.12 0.00 294 
CO 0.47 0.35 0.49 0.03 2.09 0.00 228 
01 0.39 0.14 0.49 0.03 1.98 0.00 217 
OY 0.45 0.32 0.49 0.03 2.33 0.00 213 
EF 0.56 0.52 0.45 0.02 2.83 0.00 344 
FA 0.59 0.51 0.49 0.03 3.75 0.00 292 
FI 0.48 0.35 0.52 0.04 2.98 0.00 196 
NV 0.52 0.47 0.48 0.03 1.83 0.00 248 
PA 0.55 0.48 0.54 0.03 3.75 0.00 288 
PF 0.60 0.53 0.47 0.03 2.84 0.00 336 
QL 0.62 0.57 0.45 0.02 2.62 0.00 390 
RF 0.59 0.53 0.44 0.02 2.47 0.00 328 
SF 0.54 0.50 0.44 0.02 2.52 0.00 354 
SL 0.51 0.42 0.49 0.03 2.43 0.00 238 
All 0.53 0.48 0.48 0.01 3.75 0.00 4215 
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Figure 20 Distribution of between-reviewer SD - cross-sectional contrasts 
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Table 43 Between-reviewer standard deviation - longitudinal contrasts 
Subscale Mean Median SO SE Max Min N 
AP 0.71 0.64 0.54 0.04 2.37 0.00 199 
CF 0.57 0.49 0.51 0.03 2.62 0.00 231 
CO 0.52 0.42 0.48 0.04 1.98 0.00 175 
01 0.47 0.40 0.46 0.03 1.91 0.00 176 
DY 0.58 0.50 0.45 0.03 1.67 0.00 177 
EF 0.74 0.64 0.52 0.03 2.83 0.00 267 
FA 0.78 0.76 0.49 0.03 2.62 0.00 268 
FI 0.58 0.50 0.56 0.05 2.67 0.00 130 
NV 0.66 0.63 0.48 0.03 2.55 0.00 215 
PA 0.72 0.67 0.47 0.03 2.37 0.00 230 
PF 0.80 0.71 0.50 0.03 2.69 0.00 284 
QL 0.86 0.78 0.55 0.03 2.83 0.00 304 
RF 0.79 0.65 0.51 0.03 2.62 0.00 263 
SF 0.75 0.67 0.51 0.03 2.62 0.00 279 
SL 0.60 0.57 0.42 0.03 1.74 0.00 199 
All 0.70 0.64 0.51 0.01 2.83 0.00 3397 
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Figure 21 Distribution of between-reviewer SO - longitudinal contrasts 
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6.2.2.4 A note on ICCs 
The ICCs were planned in order to use a familiar measure to assess the 
concordance. However, there is an issue with ICCs when the scale of measurement is 
small. This is discussed further in light of the ICC results below. 
ICCs are displayed for the cross-sectional and longitudinal contrasts separately 
(Table 44) and for each subscale. ICCs for the cross-sectional contrasts ranged from 
0.18 (FI subscale) to 0.6 (PF subscale). CO, 01 and FI have ICCs less than 0.4 ('poor' 
agreement). The remaining subscales would be considered 'fair' agreement, with the 
exception of PF which falls in the category of 'good' agreement. 
ICCs for the longitudinal contrasts were generally lower, ranging from 0.06 (FI 
subscale) to 0.37 (NV subscale). All subscales would be considered as 'poor' 
agreement. 
The implication of the ICCs seems to be at odds with that from the consensus 
scores and the high proportion of contrasts we found to have either perfect agreement 
or maximum differences of only one size class. This is an issue with using ICC. The 
ICC is dependent on the range of the measurement(88), the greater the variation in the 
measurement, the greater the ICC. Here we were only measuring on a scale of -3 to 3 
(and the extremes of the scale were rarely used by reviewers so in reality the scale is 
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even smaller). Therefore our ICCs look very small when in fact we know that the 
agreement is much better than the ICC might imply. 
Table 44 ICCs for the full dataset - by subscale and comparison type 
Subscale Cross-sectional contrasts Longitudinal contrasts 
ICC (no of contrasts) ICC (no of contrasts) 
AP 0.48 (249) 0.20 (199) 
CF 0.50 (294) 0.16(231) 
CO 0.35 (228) 0.31 (175) 
DI 0.23 (217) 0.34 (176) 
DV 0.43 (213) 0.20 (177) 
EF 0.56 (344) 0.23 (267) 
FA 0.55 (292) 0.35 (268) 
FI 0.18 (196) 0.06 (130) 
NV 0.41 (248) 0.37 (215) 
PA 0.50 (288) 0.28 (230) 
PF 0.60 (336) 0.30 (284) 
QL 0.57 (390) 0.25 (304) 
RF 0.57 (328) 0.30 (263) 
SF 0.58 (354) 0.30 (279) 
SL 0.41 (238) 0.28 (199) 
6.2.3 Factors affecting concordance 
The SDbetween as defined in section 4.4.3.4.2 was used as the outcome variable to 
investigate which factors may be associated with improved concordance. Note that a 
high SDbetween indicates more discordance and a low SDbetween indicates better 
concordance. 
Boxplots were used initially to visualise how SDbetween varied across the categories 
of each factor. The box plots use a '+' symbol to indicate the mean and a line across the 
box for the median value. The box represents the inter-quartile range and the whiskers 
represent the minimum and maximum values. See Table 14 for the key to the 
abbreviated labels in the plots. 
Tables were used to show the results from mixed models used to investigate the 
significance of each factor. In the table, an estimate with a '+' sign this indicates a 
higher SDbetween (more discordance) compared with the reference category for that 
factor, whereas a '-' sign indicates a lower SDbetween or better concordance. 
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6.2.3.1 Factors affecting concordance (cross-sectional contrasts) 
Each factor is discussed below. Boxplots showing the distribution of SDbetween for 
each level of the factors can be found in Figure 22 to Figure 27. The results from the 
mixed models can be found in Table 45. 
For the study design factor phase III RCTs were used as the reference category 
and all other designs compared to the concordance for the contrasts from phase III 
studies. Contrasts from the cohort studies were the only contrasts varying significantly 
from the phase III contrasts in terms of concordance. The cohort contrasts had 
significantly more discordance (p<O.0001). 
For the disease factor, breast cancer was chosen as the reference category and 
all other cancer types compared to contrasts from breast cancer studies. A number of 
the other cancer types differed significantly from breast cancer with respect to 
concordance. Lung, mixed cancer types and testicular cancer were similar to breast 
cancer. Brain, colorectal, GI, H&N and prostate had significantly higher discordance 
(p<O.0001 to p=O.0027). Haematology and urology/kidney had significantly better 
concordance (p=O.0008 and p<O.0001 respectively). 
The types of anchor all differed significantly from the reference category 
(treatment-related anchors), all with increased discordance (p<O.0001 to p=O.01). Time 
related anchors (e.g. contrasts such as; active treatment group versus follow-up group, 
<1yr post BMT versus >1yr post BMT) had the worst concordance. 
Contrasts of patients with a mix of early and late disease stage had significantly 
higher discordance compared to those contrasts from early disease patients 
(p<O.0001). Contrasts from late disease stage patients also had slightly higher 
discordance than the early stage contrasts (p=O.01 ). 
There were a number of contrasts where the timing of the comparison could not 
be identified from the full article. These contrasts with unknown timing had significantly 
higher discordance when compared with the contrasts at baseline (p<O.0001). There 
was no difference in concordance when comparing the baseline contrasts with 
contrasts post-baseline (p=O.03). 
Where an anchor was considered to be well-known the concordance was highest. 
For contrasts we considered to be known to some experts but unfamiliar to others 
(variable) and for contrasts where we were unsure of their relevance there was 
significantly higher discordance (p<O.001). 
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Figure 22 Between-reviewer SO by study design 
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Figure 23 Between-reviewer SO by cancer type 
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Figure 24 Between-reviewer SO by category of anchor 
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Figure 25 Between-reviewer SO by timing of contrast 
-
4.00 
ID 
U 
C 
ro 
"0 
~ 
0 3.00 u 
c 
0 
U 
-0 
if) 2.00 ~ 
ID 
~ 
ID 
·5 
ID 
~ 
I 1.00 c 
ID 
ID 
~ 
ID 
CD 
0.00 
Baseline NS Other 
- 152 -
Figure 26 Between-reviewer SO by strength of anchor 
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Figure 27 Between-reviewer SO by disease stage 
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Table 45 Factors affecting concordance (cross-sectional contrasts) 
Factor Level Estimate SE p-value 
Study design RCT Phase III 0.42 0.13 0.001 
Cohort +0.17 0.02 <0.0001 
RCT Phase II -0.15 0.12 0.21 
Multiple studies +0.06 0.04 0.11 
Cancer type Breast 0.55 0.19 0.003 
Brain +0.14 0.05 0.003 
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Factor Level Estimate SE p-value 
Colorectal +0.15 0.03 <0.0001 
GI +0.16 0.05 0.0009 
Haem -0.09 0.03 0.0008 
H&N +0.14 0.03 <0.0001 
Lung +0.02 0.02 0.42 
Mixed +0.01 0.03 0.62 
Prostate +0.20 0.03 <0.0001 
Testicular -0.07 0.05 0.16 
Urology -0.25 0.06 <0.0001 
Anchor category Treatment 1.45 0.12 <0.0001 
Disease +0.25 0.02 <0.0001 
Patient +0.11 0.02 <0.0001 
Physical +0.12 0.03 <0.0001 
Symptom +0.11 0.04 0.002 
Time +0.29 0.05 <0.0001 
Survival +0.19 0.08 0.01 
Disease stage Early 0.55 0.03 <0.0001 
Late +0.05 0.02 0.01 
Mixed +0.11 0.02 <0.0001 
Timing of contrast Baseline 0.49 0.03 <0.0001 
Not specified +0.14 0.02 <0.0001 
Post-baseline -0.05 0.02 0.03 
Strength of anchor Known 0.78 0.05 <0.0001 
Variable +0.13 0.04 0.0004 
Unknown +0.18 0.03 <0.0001 
6.2.3.2 Factors affecting concordance (longitudinal contrasts) 
The factors investigated here differed slightly from those investigated for the 
cross-sectional contrasts. The anchor-related factors are not relevant for the contrasts 
over time (since the anchor here is time). Factors looking at the timing of the second 
time point and the dropout over time were relevant here but were not for the cross-
sectional contrasts. Boxplots or scatterplots used initially to visualise how SDbetween 
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varied across the levels of each factor can be found from Figure 28 to Figure 31. The 
results from the mixed models are discussed below and summarised in Table 46. 
The boxplot of SDbetween by study design shows some variation in concordance 
across the designs. Contrasts from the cohort studies and articles containing multiple 
studies had significantly increased discordance compared with the RCT Phase III 
contrasts (p<0.0001). All other study designs had similar concordance to the Phase III 
randomised studies. 
Breast cancer was used as the reference cancer type. Colorectal, haematology, 
H&N and testicular cancer papers had significantly higher discordance (p<0.0001) than 
breast cancer. GI and urology/kidney papers had significantly better concordance 
compared to breast cancer (p<0.0001). Contrasts from the other cancer types were 
similar to the breast cancer contrasts with respect to concordance. 
The timing of the second time point ranged from 4 days up to a maximum of 60 
months post baseline, with the majority of contrasts being within a year of the baseline. 
The scatterplot showing timing of the second time point against SDbetween does not show 
any trend for a change in concordance as the distance between time 1 and time 2 
increases (p=0.2). 
The distribution of the percentage dropout from time 1 to time 2 shows that a few 
contrasts have more patients at the second time than at the baseline point. These are 
where there were missing baseline values but subsequent data is reported. The widest 
range of values for SDbetween was seen where there was no dropout. The mixed model 
indicates that SDbetween reduces as the dropouts increase (Le. concordance improves) 
which would be the opposite trend to that expected. The slope however is very shallow 
(a reduction in SDbetween of 0.002 per month decrease between time 1 and time 2) and 
the significance may simply be due to the large sample size rather than indicating a 
relevant change in concordance. 
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Figure 28 Between-reviewer SO by study design 
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Figure 29 Between-reviewer SO by cancer type 
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Figure 30 Between-reviewer SO by timing of second time point 
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Figure 31 Between-reviewer SO by percentage dropout 
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Table 46 Factors affecting concordance (longitudinal contrasts) 
Factor Level Estimate SE p-value 
Study design RCT Phase III 1.01 0.15 <0.0001 
Cohort +0.08 0.02 <0.0001 
RCT Phase 11 -0.07 0.06 0.29 
Non-randomised -0.10 0.09 0.28 
phase I 
Multiple studies +0.30 0.05 <0.0001 
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Factor Level Estimate SE p-value 
Cancer type Breast 1.08 0.25 <0.0001 
Brain -0.003 0.06 0.96 
Colorectal +0.25 0.03 <0.0001 
GI -0.21 0.05 <0.0001 
Gynae -0.11 0.13 0.40 
Haem +0.09 0.04 0.04 
H&N +0.42 0.03 <0.0001 
Lung -0.04 0.03 0.17 
Mixed +0.02 0.03 0.58 
Prostate -0.009 0.04 0.82 
Testicular +0.44 0.05 <0.0001 
Urology -0.33 0.07 <0.0001 
Timing of second Intercept 0.66 0.02 <0.0001 
assessment Slope 0.0012 0.001 0.21 
% dropout Intercept 0.67 0.02 <0.0001 
Slope -0.002 0.0004 <0.0001 
6.2.4 Uncertainty in reviewers scores 
6.2.4.1 Average number of categories used by reviewers 
Table 47 shows the median and range of the number of categories used (which is 
first averaged for each contrast across the two or three reviewers). On average the 
reviewers used two categories for their review of longitudinal contrasts and slightly less 
(1.7) for their review of the cross-sectional contrasts. There were not major differences 
across subscales (1.5 to 2.0). Across cancer types the haematological and lung 
reviewers used a higher number of categories on average. Across study designs the 
non-randomised phase 11 studies were associated with the highest average. 
Table 47 Number of categories used (RCT baseline contrasts excluded) 
CONTRAST TYPE I ~Cross·seCtiona~1 ~T--iongitudinai~- OVERALL 
O~RALL- ___ 1 :~·~~:51~o[~~·;.{M~O 1 Mi;{Media;J_M~f~no 
SUBSCALE i 1.7! 4.0: 1.0 I 2.0 I 4.5 i 1.0 I 1.7 i 4.51 1.0 
__________ __ "_---....L _______ --L-. _____ .J. ____ ~ __ ~ _________ '-----__ . __ l ____ .1. ____ •• _____ •• .-..1.-
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I CONTRAST TYPE 
r--Cr-oss.sectional-------LongitudInal--
I OVERALL 
____ iMedia~fMax I M_ in Medlan-- _ Max Min _ ~edian__ Max Min 
AP i 
---------------+----- --~e-----l---___,-=- ---1------ ----l--------+------l CF : 1.7 4.0 1.0 1.7 4.0 1.0 1.7 4.0 1.0 
------ ------+- - _ -c-c- __ 
CO I _ 1.51 4.0 1.0 _~ 3.5 1.0 1.7 4.0 1.0 
01 I 1.5 3.5 1.0 1.7 4.5 1.0 1.7 .fs--1]f 
I DY i 1.7 4.0 1.0 2.0 4.0 1.0 
I--------------+--=-c-+-~ 
EF 1 2.0 4.0 1.0 2.0 5.0 1.0 
FA i 2.0 4.0 1.0 2.0 4.0 1.0 
1.7 
2.0 
4.0 
5.0 
1.0 
1.0 
2.0 4.0 1.0 
Fr-------+! - 1.7 3.5 1.0 1.7 3.5 1.0 -T.f1---3-.5+-~1.--40 e----------~I---_~_~-~---~-
NV I 1.7. 4.0 1.0 2.0 4.5 1.0 1.7 4.5 1.0 
PA : 1.7 4.0 1.0 2.0 3.5 1.0 2.0 4.0 1.0 
~-- ! 2.0 I 4.0 1.0 2.0 4.5 1.0 2.0 4.5 1.0 
QL 1 2.0 _4c-._0-c+-_1:--:c.0+--_-c:-2.-:-'0 I--- 4.51 1.0 2.0 4.5 1.0 
_RF ________ -t-i ____ 2·hO_-I--_1_.0-l-_____ ~ _ ___,5--=-.0+---~1-c-.3+__--2-.0+__-5-.0+____,_1.~0 
SF I 2.0 , 4.0 1.0 2.0 4.0 1.0 2.0 4.0 1.0 
~--------~--~--,--~-~+----~+-~+---+---~-I-----
SL : 1.7 4.5 1.0 1.7 4.0 1.0 1.7 4.5 1.0 
CANCER TYPE I 
Brain 
Breast 
Colorectal 
GI 
Gynaecological 
Haematological 
Head and neck 
Lung 
Mixed 
Prostate 
I 1.7 3.0 
1.7 3.3 
1.3 3.0 
1.5 3.5 
1.0 
1.0 
1.0 
1.0 
2.5 4.5 1.0 
1.5 2.3 1.0 
2.3 3.7 1.0 
2.0 3.0 1.0 
1.7 2.7 1.0 
2.0 3.3 1.0 2.0 3.3 1.0 
1.7 3.3 1.0 1.7 3.3 1.0 
1.7 3.5 1.0 1.5 3.5 1.0 
1.7 3.5 1.0 1.5 3.5 1.0 
2.0 2.5 1.0 2.0 2.5 1.0 
2.7 5.0 1.5 2.5 5.0 1.0 
1.7 2.5 1.0 1.7 2.5 1.0 
2.3 3.7 1.0 2.3 3.7 1.0 
2.0 3.5 1.0 2.0 3.5 1.0 
2.0 2.7 1.0 1.7 2.7 1.0 
Testicular 1.5 3.0 1.0 1.5 3.0 1.0 1.5 3.0 1.0 
Urology/Kidney 1.0 2.7 1.0 2.0 I 3.5 1.5 1.5 _ 3.5 1.0 
STUDY DESIGN --I---t -t-i---t------~-?,~~rt __ - -1_mH1~ ~ 1.0 20[501 ~20 501 1.0 
Multiple T 2~ 3.0 I 1 ~ 1.:1 3.0 LI 1.3: 1.7 3.0 I 1.0 
---------_-----L__ ----~- --__ ._ '_ ---~- .. -----~ __ --L __ _ 
- 159-
I CONTRAST TYPE 
r -- - Cross-sectlonal-- -l~---LOngTtudinal--~ OVERALL 
~ -MeciiiniMai-~ MiniMedian -Max; Min! Median-] MIX] r.tin. 
- -- -- --- -~---l- -- -l- I I -----1-- -- -- - -~ 
Non-randomised, ,I 
Phase_l ___ . _____ ~'-----+--~TI---~~--~~~~--2~t---2! t-~1·7 ____ ~~~ 
Non-randomlsed i I I I! I 
~~~~I _______ ~ ____ . i . -·1 2.7 3.0 1.7 2.71~ _~ ~CT~ : 1.5! 2.0 1.0 i 1.8 3.5 1.0 -17\3.5 1.0 
RCT~__ I 2.0 I 4.5
1 
1.0 I 2.0 4.0 1.0 ~- 4.5 1.0 
6.2.4.2 Peak weighting used by reviewers 
Table 48 shows the median and range of the peak weighting used (which is first 
averaged for each contrast across the two or three reviewers). The overall average is 
high (80%), with longitudinal contrasts having a slightly lower average peak (75%) 
compared with the cross-sectional contrasts (80%). Across subscales the average 
peak ranged from 72.5% to 90.0%. The subscale with the highest average peak was 01 
and the lowest average was PF. The average peak varied more across cancer types, 
with haematological contrasts having the lowest average of 60.0% compared to the 
highest average of 100% for the testicular contrasts. Across study designs the average 
ranged from 57.5% for non-randomised phase 11 studies up to 90.0% for the 
randomised phase 11 studies. 
Table 48 Peak weighting (RCT baseline contrasts excluded) 
! CONTRAST TYPE 
r- Cross-sectional __ ~g_itu_d_l_n~a~1 __ -+ ____ ._?'!_ERA~L_L,______j 
h"edian Max Min Median Max Min Median Max Min 
'oV~E-=-RAC-:-L-'--L~~-t----8D.O -100.0 -3=0C-:.0-+----=7=5 .-=-0 t--:-1 O=-=Oc-.:. 0-+---:3=0. --c: 0+----=76=-=.7::+---:-:1 O=-=-O .-=-0 +-----:C3-=-0 .-::-l0 
~-----------~-----~~--~----+---~-~-
SUBSCALE 
f-Ap 83.3 100.0 37.5 76.7 100.0 42.0 80.0 100.0 37.5 
~ __ - 83.3
1 
1 oo~_ 35.0 . 83~~ 10~ ~O . ~3, 100.0 35.0 
~? 1 _~~~O.O l- 35.0 __ ,~_~ 5~~~~_~_~~ _ 35.~ 
~ __ --------L-~ 100.0 L~~ __ 83.3 100.0 45.0 86.7 100.0. 3~~ 
DY__ I_~::~ 1100~350 80.0 100.~ 433 _ 83~ 100.0~0 
~-------_-~t-I _~~, ~~~t_35.0t' 75·~1_100~Ot 3°~1_~~:Oi_30~ 
FA 75.0 I 100.0 i 35.0 73.3
1 
100.0 i 40.0 75.0L100.0 I 35.0 
_____ ~ ___ ... ______ J _________ J ___ . ___ .L ____ . _______ 1.. _____ .1 __ _. __ ___ L __ 
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CONTRAST TYPE I 
I -Cross:section~al---' -- Longitudinal -- l OVERALL 
-----
FI 
--- - ._-
NV 
PA~_~_ - -1-~~-80'~i 100.0 I 35.01 _~~. 100.0 46.7 - 76.7 ~_100.0 35~~ 
PF i 75.0 I 100.0 I 40.0 72.5 100.0 40.0 75.0 100.0 40.0 
--- ~----- I __ 
QL : 75.0 ~ 100.0 40.0 73.3 100.0 34.5 75.0 100.0 34.5 
RF_~~~~ __ ~Lu-75.0i 100.01 4O.oj 75.0 97.5 35.0 75.0, ~~Ol ~! 
~ __ ~ ; 76.7 1 100.0 i 37.5 75.0 100.0 40.0L 75.0 100.0 I 37-= 
SL 1 83.3! 100.01 30.0 80.0 100.0 37.51 83.3 100.0 I 30.0 
CANCER TYPE I T _n --- -~-~+-~+---t--~ 
---- ----- ---_J I I I I 
Brain_ ___ i 76.7
1 
100.0 58.3 83.3 100.0~~3.~ 80.0 100.0 53.3 
~~e:~t_ i 80.0+_100.0 48.3 76.7 100.0 _SO.~ 76.7 100.0 48.3 
Colorectal I 90.0 I 100.0 60.0 83.3 100.0 45.0 I 85.0 100.0 45.0 GI---~--~-- f- -80.0 I 100.0 37.5 75.0 100.0 I 34.5 [ 75.0 100.0 34.5 
GynaecOlogiCal-: . : 75.0 100.0 T 75-.or-75.0 100.0 75.0 
Haemato\09lc8l-T-70.a:100.0 30.0 60.0 97.51 30.0 I 67.5 100.0 30.0 
Head and neck I 83.3 100.0 56.7 83.3 100.0 50.0 I 83.3 100.0 50.0 
Lung----~--- : 70.0 100.0 43.3 66.7 100.0 40.0 70.0 100.0 40~O 
-----_. ! - - ~ 
Mixed I 78.8 100.0 45.0 75.0 100.0 57.5 75.8 100.0 45.0 
I-------------T-----=-=--:+-~~:=-::-t--___: 
Prostate 1 80.0 100.0 50.0 75.0 100.0 50.0 79.2 100.0 50.0 
Testicular I 82.5 100.0 50.0 95.0 100.0 50.0· 90.0 100.0 50]) 
ITrOlQgy/Kidney I- 100.0 100.0 61.7 75.0 95.0 45.0 87.5 100.0 45.0 
STUDY DESIGN -- ----
COhorf---- =-1- 80.0 100.0 43.3 75.0 100.0 30.0 76.7 100.0 30.0 
~~:::~-=i- 75.0 100.0 55.0 75.0 93S -55]): - 7~:~+ 10~0 55.0 
~hase_1 I --~l----1---' ~~e--8~2c--66.7 80.0 83.3 66.7 
Non-randomised -1- I I 
Phase 11 • . I • --~l- 57.5 83.3 45.0 I 57.5 83.3 45.0 
,'leT 11_= --1 90.1 100] i --:1-__ ~~?tf-jOO{ 3451_ 75~~100~ ~ ~~_!_I_II I SO.Ol 100])1 30.0 I _!O.O 100.0 I 35.0taoo _ 100~L 300 
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6.2.4.3 Within-reviewer SO 
The average uncertainty (as measured by the within-reviewer SO) was 0.41 for 
the cross-sectional and 0.46 for the longitudinal contrasts. Uncertainty was consistently 
worse across all subscales for the longitudinal contrasts although some of the 
differences were relatively small. 
Table 49 Within-reviewer standard deviation (uncertainty) 
Cross-sectional Longitudinal 
, c_;~ .. n i MOiIlanF\ SE I Maltn 'N'r.ean Media"-SDJSf Mu Min IN -
S~bscale T I I i I 
~P ___ ~i _~~L_~·_~71 0.24 1 0.02 1.04 0.00 I 249 0.45 0.43 0.23 0.02 1.13 0.00 199 
~~ ___ J 0.38 1 0.35 i 0.24 1 O.O~}~.OO 1 294 0.39 0.37 0.19 0.01 0.99 0,00 231 
~o _ _ _~ _ ~,32+-~~~.26 : 0,02
1
1, 11[ 0.00 228 f- 0,32 _ 0,32 0.2310,02 0,90 0,00 175 
01 I 0,26 i 0,24! 0.22 t 0,02
1 
1.04 1 0.00 217! 0~33 0,29 0,24 0.02 1.09 0,00 176 
DY -- - I 0,35: 0,32 1
1
0.25 fO.02 i 1.17 i 0,00 I 213 0,43 -0,41 0.-25 0,021 0.95 0,00 177 
- -- ! -i t I I -, - .--c+-c=----=-=-+-:::-==i :F_ I 0,45 i 0.44: 0,24 I 0.01\1,15 1 0.00 I 344 0.47 0,45 0.21 0,01 1.41 0,00 267 
:A _: ~.:: I 046 : 0.231 0 01 h·15 1 0.00 1 2921 0.53 0.49 0.20 0.01 1.06 0.00 268 
FI . 0,32
1 
0,29: 0,22 i 0.02 1.04 i 0,00 I 196 I 0.36 0.32 1 0.21 10.02 1.06 0,00 130 
NV~----r- 0.37! . 0.351 0.2410.02 1.04 6.0024at 0.43 0.43 [ 0.211 0~01 . 0.98 0,00 215 
PA--~! -0.43\ 0.41 0,24 0.01 1.18
1 
0.00 288 0.46 0.45 0,2110.01 0.95 0,00 230 
~PF---l--0.49 0.4810.22 0,01 1.07 0,00 336 0.52 - 0.53 0,21 0.01 1.07 0,00 284 
01.--1 0,48 0.49 0.22 0.01 1.09 0,00 390 0.54 0,53 0.22 0.01 1.17 0,00 --304 
-.----+---+-------:-----:=+--;:-;::-::+:-----::-:-f--:--:=+=-=+--::-::-::+---::---:-::--t------=---:c-::-+-:--:-::-+-::--::-:-t----:---=-c::-+-::---:--:-Ir------::-c:-::-i RF I 0.48 0.47 0.22 0,01 1.02 0,00 328 0.49 0.46 0.19 0.01 1.28 0,14 263 
i 
0.47 0.19 0.01 1.14 0,00 279 rsF I 0.45 0.45 I 0.23 0.01 1.04 0,00 354 0,50 
SL 1 0.38--- 0,35 0.23 0,02 1.20 0,00 238 f--6:-.-4-:-:1·+----=--=+::-:::-:-~·~c-:-:-l--=----=--=+--:-:-:-l 
A"-~1 0.41 0.24 0.00 1,20 0.00 4215 0.46 
0.40 O,~11 0.02 1.11 0,00 199 
0.44 0,22 i 0,00 1.41 0,00 3397 
6.2.5 Factors affecting uncertainty 
The SOwilhin as defined in section 4.4.3.4.3 was used as the outcome variable to 
investigate which factors may be associated with greater uncertainty. Note that a high 
SOwilhin indicates more uncertainty and a low SOwilhin indicates more certainty. 
Boxplots were used initially to visualise how SOwilhin varied across the categories 
of each factor. The boxplots use a '+' symbol to indicate the mean and a line across the 
box for the median value. The box represents the inter-quartile range and the whiskers 
represent the minimum and maximum values. 
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Tables were used to show the results from mixed models used to investigate the 
significance of each factor. In the table, an estimate with a '+' sign this indicates a 
higher SDwithin (more uncertainty) compared with the reference category for that factor, 
whereas a '-' sign indicates a lower SDwithin or greater certainty. 
6.2.5.1 Factors affecting uncertainty (cross-sectional contrasts) 
Figure 32 to Figure 37 show how uncertainty (as measured by the within-reviewer 
SD) varied across levels of the factors. Table 50 summarises the results from the 
mixed models. There were some levels in each of the factors with significantly different 
levels of uncertainty to the chosen reference levels. 
In terms of study design only the cohort studies differed significantly from the 
RCT Phase III studies (p<0.0001), with more uncertainty for the contrasts from cohort 
studies. 
The boxplot shows there was considerable variation in uncertainty across cancer 
types. Haematology, prostate and lung cancer contrasts had Significantly more 
uncertainty than breast cancer (p<0.0001). Colorectal, H&N, testicular and 
urology/kidney contrasts had significantly less uncertainty than the breast cancer 
contrasts (p<0.0001). 
For the anchor types, all categories had higher uncertainty than the treatment-
related anchors. This increase was significant for all except the survival category 
(p<0.0001 for disease, patient, physical, symptom and time-related anchors). 
The contrasts from patients with late stage disease had significantly less 
uncertainty than those from early stage disease «0.0001). Contrasts from early stage 
patients and a mixture of early and late stage patients were similar in terms of 
uncertainty. 
Baseline contrasts had the lowest uncertainty. Contrasts at other points in time 
and those where the timing was not clear from the full article had higher uncertainty 
(p<0.0001 ). 
Anchors with an unknown link to aOL had significantly higher uncertainty than the 
known anchors (p=0.0007). However, the anchors we classed as 'variable' had 
significantly less uncertainty than the known anchors (p=0.0003). 
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Figure 32 Within-reviewer SO by study design 
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Figure 33 Within-reviewer SO by cancer type 
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Figure 34 Within-reviewer SO by category of anchor 
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Figure 35 Within-reviewer SO by timing of contrast 
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Figure 36 Within-reviewer SO by strength of anchor 
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Figure 37 Within-reviewer SO by disease stage 
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Table 50 Factors affecting uncertainty (cross-sectional contrasts) 
Factor Level Estimate SE p-value 
Study design RCT Phase I11 0 .36 0.07 <0.001 
Cohort +0.06 0.01 <0.001 
RCT Phase 11 -0.06 0.06 0.33 
Multiple studies +0.04 0.02 0.09 
Cancer type Breast 0.07 0.09 0.46 
Brain -0 .04 0.02 0.1 2 
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Factor Level Estimate SE p-value 
Colorectal -0.13 0.02 <0.001 
GI -0.01 0.02 0.80 
Haem +0.21 0.01 <0.001 
H&N -0.09 0.01 <0.001 
Lung +0.07 0.01 <0.001 
Mixed -0.01 0.01 0.45 
Prostate +0.04 0.01 0.006 
Testicular -0.09 0.02 <0.001 
Urology -0.23 0.03 <0.001 
Anchor category Treatment 1.11 0.06 <0.001 
Disease +0.11 0.01 <0.001 
Patient +0.09 0.01 <0.001 
Physical +0.18 0.01 <0.001 
Symptom +0.20 0.02 <0.001 
Time +0.13 0.03 <0.001 
Survival +0.07 0.04 0.07 
Disease stage Early 0.30 0.01 <0.001 
Late -0.08 0.01 <0.001 
Mixed -0.001 0.01 0.87 
Timing of contrast Baseline 0.49 0.01 <0.001 
Not specified +0.13 0.01 <0.001 
Post-baseline +0.08 0.01 <0.001 
Strength of anchor Known 0.34 0.03 <0.001 
Variable -0.07 0.02 0.003 
Unknown +0.06 0.02 0.007 
6.2.5.2 Factors affecting uncertainty (longitudinal contrasts) 
Figure 38 to Figure 41 show how uncertainty (as measured by the within-reviewer 
SO) varied across levels of the factors. Table 51 summarises the results from the 
mixed models. The boxplots show considerable variation in uncertainty for study 
designs and cancer types. The scatterplots do not show any clear trends for an 
increase or decrease in uncertainty as the second time point gets later or the dropout 
increases. 
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Contrasts from cohort studies and from phase 11 studies (both randomised and 
non-randomised) had Significantly higher uncertainty than the Phase III RCTs 
(p<O.0001 to p=0.002). The other study designs did not differ significantly with respect 
to uncertainty from the Phase III RCTs. 
Colorectal , H&N and testicular cancer sites had less uncertainty than the breast 
cancer contrasts (p<0.0001). Haematology, lung, prostate and urology/kidney had 
significantly more uncertainty (p<0.0001 to 0.0005). 
The results from the mixed models indicated that there was a decrease in 
uncertainty as the timing of the second time point increased from baseline (p<0.0001) 
and as the percentage dropout increased (p<0.0001). However, the slope in both 
models is very shallow and the statistical significance may be a result of the high 
numbers of contrasts rather than indicating relevant changes in uncertainty. 
Figure 38 Within-reviewer SO by study design 
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Figure 39 Within-reviewer SO by cancer type 
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Figure 40 Within-reviewer SO by timing of second time point 
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Figure 41 Within-reviewer SO by percentage dropout 
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Table 51 Factors affecting uncertainty (longitudinal contrasts) 
Factor Level Estimate SE p-value 
Study design RCT Phase III 0.75 0.07 <0.001 
Cohort +0.07 0.01 <0.001 
RCT Phase 11 +0 .09 0.03 0.002 
Non-randomised -0.08 0.04 0.05 
phase I 
Non-randomised +0.31 0.03 <0.001 
phase II 
Multiple studies -0.05 0.02 0.02 
Cancer type Breast 0.55 0.1 0 <0.001 
Brain -0.06 0.02 0.02 
Colorectal -0.08 0.01 <0.001 
GI -0.001 0.02 0.95 
Gynae -0.13 0.05 0.02 
Haem +0.29 0.02 <0.001 
H&N -0.06 0.01 <0.001 
Lung +0.14 0.01 <0.001 
Mixed 0.00 0.01 0.94 
Prostate +0.05 0.02 0.005 
Testicular -0.16 0.02 <0.001 
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Factor Level Estimate SE p-value 
Urology +0.11 0.03 <0.001 
Timing of second Intercept 0.45 0.01 <0.001 
assessment Slope -0.003 0.0004 <0.001 
% dropout Intercept 0.46 0.007 <0.001 
Slope -0.001 0.0002 <0.001 
6.2.6 Summary and Conclusions 
The cross-sectional contrasts had slightly better correlation with the scores from 
the papers then the longitudinal contrasts. When considering all contrasts together the 
physical functioning and fatigue subscales had the highest correlation between the 
overall opinion from the experts and the actual aOL scores. The financial impact 
subscale had almost zero correlation between the experts and the actual aOL scores 
therefore it is questionable as to whether guidelines for this subscale can realistically 
be developed using this method. 
Some individual reviewers had close to zero or a negative correlation with the 
actual QOL differences. However as these reviewers only reviewed a small number of 
papers the impact on the analysis should be minimal. 
Agreement between reviewers on the same contrast was fairly high, with 76% of 
cross-sectional and 63% of longitudinal contrasts with the maximum distance between 
reviewers of one size class or less. There were less than 10% of contrasts with 
reviewers a distance of more than three categories apart. 
Generally the certainty attached to the reviews was high (with an average of two 
categories used and an average peak weight of 80%). 
All of the factors investigated had some influence on concordance and 
uncertainty. Across cross-sectional and longitudinal contrasts only study design and 
cancer type were the factors relevant to both. In terms of study design, contrasts from 
cohort studies had the worst concordance between reviewers and the highest 
uncertainty. For cancer types, urology/kidney consistently had better concordance and 
uncertainty when compared with breast cancer. The cancer-type factor is confounded 
with reviewer (since there was a subset of reviewers reviewing in each disease area). 
Therefore the observation that cancer site influences both concordance and uncertainty 
may be due to the papers within disease areas, the reviewers who took part in 
reviewing them or a combination of the two. For urology/kidney there were only three 
reviewers so all papers will have been reviewed by the same reviewers and we have 
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shown that they had consistently higher concordance and certainty. Similarly for brain 
cancer there were only three reviewers and two of these had poor correlation with the 
actual QOL scores. Brain cancer was shown to have among the worst concordance 
between the reviewers compared with the other disease types. 
Additionally for the cross-sectional contrasts non-treatment related anchors had 
poorer concordance and higher uncertainty, as did contrasts where the timing was 
unclear from the full article and anchors not considered well-known (Le. strongly 
associated with QOL). For the longitudinal contrasts there were no additional factors 
that consistently affected both concordance and uncertainty. 
There was an indication that concordance may be better when the level of 
dropout is higher. Initially one might expect that judging the expected QOL difference 
may be harder in the presence of dropout. However, it is well known that dropout in 
QOL studies is informative, Le. the patients dropping out are more likely to be the 
sicker patients with poorer QOL. It may have been the case that where attrition was 
higher the experts knew that the subset remaining would have better QOL than those 
dropping out and therefore may actually find the judgments easier thus leading to 
improved concordance between the reviewers. This highlights the importance of 
including the contrasts with high attrition, whereas the EBES project excluded studies 
with high attrition from the project. It may be that these provide important contrasts to 
contribute to the guidelines. 
6.2.7 Exclusion of poor quality contrasts 
As summarised above, the agreement between reviewers and the certainty with 
which the reviewers judged the QOL differences seems high, indicating quality reviews 
for the meta-analysis. The main issue is with correlation between expert scores and the 
score from the original article and this led to a decision to exclude some of the poorer 
quality contrasts from the analysis. 
The scatterplots of mean difference from the original article against the average 
expert score showed that there were a subset of contrasts where the actual mean 
differences between groups was in one direction (e.g. group A better than group B) and 
the expert opinion was in the opposite direction. We could speculate as to why this may 
occur; confusion in assessing direction by the experts, quality of the study the contrast 
belongs to, chance results from the study, small sample size, anchor not closely related 
to QOL, insufficient detail in the original article for experts to base their opinion on 
could all contribute. However, regardless of the reason, grouping contrasts using the 
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expert opinion places the mean difference from these contrasts in a completely 
inappropriate category and therefore we felt the resulting estimates from the meta-
analysis would be unreliable. For example, say a longitudinal contrast had a mean 
difference of 10 points which represented an improvement for patients but the expert 
size class grouped this with other mean differences representing medium 
deteriorations over time. Given a number of these contrasts in the medium 
deterioration size class the estimate from the meta-analysis would be brought closer to 
zero. 
In order to get the best possible estimates from the meta-analysis it was clear that 
contrasts with this particular issue should be excluded. The dataset may still contain 
other data where the relationship between average expert score and actual mean 
difference was possibly incorrect (such as contrasts with a medium expert size class 
and actually a zero mean difference for example). However, there is no way to exclude 
contrasts of this nature without making an assumption about the very size of 
differences we were trying to estimate. Assuming there are errors of this nature at both 
ends of the range (i.e. very low scores and very high scores placed in the size class) 
then the use of the mean estimate should be able to allow for this. 
I had originally planned a sensitivity analysis excluding the reviewers with 
negative or close to zero correlation. However, by excluding the poor quality contrasts 
defined in this way those specific reviewers no longer contributed to the analysis 
anyway. 
This exclusion criterion only applies to the contrasts placed in the small, medium 
and large categories by the expert review. The contrasts placed in the trivial size class 
do not have the same concept of direction (in theory they should be differences that 
have some variation around zero) therefore one cannot exclude any based on 
discrepancies in direction between the papers and experts. The trivial differences 
therefore had to be treated in a slightly different way when it came to assessing their 
quality. However, the exclusion criteria had the same aim of excluding only contrasts 
where there was clearly something wrong with either the score in the paper or with the 
expert size class. I thought that the main reason for 'error' in this size class would be 
where contrasts with a likely real difference were placed in the trivial category because 
of averaging across experts. For example, a contrast with two reviewers and individual 
weighted averages of -2 and 2 would be placed in the trivial group as the average of 
the two reviews is zero. However, in reality, this probably represents a contrast with a 
medium sized difference but the reviews showed uncertainty as to which way the 
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difference would be. It was impossible to identify the contrasts with this problem 
because, as we found earlier, it would require making an assumption about a cut-off for 
a meaningful difference. For example, possible scenarios include weighted averages at 
the opposite extremes such as -2 and 2 but also reviews such as 0.5 and -0.1. In order 
to exclude reviews where the direction was unclear we would have to decide which 
were clear errors and which were just variation around the mean. Therefore the 
exclusion criteria for contrasts in the trivial size class was based on obtaining the 
contrasts with the best agreement between reviewers rather than on the direction of the 
scores. This was decided since the completely opposing reviews would have high 
levels of disagreement. Only contrasts where the weighted averages from each 
individual expert placed the contrast in the trivial size class were therefore included in 
the analysis dataset for the trivial size class. Although this is quite harsh as a criterion 
and some genuinely trivial differences are probably being excluded, it avoided 
introducing further subjectivity by having to define a level that represented poor quality 
on one of the agreement measures. 
6.2.8 Correlation, concordance and uncertainty in final analysis 
dataset 
Concordance and uncertainty were not altered much by applying the agreement 
criteria (full details not shown). There were 75% of the cross-sectional contrasts with a 
maximum distance of one category between them and 67% of the longitudinal 
contrasts. This is similar to the full dataset for the cross-sectional contrasts and 
improved slightly in the analysis dataset for the longitudinal contrasts. The median 
number of categories used for reviews was two (as it was for the full dataset). The 
average peak weighting was also similar (77.5% overall). 
The correlation statistics were improved as we would expect since we had 
removed the observations contributing to poor correlation. The graphs of expert 
average score versus mean difference are shown however for comparison with the full 
dataset shown earlier. The trivial differences are now only those where all experts 
agree (hence the average score is 0 and expert average scores between zero and 0.5 
no longer exist). There is still a considerable amount of scatter around the rest of the 
scale but removing the contrasts where experts and the paper disagreed on direction 
means that there is a more positive relationship between the two for both cross-
sectional (Figure 42) and longitudinal contrasts (Figure 43). 
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Figure 42 Expert average scores versus mean difference from papers (cross-
sectional analysis dataset) 
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Figure 43 Expert average scores versus mean difference from papers 
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7 Meta-analysis results and Evidence-Based Interpretation 
Guidelines 
The meta-analysis results and guidelines for the cross-sectional contrasts have 
been published in the Journal of Clinical Oncology (2011). with full reference as 
follows:-
Kim Cocks. Madeleine T. King. Galina Velikova. Marrissa Martyn-St-James. Peter 
M. Fayers and Julia M. Brown. "Evidence-Based Guidelines for the Determination of 
Sample Size and Interpretation of the European Organisation for the Research and 
Treatment of Cancer Quality of Life Questionnaire Core 30" Journal of Clinical 
Oncology (Jan 2011), Number 29, Issue 1, p89-96. 
The results in Section 7.1 are based on this publication but have been re-written 
to include more information on the results from the meta-analysis than could be 
included in the published article. 
7.1 Cross-sectional contrasts 
7.1.1 Number of contrasts 
There were 2212 cross-sectional contrasts in the analysis dataset. Within the 
different subscales this led to a sample size of between 0 and 102 contrast available 
for the estimates of trivial. small. medium and large effects (Table 52). Although the 
initial number of contrasts in the dataset was very large, there were only 30 contrasts 
across all of the subscales which were classed as large differences by the expert 
review process. The number of contrasts was therefore generally too low to reliably 
estimate large effects by subscale (zero to six contrasts) so meta-analyses were not 
carried out for the large size class. There were also fewer than five contrasts for the 
medium size class in the 01 and FI subscales therefore estimates for these were also 
excluded. 
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Table 52 Number of contrasts for estimates of cross-sectional effects 
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7.1.2 Meta-analysis of mean differences 
7.1.2.1 Estimates of random effects 
The random effects and 95% confidence intervals were estimated using the 
residual (restricted) maximum likelihood (REML) method (using SAS® PROC MIXED). 
These were then used in the weighting of the contrasts in the meta-analysis (see 
Section 4.4.2.3 for details). The mean estimate of the random effect was used for the 
main analysis, with sensitivity analyses carried out using the upper and lower 95% 
confidence intervals for the estimate instead. The size of the estimated random effects 
variance gives an indication of the degree of heterogeneity of the mean differences 
across contrasts. The lowest estimate was for the 01 subscale (14.9) and the highest 
estimate of the random effect was for RF (80.0). 
7.1.2.2 Random effects models results 
Table 53 shows the results from the meta-analysis of mean differences from the 
cross-sectional contrasts. The table shows the weighted mean differences from the 
random effects model along with 95% confidence intervals for each expert size class 
within a subscale. 
The results are also shown in a box and whisker plot (Figure 44). There are three 
plots for each subscale, representing trivial, small and medium estimates from left to 
right. An 'X' has been used to show where there is no data to display for a certain size 
class for that subscale. Each subscale is shown with a different plot symbol (see key 
below the graph). 
Most subscales showed clear trends across size classes, with an increase in 
estimates from trivial through to medium. Role functioning showed the widest range 
between the estimates (0, 13 and 25 points for trivial, small and medium size classes 
respectively), while other subscales, such as global quality of life had a smaller range 
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of estimates between trivial and medium size classes (1 , 7 and 13). For the EF, SF, 
CF, CO and DY subscales there was some degree of overlap between the confidence 
intervals for the small and medium size classes. Of particular concern was the EF 
subscale which had a higher estimate for small (8.3) than for the medium size class 
(6 .5). For this reason the subscale was not taken forward to derive the guidelines. (See 
7.4 for further discussion.) Estimates for average trivial effects were at most 1.1 points 
(PF). Estimates for average small effects ranged from 4.7 to 12.7 points (for NV and 
RF subscales respectively). Estimates for average medium effects ranged from 10.1 
(DY) to 25.1 points (RF). 
Note for the trivial size class there were some estimates above and some below 
zero, however all of the confidence intervals span zero as one would expect for this 
category. A negative mean difference estimate means that on average Group 2 was 
worse than Group 1. However, as discussed in Section 4.4.1.2.2, the allocation of 
Group 1 and Group 2 had arbitrary meaning for the majority of contrasts therefore a 
slightly negative or positive mean difference simply means the absolute magnitude of 
the mean differences was slightly different to zero on average. 
Table 53 Estimates for mean difference outcome variable by size category 
(cross-sectional contrasts) 
Subscale Expert Weighted Lower Upper Number 
size effect confidence confidence of 
class size interval interval contrasts 
CF Trivial -0.98 -2.65 0.70 39 
CF Small 7.47 5.82 9.12 97 
CF Medium 10.64 7.19 14.09 54 
EF Trivial -0.54 -2.58 1.49 32 
EF Small 8.30 6.77 9.82 102 
EF Medium 6.50 3.89 9.12 48 
PA Trivial 1.04 -1.31 3.40 40 
PA Small 10.40 8.14 12.66 96 
PA Medium 15.86 12.83 18.89 32 
PF Trivial 1.11 -2.09 4.30 54 
PF Small 9.18 7.41 10.94 91 
PF Medium 19.21 16.58 21.85 33 
QL Trivial 0.63 -1.49 2.75 42 
QL Small 7.33 5.99 8.67 101 
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Subscale Expert Weighted Lower Upper Number 
size effect confidence confidence of 
class size interval interval contrasts 
QL Medium 12.67 10.82 14.52 36 
RF Trivial -0.37 -3.74 2.99 70 
RF Small 12.67 10.58 14.76 74 
RF Medium 25.08 21.26 28.89 19 
SF Trivial -0.67 -3.08 1.74 53 
SF Small 9.78 8.27 11 .29 62 
SF Medium 12.23 9.61 14.84 30 
FA Trivial -0 .14 -2.71 2.44 38 
FA Small 9.48 7.59 11.36 71 
FA Medium 16.02 13.48 18.57 39 
NV Trivial 0.90 -0.61 2.41 58 
NV Small 4.73 3.16 6.30 56 
NV Medium 11.85 8.97 14.73 17 
AP Trivial -0.45 -2.47 1.57 62 
AP Small 10.18 8.05 12.30 56 
AP Medium 18.52 14.20 22.84 14 
CO Trivial -0.16 -2.00 1.67 72 
CO Small 10.56 8.15 12.97 44 
CO Medium 14.73 9.96 19.50 11 
01 Trivial 0.57 -0.49 1.64 96 
01 Small 5.52 3.81 7.24 38 
01 Medium 1* 
DY Trivial 0.05 -1.93 2.03 62 
DY Small 8.06 5.30 10.82 38 
DY Medium 10.08 5.15 15.01 12 
SL Trivial -0.28 -2.21 1.65 47 
SL Small 7.38 5.51 9.25 57 
SL Medium 18.57 12.68 24.45 6 
FI Trivial -0.38 -2.44 1.67 54 
FI Small 6.60 3.68 9.51 25 
FI Medium 3* 
*Slze classes with number of contrasts less than 5 not Included In the gUidelines 
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Figure 44 Estimates for mean difference outcome variable by expert size class (cross-sectional contrasts) 
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7.1.3 Meta-analysis of effect sizes 
7.1.3.1 Estimates of random effects 
The random effects and 95% confidence intervals were estimated using the 
residual (restricted) maximum likelihood (REML) method (using SAS® PROC MIXED). 
The mean estimate of the random effect was used in the weighting of the contrasts in 
the meta-analysis (see Section 4.4.2.3 for details). Note that sensitivity analyses 
regarding the use of the mean random effects variance for the effect size outcome 
variable were not carried out separately from those for the mean difference outcome 
variable. The sensitivity analyses for the mean difference outcome variable should 
indicate the robustness of results compared to using the upper/lower 95% confidence 
limits of the random effects estimates. 
There were problems in estimating the random effects for the effect size outcome 
variable. with models not converging in four of the subscales. This can be caused by 
small numbers within a group. However. even after excluding any size classes with 
very small numbers of contrasts the models still had convergence issues. One of the 
other issues that can cause convergence problems in SAS® PROC MIXED is working 
with small numbers (i.e. where the outcome variable is on a small scale rather than 
number of contrasts being small). Since effect sizes are relatively small numbers (i.e. 
generally less than one) I tried rescaling the effect sizes using a multiplier of 100 in 
order to run the models and then adjusted the results back to the original scale. Note to 
adjust the variances back to the original scale a divisor of (100)(100) was thus required. 
This resolved any problems with convergence and makes no difference to the resulting 
random effect estimates. 
The size of the estimated random effects variance gives an indication of the 
degree of heterogeneity of the effect sizes across contrasts. As would be expected. the 
observations made on the mean difference outcome variable also held true here, i.e. 
that 01 had the lowest estimate of random effects variance (0.05) and RF had the 
highest (0.39). 
7.1.3.2 Results from random effects models 
Table 54 shows the results from the meta-analysis of effect sizes from the cross-
sectional contrasts. The table shows the weighted effect sizes from the random effects 
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models along with 95% confidence intervals for each expert size class within a 
subscale. 
The results are also shown in a box and whisker plot (Figure 45). There are three 
plots for each subscale, representing trivial , small and medium estimates from left to 
right. Each subscale is shown with a different plot symbol (see key below the graph). 
Within most subscales the increase in estimates was clear from trivial through to 
medium size classes. Role functioning had the widest range of estimates from zero for 
trivial , 0.5 for small and 0.8 for medium. The QL subscale in comparison had a much 
smaller range (although the confidence intervals do not overlap between the size 
classes) with zero for trivial , 0.3 for small and 0.5 for medium size classes. Confidence 
intervals for the small and medium estimates were overlapping for EF, SF, CF, CO and 
DY subscales . EF also had a higher estimate for the small size class than for the 
medium size class so was excluded from the guidelines. 
Table 54 Estimates for effect size outcome variable by expert size class (cross-
sectional contrasts) 
Subscale Expert Weighted Lower Upper Number 
size effect confidence confidence of 
class size interval interval contrasts 
QL Trivial 0.02 -0.09 0.13 39 
QL Small 0.33 0.26 0.40 97 
QL Medium 0.53 0.43 0.62 54 
PF Trivial 0.04 -0.14 0.22 32 
PF Small 0.41 0.31 0.51 102 
PF Medium 0.84 0.68 0.99 48 
RF Trivial -0.03 -0.23 0.18 40 
RF Small 0.46 0.33 0.60 96 
RF Medium 0.84 0.61 1.07 32 
EF Trivial -0.03 -0.13 0.07 54 
EF Small 0.35 0.28 0.43 91 
EF Medium 0.28 0.16 0.41 33 
SF Trivial -0.03 -0.13 0.07 42 
SF Small 0.38 0.31 0.44 101 
SF Medium 0.46 0.35 0.57 36 
CF Trivial -0.03 -0.12 0.06 70 
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Subscale Expert Weighted Lower Upper Number 
size effect confidence confidence of 
class size interval interval contrasts 
CF Small 0.34 0.25 0.43 74 
CF Medium 0.48 0.29 0.66 19 
PA Trivial 0.04 -0.05 0.14 53 
PA Small 0.38 0.29 0.48 62 
PA Medium 0.62 0.49 0.75 30 
FA Trivial 0.04 -0.08 0.17 38 
FA Small 0.37 0.28 0.47 71 
FA Medium 0.63 0.51 0.76 39 
NV Trivial 0.05 -0.05 0.15 58 
NV Small 0.28 0.18 0.38 56 
NV Medium 0.63 0.45 0.81 17 
AP Trivial 0.01 -0.08 0.11 62 
AP Small 0.41 0.31 0.51 56 
AP Medium 0.76 0.55 0.96 14 
CO Trivial -0.01 -0.1 0.07 72 
CO Small 0.41 0.3 0.52 44 
CO Medium 0.58 0.36 0.79 11 
DI Trivial 0.03 -0.03 0.09 96 
DI Small 0.26 0.17 0.35 38 
01 Medium 1* 
DY Trivial 0 -0.08 0.08 62 
DY Small 0.29 0.18 0.40 38 
DY Medium 0.36 0.17 0.55 12 
SL Trivial 0.02 -0.07 0.11 47 
SL Small 0.24 0.16 0.33 57 
SL Medium 0.67 0.38 0.95 6 
FI Trivial -0.01 -0.09 0.07 54 
FI Small 0.26 0.14 0.38 25 
FI Medium 3* 
*Slze classes with number of contrasts less than 5 not Included In the gUidelines 
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Figure 45 Estimates for effect size outcome variable by expert size class (cross-sectional contrasts) 
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7.1.4 Guidelines for comparing between groups of patients 
The resulting guidelines for trivial, small, medium and large effects are provided in 
Table 55 for both mean differences and effect sizes. Section 4.5 describes how the 
guidelines were calculated from the meta-analysis weighted estimates. Although there 
was insufficient data to estimate the size of large effects, the upper limit of the 95% 
confidence intervals around the medium estimates have been used as a guide. 
The method of obtaining the guidelines is illustrated here using the global quality 
of life scale as an example. Mean estimates for trivial, small and medium mean size 
classes were 1, 7 and 13 points respectively (Table 53). The threshold between size 
classes was set at the midpoint between estimates. Therefore the threshold between 
trivial and small is 4 points, i.e. the midpoint between 1 and 7. The threshold between 
small and medium differences is 10 points, i.e. at the midpoint between 7 and 13. The 
threshold between medium and large differences cannot be determined as there was 
insufficient data to obtain an estimate for the large size class. Instead the threshold is 
set at the upper limit of the 95% confidence interval around the medium size class 
estimate, i.e. at 15 points. 
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Table 55 Guidelines for size of cross-sectional differences (from meta-analysis) 
Threshold Sub· Mean difference Effect size 
between scale Triv Small Medium Large Triv Small Medium Large 
small and 
medium 
estimates 
<10 points DI 0-3 3- 7 >7 - 0-0.1 0.1-0.4 >0.4 -
NV 0-3 3- 8 8 - 15 >15 0-0.2 0.2-0.5 0.5-0.8 >0.8 
CF 0- 3 3-9 9 -14 >14 0-0.2 0.2-0.4 0.4-0.7 >0.7 
DY 0-4 4 - 9 9 -15 >15 0-0.1 0.1-0.3 0.3-0.6 >0.6 
10-15 FI 0 - 3 3 - 10 >10 - 0-0.1 0.1-0.4 >0.4 -
points QL 0 - 4 4 - 10 10 - 15 >15 0-0.2 0.2-0.4 0.4-0.6 >0.6 
SF 0 - 5 5 - 11 11 - 15 >15 0-0.2 0.2-0.4 0.4-0.6 >0.6 
SL 0 - 4 4 - 13 13 - 24 >24 0-0.1 0.1-0.5 0.5-1 >1 
FA 0 - 5 5 - 13 13 - 19 >19 0-0.2 0.2-0.5 0.5-0.8 >0.8 
CO 0 - 5 5 - 13 13 - 19 >19 0-0.2 0.2-0.5 0.5-0.8 >0.8 
PA 0 - 6 6 - 13 13 - 19 >19 0-0.2 0.2-0.5 0.5-0.8 >0.8 
PF 0 - 5 5 - 14 14 - 22 >22 0-0.2 0.2-0.6 0.6-1 >1 
AP 0 - 5 5 - 14 14 - 23 >23 0-0.2 0.2-0.6 0.6-1 >1 
>15 points RF 0-6 6 - 19 19 - 29 >29 0-0.2 0.2-0.7 0.7-1.1 >1.1 
In order to use these guidelines to calculate a sample size (assuming it is 
required to detect the smallest clinically relevant difference) the threshold between 
trivial and small should be used in the calculation, i.e. 4 points for the QL subscale, 5 
points for the PF subscale and so on. To use the guidelines for interpretation, an 
observed difference of 5 points for example would be interpreted as trivial for the PA 
and RF subscales but would lie in the small range for all other subscales. Note that 
where the threshold between trivial and small is 5 points this is interpreted as a small 
difference. 
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7.2 Longitudinal contrasts 
7.2.1 Number of contrasts 
There were 1232 contrasts in the analysis dataset which compared groups over 
time. For these contrasts there were more groupings from the expert size classes than 
for the cross-sectional contrasts, since the direction of the difference (improving or 
declining over time) is meaningful. Due to the increased number of size classes and 
also the agreement criteria reducing the available contrasts, the numbers of 
longitudinal contrasts was quite small when split into subscales and then size classes 
within the subscales (Table 56). 
As with the cross-sectional contrasts, the number of contrasts judged as a large 
difference in either direction was very low, even before applying the agreement criteria. 
There were only three contrasts deemed large in the analysis dataset. The number of 
contrasts deemed medium in either direction was also low (ranging from zero to 24 
across subscales). The number of contrasts meeting the agreement criteria was 
particularly low for the trivial size class (Le. for some subscales there were very few 
contrasts where all experts were in agreement that the difference would be trivial). 
There were five subscales where an estimate from meta-analysis was not obtained for 
the trivial size class as the number of contrasts was less than five. 
Table 56 Number of contrasts for estimates of longitudinal effects 
Expert size Subscale 
class ! AP CF CO 01 DY EF I FA FI NV PA PF QL RF SF SL Total 
Large J! 
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1---,----,-------4---+----'1---+----+---+--+-+--t--+----+--- ----+----+--+---+---1 
Small 
deterioration 25 28 11 14 14 11 40 9 27 17 39 30 35 38 12 350 
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7.2.2 Meta-analysis of mean differences 
7.2.2.1 Estimates of random effects 
The random effects and 95% confidence intervals were estimated using the 
residual (restricted) maximum likelihood (REML) method (using SAS® PROC MIXED). 
The mean estimate of the random effect was used in the weighting of the contrasts in 
the meta-analysis (see Section 4.4.2.3 for details) and sensitivity analyses were used 
to check for the robustness of the results to using the mean estimate. 
There were several problems in estimating the random effects variance using the 
REML method in SAS® PROC MIXED. A number of the models did not converge. 
Initially I treated each subscale independently and removed any size classes that had a 
small number of contrasts in them. (For cross-sectional models I had excluded where 
the number of contrasts was less than five and here I also tried where there were less 
than ten contrasts if convergence problems remained.) The subscales had to be 
treated individually as it was no longer the case that only the large size classes had 
small numbers in them. For some subscales the trivial and medium size classes were 
also too small but this did not apply universally across subscales. There were still 
convergence issues with four subscales (CF, EF, PF and QL) indicating that there was 
probably another reason for the convergence problem. As for the effect size analysis 
within the cross-sectional results I tried re-scaling the outcome variable instead. The 
longitudinal mean differences were fairly small in comparison to the cross-sectional 
ones therefore it was possible that this was also causing problems with the model 
convergence. I multiplied the mean differences by a factor of 10 and then ran the 
models to estimate the random effects variances. All of the models then converged, 
indicating that the overriding factor here was the small scale of the analysis variable 
rather than small numbers of contrasts. The variances were re-scaled back to the 
original scale by dividing by 100, i.e. 10x10). 
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The AP subscale had the highest random effect estimate (77.3) and FI had the 
lowest (24.1). This differs from the cross-sectional analysis where RF had the highest 
and 01 the lowest estimate. 
7.2.2.2 Results from random effects models 
Table 57 shows the results from the random effects models. The table shows the 
weighted mean differences along with 95% confidence intervals for each expert size 
class within a subscale. 
The results are also shown in a box and whisker plot (Figure 46). There are five 
plots for each subscale, representing medium deterioration, small deterioration, trivial, 
small improvement and medium improvement from left to right. Each subscale is 
shown with a different plot symbol (see key below the graph) . An 'X' has been used to 
show where there is no data to display for a certain size class for that subscale . Note 
that estimates where number of contrasts is less than 5 have been excluded in the 
graph. 
Table 57 Estimates for mean difference outcome variable by expert size class 
(longitudinal contrasts) 
Sub- Expert size class Weighted Lower Upper Number 
scale mean confidence confidence of 
difference interval interval contrasts 
Medium 
OL deterioration -12.89 -15.98 -9.80 16 
OL Small deterioration -7.25 -9.47 -5.02 30 
OL Trivial 1* 
OL Small improvement 6.33 4.74 7.92 56 
Medium 
OL improvement 5.37 1.93 8.81 12 
Medium 
PF deterioration -12.94 -16.50 -9.38 15 
PF Small deterioration -7.73 -10 .00 -5.46 37 
PF Trivial 2* 
PF Small improvement 4.86 2.24 7.47 27 
Medium 
PF improvement 4.33 -0.71 9.37 7 
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Sub- Expert size class Weighted Lower Upper Number 
scale mean confidence confidence of 
difference interval interval contrasts 
Medium 
RF deterioration -17.04 -22.18 -11.89 13 
RF Small deterioration -10.68 -13.89 -7.48 33 
RF Trivial 2* 
RF Small improvement 8.65 5.55 11.76 35 
Medium 
RF improvement 4* 
Medium 
EF deterioration 2* 
EF Small deterioration -7.50 -11 .53 -3.47 11 
EF Trivial 4* 
EF Small improvement 7.85 6.49 9.2 86 
Medium 
EF improvement 7.37 3.28 11.46 9 
Medium 
SF deterioration -8.44 -12.71 -4.18 10 
SF Small deterioration -8.67 -10.91 -6.44 38 
SF Trivial 3* 
SF Small improvement 5.48 3.39 7.57 40 
Medium 
SF improvement 7.90 2.20 13.6 5 
Medium 
CF deterioration 1* 
CF Small deterioration -4.47 -6.65 -2 .29 28 
CF Trivial 2.12 -0.69 4.92 17 
CF Small improvement 4.52 1.93 7.10 20 
Medium 
CF improvement 0* 
Medium 
PA deterioration -12.58 -19.5 -5.65 5 
PA Small deterioration -9.08 -13.09 -5.06 17 
PA Trivial 2.26 -2.20 6.72 11 
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Sub- Expert size class Weighted Lower Upper Number 
scale mean confidence confidence of 
difference interval interval contrasts 
PA Small improvement 8.13 5.95 10.32 50 
Medium 
PA improvement 8.93 3.72 14.15 9 
Medium 
FA deterioration -12.02 -14.52 -9.51 24 
FA Small deterioration -7.42 -9.47 -5.36 38 
FA Trivial 4* 
FA Small improvement 6.55 4.11 8.99 28 
Medium 
FA improvement 6.23 1.29 11 .17 6 
Medium 
NV deterioration -12.78 -16.28 -9.28 16 
NV Small deterioration -9.56 -12.21 -6.91 27 
NV Trivial -0.16 -3.85 3.52 14 
NV Small improvement 6.00 2.80 9.19 20 
Medium 
NV improvement 2· 
Medium 
AP deterioration -18.21 -25.72 -10.71 7 
AP Small deterioration -8.93 -12.7 -5.16 25 
AP Trivial 5.70 1.59 9.80 21 
AP Small improvement 8.68 4.36 13.00 20 
Medium 
AP improvement 3* 
Medium 
CO deterioration 3· 
CO Small deterioration -10.64 -15.05 -6.23 11 
CO Trivial 0.16 -2.10 2.42 37 
CO Small improvement 6.91 3.43 10.40 17 
Medium 
CO improvement 2· 
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Sub- Expert size class Weighted Lower Upper Number 
scale mean confidence confidence of 
difference interval interval contrasts 
Medium 
01 deterioration 4* 
01 Small deterioration -11 .03 -15.05 -7.02 14 
01 Trivial 0.11 -2.07 2.30 46 
01 Small improvement 5.70 0.70 10.70 10 
Medium 
01 improvement 1* 
Medium 
DY deterioration 2* 
DY Small deterioration -7.60 -11.45 -3.75 14 
DY Trivial -1.62 -4.51 1.27 21 
DY Small improvement 6.13 3.04 9.22 21 
Medium 
DY improvement 0* 
Medium 
SL deterioration -10.89 -16.98 -4.81 5 
SL Small deterioration -6.31 -10.41 -2 .20 12 
SL Trivial 8.81 4.69 12.92 10 
SL Small improvement 7.00 4.81 9.19 35 
Medium 
SL improvement 3* 
Medium 
FI deterioration 2* 
FI Small deterioration -5.71 -9.64 -1.77 9 
FI Trivial 0.83 -1.58 3.23 22 
FI Small improvement 4* 
Medium 
FI improvement O· 
*Size classes with number of contrasts less than 5 not included in the guidelines 
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Figure 46 Estimates for mean difference outcome variable by expert size class (longitudinal contrasts) 
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There were less estimates obtainable through meta-analysis than for the cross-
sectional contrasts. Only the PA subscale had an estimate for all of the size classes 
from medium deterioration up to a medium improvement. FI had the least available 
estimates with only two of the size classes with obtainable estimates. 
Medium deteriorations in scores could be estimated in nine subscales and these 
all lay in the 10-20 points range except for the SF subscale where a medium 
deterioration was estimated at 8 points (although this estimate was only from 10 
contrasts). Medium improvements were only obtainable in six subscales and ranged 
from 4 to 9 points. All subscales with estimates for both medium deteriorations and 
improvements available had deterioration estimates of a larger magnitude than the 
improvements. For example, for the PA subscale the medium deterioration estimate 
was -12.6 compared with the medium improvement estimate of 8.9. 
Small deteriorations in scores could be estimated in all subscales. The estimates 
lay between 4 and 11 points. Small improvements could also be estimated in 14 of the 
subscales. The estimates for improvements were again lower in magnitude than their 
corresponding estimate for a small deterioration in score for 11 of the subscales. 
However, across most subscales there was some overlap of the confidence intervals 
between the small and medium estimates. 
Estimates for trivial differences were possible for nine of the subscales. The 
estimates were close to zero with confidence intervals spanning zero for all subscales 
except the AP and SL subscales where trivial differences were estimated at 6 and 9 
points respectively. 
7.2.3 Guidelines for comparing groups of patients over time 
As several of the size classes could not be estimated within subscales the 
derivation of guidelines was more difficult than for the cross-sectional contrasts. The 
same methodology was followed with some minor adjustments. As for the cross-
sectional contrasts, the midpoint between two estimates was used as the threshold 
between size classes and 95% confidence intervals from the medium estimates were 
used to inform the guidelines for large size classes. However, in a number of subscales 
medium estimates were not available, in which case an estimate for the large class 
was unobtainable and the 95% confidence intervals around the small estimates were 
used to inform the size of medium size classes. There were a couple of subscales (RF 
and FI) where estimates were available for some size classes but not necessarily from 
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neighbouring size classes (e.g. for RF where estimates of small deteriorations and 
small improvements were possible but not for the trivial size class). Using midpoints 
between estimates meant that the guidelines could only be written for large and 
medium deteriorations, losing all of the information we had around the estimates for 
small size classes. For this reason I used the confidence intervals around the small 
estimates to add to the guidelines (e.g. the upper 95% confidence interval (Cl) of the 
small deterioration and lower 95% Cl of the small improvement class defined the trivial 
guidelines). In this way all of the information could be used and the guidelines could be 
more informative for the RF and FI subscales. 
Table 58 shows the subscales with guidelines that can be derived from the meta-
analysis estimates. (NE indicates a guideline for that size class was unobtainable.) 
There were six subscales (Ql, PF, EF, SF, FA and Sl) where the ordering of 
estimates across size classes did not follow the expected gradient. For example, the 
Ql subscale had a small estimate of 6.3 and a medium estimate of 5.4. Typically, the 
size classes that displayed this illogical ordering contained relatively few contrasts (six 
to 12). Although the team decided during the development of the methods to exclude 
estimates where the number of contrasts was less than 5, this was a fairly arbitrary 
decision and it may be that the common illogical ordering of longitudinal estimates 
indicates that more than 5 contrasts are required for a reliable estimate. For the 
purposes of developing guidelines for longitudinal results, I have used the information 
from the size class with the larger number of contrasts for these subscales. So for the 
above example in the Ql subscale, I have used the estimate for the small size class 
(from 58 contrasts) and its 95% confidence interval to inform the guidelines rather than 
the medium estimate (which was only from 12 contrasts). This allowed guidelines to be 
provided for these important subscales. 
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Table 58 Guidelines for size of longitudinal differences (from meta-analysis) 
Threshold Sub· Deteriorations No Improvements 
between small scale difference 
and medium Large Medium Small Trivial Small Medium Large 
improvements 
(deteriorations) 
<10 (>-14) FI NE <-10 -10 to-2 -2 to 3 >3 NE NE 
CF NE <-7 -7 to -1 -1 to 3 3 to 7 >7 NE 
PF <-17 -17 to -10 -10 to -5 -5 to 2 2 to 7 >7 NE 
QL <-16 -16to-10 -10 to ·5 -5 to 5 5 to 8 >8 NE 
SF NE <-11 -11to-6 -6 to 3 3 to 8 >8 NE 
EF NE <-12 -12 to-3 -3 to 6 6 to 9 >9 NE 
NV <-16 -16 to -11 -11 to -5 -5 to 3 3 to 9 >9 NE 
DY NE <-11 -11 to -5 -5 to 2 2 to 9 >9 NE 
FA <-15 -15 to -10 -10 to -5 -5 to 4 4 to 9 >9 NE 
SL <-17 -17 to -9 -9 to-2 -2 to 5 5 to 9 >9 NE 
PA <-20 -20 to -11 -11 to -3 -3 to 5 5 to 9 9 to 14 >14 
~10 (S- 14) CO NE <-15 -15 to -5 -5 to 4 4 to 10 >10 NE 
01 NE <-15 -15 to -5 -5 to 3 3 to 11 >11 NE 
RF <-22 -22to-14 -14 to-7 -7 to 6 6 to 12 >12 NE 
AP <-26 -26to-14 -14to-2 -2 to 7 7 to 13 >13 NE 
To use these guidelines for interpretation, an observed improvement of five points 
would be classed as trivial for AP, RF and EF subscales, whereas for the Ql, SF, CO, 
CF, 01 , DY, FA, NV and PA subscales a difference of this size would be classed as 
small. If there was a deterioration over time of the same magnitude (Le. 5 points) then it 
would only be considered trivial for the RF and SF scales; for the remaining subscales 
it would represent a small deterioration. 
In order to use these guidelines for a sample size calculation (assuming it is 
required to detect the smallest clinically relevant improvement) the threshold between 
trivial and small should be used in the calculation . 
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7.3 Results from sensitivity analyses 
7.3.1 Imputed variance estimates 
A hierarchical approach to obtaining the required variances for the meta-analysis 
was used. Where possible variances were derived using other information in the paper 
such as p-values (see details in Section 4.4.1.1), followed by methods requiring an 
assumed correlation value or, finally, single imputation by subscale using the reported 
variance estimates from other studies. A sensitivity analysis was carried out grouping 
the contrasts by the method of obtaining variances. This was carried out across 
subscales and expert size class in order to give an overall indication of the weighted 
mean estimates for each method. 
For the cross-sectional contrasts, 57% of contrasts had variance data available 
directly or derived using other data in the original article (Table 59). The remaining 
contrasts (43%) had variance data imputed using single imputation. This is probably 
analogous to standard meta-analyses where less than half of the studies may report 
the necessary variances for analysis (72). There were substantially less longitudinal 
contrasts with variance data available from the original article (8%). Around 40% of 
contrasts had variances imputed using an assumed correlation coefficient of 0.5 (Le. a 
mean change and the standard deviation for the change were reported but not 
standard deviations at the individual times). 50% needed single imputation. This is 
probably a much higher level of missing variance data than found in standard meta-
analyses. However, here we were looking at comparisons over time whereas standard 
meta-analyses tend to look at between group comparisons. We also took longitudinal 
contrasts from articles where data over time was being reported (e.g. in a summary 
table or graph) but these were not necessarily the comparisons being focussed on in 
the article therefore a lower proportion of variances available was to be expected. 
Table 59 Number of contrasts with available or imputed variance data 
Number of contrasts (%) I Cross-sectional Longitudinal 
~a_ri~n:~(fata ~~aTla~e l- ~_~52 (S6.6%) ! _ ~201(8.2%_) 
Variance data through p: 21 (0.9%)1 5 (0.4%) 
I I 
---------- ---~-----------~--_+_---------------_l_-----____ _ 
A_ssum~~ corr:~~tio~_~~lue I ______ ~ (O.~%) I 507 (41.~~o) 
Single imputation ! 939 (42.5%) i 619 (50.2%) 
--------- - ----------1- -- ---------- --~--- -----+ --- ---~-----
Total . 2212. 1232 
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Figure 47 shows the meta-analysis estimates with 95% confidence intervals for 
contrasts from each of these subsets. Note, the number of contrasts imputed using p-
values were too small to obtain separate estimates and are not displayed here. 
Estimates for contrasts with variance data available and for those where single 
imputation was used were very similar for both the longitudinal and cross-sectional 
contrasts. However, the longitudinal contrasts where an assumed correlation coefficient 
was used had a lower estimate. On average these were deteriorations in QOL whereas 
those with data available were improvements in QOL. 
An estimate of the correlation coefficient (rho) is required for the analysis where a 
contrast has the mean change and standard deviation for the change reported rather 
than the standard deviations at each time point. Regardless of why the contrasts with 
data available or not are different with respect to the mean difference, it shows that it is 
important to include contrasts without full data available (otherwise the results would be 
biased) and therefore an estimate of the correlation coefficient is necessary. A 
sensitivity analysis was therefore carried out around the choice of correlation coefficient 
used in the analysis. 
Figure 47 Forest plot for weighted mean difference grouped by method of 
obtaining variance for analysis 
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The meta-analysis was carried out assuming a correlation coefficient of 0,5 for 
the relationship between measurements on the same patient(70). I carried out 
sensitivity analyses by creating extra data sets where the imputation used correlation 
coefficients of 0.25 and 0.75 instead. The meta-analyses were repeated using these 
datasets and the results compared to see how much they varied. The median 
difference was 0 (range 0 to 0.13). The majority of estimates varied by 0 to 0.02 points. 
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The only differences larger then this were medium improvement for PA subscale and 
small deterioration for the FI subscale with differences of 0.12 and 0.13 respectively. 
These both had a relatively small number of contrasts (n=9) and if these consist mostly 
of contrasts requiring the assumption of a value for rho, this would explain why the 
change in assumption has a larger impact. However, changes even at this level would 
make no difference to the resulting guidelines. 
7.3.2 Comparison of results from full dataset 
The criteria for defining the analysis dataset were defined post hoc therefore the 
results from the full dataset are also displayed here for clarity. 
These results confirm that the full dataset cannot be used to derive valid and 
useful estimates for the guidelines. There needs to be some rules applied so that the 
estimates from the meta-analysis represent the modulus of the combined contrasts 
rather than a diluted average arising from including estimates with uncertainty around 
the expert review or results. 
Table 60 shows the proportion of contrasts from the full dataset that were used in 
the analysis dataset. The proportion used was higher for the medium size classes than 
for the small size classes. The proportion was lowest for the trivial difference but this is 
not surprising as the agreement criteria applied to the trivial size class was different to 
the other size classes and was quite strict. 
Table 60 Proportion of cross-sectional contrasts included in analysis dataset by 
expert size class 
Contrast type Proportion of contrasts in full dataset Total 
included in analysis dataset (%) 
Cross-sectional Trivial 36% 
Small 59% 
Medium 79% 
Longitudinal Medium deterioration 84% 
Small deterioration 64% 
Trivial 12% 
Small improvement 56% 
Medium improvement 80% 
Figure 48 shows the results from the meta-analysis using all cross-sectional 
contrasts from the full dataset (i.e. those contrasts with at least two expert reviews). 
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Compared to the main results from the analysis subset, the estimates for medium 
differences were lower (around 5 points lower on average) using the full dataset. The 
estimates for small differences were also smaller, they were all between zero and five 
in the full dataset, compared to 5 to 13 in the analysis dataset. The trivial estimates and 
confidence intervals no longer all span zero (three subscales were below and one 
subscale above zero in using the full dataset). 
The small and medium estimates were lower from the full dataset because 
contrasts were included where the experts thought the difference would be in favour of 
one group whereas the observed mean difference showed a difference in the opposite 
direction (and hence would be a negative mean difference). By including all contrasts in 
the meta-analysis to get an estimate for small and medium contrasts these negative 
mean differences combined with the rest of the positive scores had the net result seen 
of reducing the estimates. 
In terms of the trivial estimates, the full dataset contained contrasts where the 
experts did not agree that the contrast was a trivial one. These contrasts would be 
placed in the trivial size class because the average expert review was between -0.5 
and 0.5 rather than becau'se the consensus was that the effect was trivial. This 
confuses the estimates of trivial as seen here as some with reasonable sized mean 
differences have been included which skew the estimate. 
These factors combine to make the trivial and small estimates largely 
indistinguishable from each other, Le. the confidence intervals overlap. As an extreme 
example, there is a contrast in the full dataset where one expert had an average review 
of -3 and one had a review of +2.3. Therefore both reviewers considered the mean 
difference would be of a reasonable size (medium or large) but either they disagreed 
on the direction of the difference or one reviewer made an error when assigning the 
direction to their score. This contrast would be placed in the trivial size class as the 
average of -3 and 2.3 is -0.35 (Le. between -0.5 and 0.5). However, when we look at 
the mean difference between the groups it is actually very high (42 points) and clearly 
does not belong in the trivial size class. 
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Figure 48 Meta-analysis results using full dataset - cross-sectional contrasts 
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Figure 49 shows the results from the random effects meta-analysis including all 
longitudinal contrasts from the full dataset (Le. contrasts with more than one expert 
review available). For five subscales the confidence intervals around the trivial 
estimates do not span zero. Table 60 shows that only 12% of the contrasts in the trivial 
size class could be used in the analysis dataset therefore estimates from the full 
dataset are likely to be very unreliable as a large proportion of contrasts were placed in 
the trivial size class due to averaging the experts judgements rather than all experts 
agreeing the contrast belonged in the trivial category It is likely that a large proportion 
of the contrasts in the full dataset that were classed as trivial actually contained 
reasonably sized mean differences. 
We can also see that for 10 subscales the estimates and confidence intervals for 
small and even medium improvements are below or around zero, whereas for the 
analysis dataset the majority of estimates in these classes were above zero. Using PF 
as an example of one of these subscales we can see that none of the estimates are 
above zero. This implies that there are a number of contrasts where the experts judged 
a difference would be an improvement when actually the observed scores from the 
paper showed a deterioration or no difference. Including these contrasts diluted the 
estimates where there was good agreement between the experts and the original 
article, e.g. a mean difference of 10 points judged to be a medium improvement by the 
experts would be pooled with a mean difference of -10 points also judged to be a 
medium improvement by the experts. This had the net effect of zero points as an 
estimate for medium improvements when actually the modulus of the effect is around 
10 points. 
The agreement criteria used to reduce the full dataset to the analysis dataset 
were chosen such that contrasts where the expert size class and observed scores 
disagreed in direction were removed from the meta-analysis to avoid this dilution of the 
estimates. As Table 60 shows, just over half of the contrasts in the small improvement 
size class and 80% of the medium improvement contrasts met the criteria for the 
analysis dataset. A comparison of results from the full versus the analysis datasets, for 
these categories in particular, indicated that contrasts where the experts disagreed with 
the direction of the observed effect had a big difference on the resulting meta-analysis 
estimates, some of which did not make sense (such as a medium improvement 
estimate below zero). 
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Figure 49 Meta-analysis results using full dataset - longitudinal contrasts 
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7.3.3 Impact of using different estimates of the random effects 
variance 
The main analysis results use an estimate of the average random effects 
variance for the random element of the weighting of contrasts in the meta-analysis. 
Sensitivity analyses were carried out to see how much the results varied when different 
estimates for the random effects variance were used. The upper and lower 95% 
confidence limits for the random effects variance were used to check how much the 
results could change if our estimate of the random effects variance was at either 
extreme rather than at the average. 
For the cross-sectional analysis, changing the random element of the weighting 
affected the meta-analysis results only slightly, i.e. by an average of 0.05 pOints. In the 
worst cases the estimate changed by 0.2 points (PA subscale in the medium size class 
and DY subscale in the trivial size class). The midpoints between estimates were 
calculated for each scenario and there were no differences compared with the 
midpoints used to create the guidelines reported in Section 7.1.4. 
For the longitudinal analysis the sensitivity analyses showed an average change 
in the meta-analysis estimates of only 0.01 points. The worst case changed by 0.27 
points (EF subscale in the small deterioration size class). The midpoints between 
estimates were calculated again for each scenario. The midpoints were generally 
robust to changes in the estimate used for the random effects variance. There were 
two midpoints altered by one point when using the upper confidence limit and one 
midpoint altered by one point if the lower confidence limit was used. The guidelines are 
therefore affected for the AP subscale (when using the lower limit) and the PA subscale 
(when using the upper limit) but the difference was only one point and affected at most 
two of the thresholds. 
7.4 Summary of results and conclusions 
It was possible to derive guidelines for the size of QOL differences from published 
mean differences using this methodology. Differences considered to be large by 
average expert opinion were rare and estimates of large differences were not possible 
directly from the meta-analysis, although approximate guidelines were still obtainable 
for some subscales. 
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For both cross-sectional and longitudinal comparisons, the guidelines for small 
and moderate differences varied according to subscale, indicating that a global rule 
across subscales is not appropriate. For a given scale and size-class, cross-sectional 
differences were different to the longitudinal differences, although not consistently 
smaller or larger. Longitudinal guidelines for changes for improvement differ from those 
for deterioration. 
It should be noted that there was some overlap of confidence intervals between 
the estimates in adjacent size classes. This was potentially explained by small sample 
sizes in the longitudinal contrasts. Subscales were excluded from the guidelines if the 
meta-analysis estimates were not logical (Le. medium estimates below the small 
estimates) and this could not be explained by a small numbers of contrasts. However, 
there was still some overlap between the 95% confidence intervals across the size 
classes. 
Sensitivity analyses showed the method for imputing variances was acceptable 
and the impact of variation in estimates of around the random effects was minimal on 
the resulting guidelines. 
The sensitivity analysis on the full dataset showed that not all contrasts were 
useful and appropriate to include in the meta-analysis. This analysis confirmed that the 
agreement criteria we devised had the desired effect of refining the contrasts to the 
better quality ones and as a result sensible guidelines were derived. 
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8 Patient interviews 
8.1 Background 
Although the main study was carried out using an expert panel we also wanted to 
develop a method for obtaining patient opinion on QOL differences. However, there 
were barriers to carrying out an identical task with patients. 
Firstly, the EBIG project sought to quantify the size of differences between groups 
of patients rather than looking at changes for individual patients. The experts had to 
have clinical experience of similar groups of patients. In contrast, patients are not likely 
to have had experience of each clinical scenario, they are likely to have a fairly narrow 
experience compared to the wide range of clinical settings found in the papers. 
Secondly, the experts also needed to be familiar with the QLQ-C30, so they could 
use their knowledge of the specific questions. Patients are also unlikely to have 
previously come across the QLQ-C30 questionnaire (or even the concept of measuring 
aOL). 
Thirdly, the desired interpretation guidelines are partly aimed at obtaining sample 
sizes for clinical trials, and differences that result in a change in clinical practice are 
usually desired for this purpose. The definition of size class for the reviews was 
therefore based on 'clinical relevance' which would not necessarily be meaningful to 
patients. 
Fourthly, the methodology required reviewers to read papers from medical 
journals which can be quite technical and likely to contain terminology unfamiliar to 
patients. There was also a practical issue with the number of comparisons and 
subscales a patient would be able to judge. Experts were involved in the study for up to 
three years and this would be a big commitment to expect from patients. 
This pilot study was designed to explore if the methodology could be adapted in 
order to obtain patient reviews of the same data the experts were reviewing. In future 
studies, the methodology tested in this pilot study could enable expert and patient 
opinion to be combined for the development of the guidelines. 
I conducted a further literature search to review how patients have previously 
been used to elicit opinions on the size of QOL differences. A number of other authors 
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have directly used patient opinion to elicit the minimally important difference in QOL 
scores from various instruments. Methods include using patients to rate each 
other(89;90) and within-patient global ratings(17;28;29;49;86). A number of these 
methods were discussed in Chapter 2. I did not find previous research where patients 
directly gave an opinion on QOL differences for groups of patients rather than 
individuals. 
8.2 Ethical approval 
This study was submitted to and received a favourable opinion from the Leeds 
East Research Ethics Committee and was approved by the local research and 
development (R&D) department. The full protocol is described in more detail in this 
chapter. The approved patient information sheet can be found in Appendix IV. 
8.3 Objectives 
8.3.1 Primary Objectives 
• Can patients use information from published papers to form an opinion on 
meaningful differences in QOL scores? 
• Can adequate familiarity with the QLQ-C30 and the way it produces quality 
of life scores be gained during an interview situation? 
8.3.2 Secondary Objectives 
• To what extent can patients form their opinion using data from a group of 
patients rather than their own individual experience? 
• How do patients' opinions compare with clinicians opinions when using 
the same published data? 
• Does the proposed interview need developing further prior to a larger 
study? In particular, is the information presented in a way patients can 
understand? 
• Which types of scenarios should be developed for a further study? 
8.4 Methods 
The design and analysis of the study are reported as recommended in the 
consolidated criteria for reporting qualitative research (COREQ) checklist(91). 
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8.4.1 Study design 
As this was a pilot study and it was largely unknown as to the best approach to 
getting patient opinions we felt an interview would be the best approach. This would 
allow plenty of discussion with the patients and opportunity to explore in-depth the way 
they approached the task and the reasoning behind their opinions. Cognitive 
interviewing(92) was used as this is aimed at gaining an understanding of how the 
patients approach their answers to questions in the interview. 
I wrote an outline interview schedule and this was subjected to ethical review as 
part of the protocol. The schedule is displayed in Figure 50 and described more fully in 
the subsequent text. 
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Figure 50 Outline interview schedule 
1. Introduction to project and QLQ-C30 questionnaire 
a. Confirmation of agreeing to tape record interview 
b. Thank for volunteering and ask for questions at any time 
c. Explanation of project 
d. Introduction to questionnaire/scoring 
e. Explain problem of interpreting what scores mean to patients 
f. Explain that different scenarios will be presented and they will 
be asked for their opinion on the size of differences in QOL 
between groups of patients or patients over time 
2. Show first scenario description; explain verbally, allow time to read 
and ask questions 
3. Get patient opinions on two subscales for that scenario 
a. Highlight the questions involved in creating a score for that 
subscale 
b. Ask if there will be a noticeable difference between the groups 
and, if so, whether this difference would be small, medium or 
large 
c. Show pictures representing actual scores from these groups 
and ask if this changes their opinion 
4. Show second scenario and repeat section 3 
5. Explore what patient's needed to make a decision and their 
interpretation of small, medium and large. 
a. Were any of the scenarios easier to think about and why, do 
they think you need previous experience of the specific 
scenario in order to make a decision 
b. What did they think about to make their decision 
c. What did they think made a difference large, i.e. how were 
they interpreting the words 'large', 'medium' and 'small' 
6. Interview close 
a. Questions or comments 
b. Feedback on the format of the interview and 
recommendations for any changes 
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The interview consisted of 4 parts; completion of informed consent, completion of 
socio-demographic details by the patient, an explanation of the purpose of the project 
and then the main content of the interview. The main interview started with 
familiarisation with the EORTC QLQ-C30 questionnaire and scoring. I showed the 
patients a copy of the questionnaire and described how each question contributed to a 
score for a subscale. I used an overlaying transparent sheet to demonstrate what the 
score would be when some of the questions were answered in a certain way and then 
a second overlay which showed how the score changed when one answer differed by 
only one category. Once the patient was happy with the questionnaire and the concept 
of scoring I moved on to discuss the first study scenario. 
I developed four scenarios for use in the interview from published breast cancer 
studies also undergoing the expert review process. The studies chosen had all already 
been through the expert review process and had received three expert reviews at the 
time of designing this pilot study. I chose studies which demonstrated a range of 
disease stages, study designs, interventions and settings. I also looked at whether the 
experts agreed or disagreed on their assessment of the size of difference they would 
expect and included examples of both extremes. Finally I considered whether the 
actual QOL differences were large or small in order to include a range of actual sizes 
for the scenarios. I selected a variety of subscales across the scenarios but ensured 
some overlap between the subscales across the scenarios. Only two subscales were 
considered for each scenario to reduce the burden on the patient and length of the 
interview. Part of Scenario D is used as a worked example in Appendix V. A summary 
of the scenarios can be found in Figure 51. 
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Figure 51 Patient interview scenario summary 
Design 
Patients 
Aim 
Contrasts 
Subscales 
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During the interview I read a summary of the first study scenario with the patient 
and then asked if they wanted some time to read it again. The summary started with a 
description of the study and then described the two groups to be compared or one 
group and a description of the time points if it was a longitudinal contrast. I then 
described the subscales they were going to be asked to consider for that scenario, 
showing them the questions relevant to that subscale and examples of scores when 
the questions were answered in different ways. The patient was then asked to say 
whether they thought there would be a difference between the groups, or group over 
time, with respect to those subscales. If they thought there would be a difference they 
were then asked to comment on the size of that difference. 
Patients were then shown the actual results from the study using a graph to show 
average scores and asked if that affected their earlier assessment. Graphical 
approaches have previously been shown to successfully convey aOL information to 
cancer patients(93;94). I developed graphs for this study based on a similar approach 
used in the PROMIS® study, www.nihpromis.org(95). The format I used showed the 
actual means for each contrast using text and 'stick people' to represent the group of 
patients on a graph. They were designed to show that the mean score comes from a 
group of individuals with varying aOL scores. I showed patients a graph for each of the 
two groups in the contrasts so they could use them to re-consider their opinion on the 
size of difference. An example of one of the graphs is shown in Figure 52 and further 
examples can be found in Appendix V. 
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Figure 52 Example graph to show patients the actual QOL means 
Patients with symptoms 
Average pain score = 20 
An average pain score of 20 means 
the majority of patients answered at 
least one of the questions with A 
LITTLE 
o 10 20 30 40 50 60 70 80 90 100 
Lowest pain Highest pain 
Once the patients had looked at the actual scores and commented on how it may 
change their original assessment of the aOL difference I then showed them the results 
of the expert review for the same contrasts and probed for their comments. 
Finally, there were some more general questions at the end of the interview 
designed to find out if particular subscales or scenarios worked better than others and 
to find out how the patient had approached the task. 
8.4.2 Interviewer training and pilot testing 
Since I had no previous experience of interviewing patients I received some 
training from the CRUK Psychosocial Oncology Group at 8t James' University Hospital. 
Once I had written the interview I piloted the format on one of the research assistants 
who had experience of conducting patient interviews. I also shadowed a research 
assistant in the breast cancer clinic to observe the patient consent process before I 
approached patients for this study. 
8.4.3 Patient sample and recruitment 
There are no set guidelines for the appropriate size of sample in qualitative 
research. Generally qualitative studies require much smaller numbers of patients than 
quantitative studies. Using the principle of saturation, patients are recruited until a point 
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is reached where no new information emerges from subsequent interviews. As the 
interviews here were focussed on specific issues (in-depth rather than broad-ranging) 
and the content of the interview was novel and experimental, I considered that a 
maximum of 12 patients should be adequate to achieve the study objectives. 
Purposive sampling was used to obtain a heterogeneous sample with respect to 
age and extent of disease according to the matrix in Table 61. These two factors were 
chosen as the most appropriate ones in order to obtain a sample containing a broad 
range of breast cancer patients. Recruiting up to 12 patients allowed for one to two 
patients per group and provided adequate opportunity to interview patients across a 
broad range of ages and with varying degrees of disease. 
Table 61 Purposive sampling matrix 
Extent of disease Primary local Local recurrent Metastases Disease-free 
Age <50 I ~50 <50 I ~50 <50 J ~50 <50 I ~50 
Patients were eligible for inclusion if they met the following inclusion criteria and 
none of the exclusion criteria applied:-
Inclusion criteria:-
• Ability to read and understand English 
• Patients with a diagnosis of breast cancer 
• Patients more than 18 years of age 
• Patients who have received at least three months of treatment for their 
breast cancer 
Exclusion criteria:-
• Patients who have just been informed about diagnosis of primary or 
recurrent disease 
• Patients already participating in a psychosocial oncology research 
projects 
• Patients attending their first oncology appointment 
Potentially eligible patients attending breast cancer clinics were identified using 
the Patient Pathways Manager (PPM) system. Patients were identified by a Research 
Assistant member of the CRUK Psychosocial Oncology Group. 
I approached eligible patients consecutively (in order of arrival) in the waiting 
room of a breast cancer clinic at St James University Hospital. I asked if they were 
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willing to talk with me about participation in a research study and if so I then briefly 
described the study to them while they were waiting for their appointment. If the patient 
was still interested I gave them patient information sheet and consent form to take 
away so they could read it in detail and decide whether to participate. Patients gave 
their phone number if they wished to be contacted regarding possible participation and 
to arrange an interview date. All patients had at least 24 hours to decide if they wished 
to participate. 
8.4.4 Interview content and setting 
I used two of the study scenarios during each interview. I wanted to use all four 
scenarios in the first two interviews in order to test them in case of any problems with 
the design of the scenarios or interview script. Following these first two interviews I 
wanted to use the scenarios equally where possible and ensuring that a range of 
patients received each scenario. I also ensured that the scenarios were used in 
different orders during the interviews, in case the patient was more rushed or fatigued 
by the second scenario. The first two interviewees received scenarios A then Band 
scenarios C then D respectively. Once the four scenarios had been tested in these first 
two interviews I chose scenarios for each interview according to the characteristics of 
the next patient in order to achieve the desired mix of ordering and patient 
characteristics using each scenario. 
I interviewed patients at St James University hospital (if they were attending for 
an appointment in the few weeks following agreeing to take part in the study) or at their 
home if they preferred. The interviews were audio-recorded so that they could be 
transcribed in full for the analysis. This allowed for some external validity checking of 
the analysis (as detailed in section 8.4.6). 
8.4.5 Analysis methods 
8.4.5.1 Transcription 
The recorded interviews were transcribed verbatim as soon as possible following 
the interview. I transcribed the first interview and then used a third party to complete 
the subsequent transcriptions. Non-relevant discussion was excluded from the 
transcripts (e.g. telephone calls received by the patient during interview, use of the 
word 'umm' etc). Place names or names of people were anonymised during 
transcription. Interview recordings were identified only by study number for the 
purposes of confidentiality during transcription. I verified all of the transcriptions by 
listening to the full interview and comparing against the transcript. 
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8.4.5.2 Theoretical framework 
Framework analysis(96) was used to analyse the interview transcripts. I chose 
this as it closely follows the information from the interviews and reports the data fully. It 
was suitable for this study as I had defined set objectives in the protocol which would 
guide the information required from the interviews. These objectives could therefore 
form the basis of the framework. Framework analysis allows for development of the 
framework during the analysis and since this methodology was being tried for the first 
time this seemed appropriate as it also allowed for information to emerge that had not 
been considered a priori. No specific software for analysing qualitative data was used 
for the analysis. I coded transcripts by hand. 
Framework analysis was undertaken in stages as described by Bryman and 
Burgess(96):-
• Stage 1: Familiarisation 
I prepared initial summary sheets immediately after each interview containing any 
relevant notes regarding the interview. Verifying the transcripts was also part of the 
familiarisation process, and I usually carried this out after every three interviews. On 
verifying the transcription I expanded the summary sheet by adding any key ideas or 
themes I saw emerging. I also included a summary of the patients' responses to the 
size of differences for each contrast so these were more easy to compare later across 
patients and with the experts . 
• Stage 2: Identifying a thematic framework 
The protocol was used to identify an initial thematic framework by using the 
objectives and other specific questions the study aimed to address. There were 11 
items in the initial framework, the shortened descriptions in bold were used as the 
theme headings:-
1. Ability to use published data: Can patients use information from 
published papers to form an opinion on meaningful differences in QOL 
scores? 
2. Familiarity with questionnaire and scoring: Can adequate familiarity 
with the QLQ-C30 and the way it produces quality of life scores be gained 
during an interview situation? 
3. Group vs individual: To what extent can patients form their opinion using 
data from a group of patients rather than their own individual experience? 
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4. Patient vs clinician: How do patients' opinions compare with clinicians 
opinions when using the same published data? 
5. Interview development: Does the proposed interview need developing 
further prior to a larger study? In particular, is the information presented in 
a way patients can understand? 
6. Scenario feedback: Which types of scenarios should be developed for a 
further study? Do patients find some scenarios easier to think about and 
why? 
7. Understanding of questionnaire and scoring: Do patients understand 
the questionnaire and scoring system given the description and examples 
in the interview? 
8. Information used to inform decision: An understanding of what 
information patients use to decide if groups of patients will have a 
noticeably different QOL from each other. 
9. Similar experience to scenario required: Do patients need to have a 
similar personal experience to identify with groups of patients? 
10. Definitions of large, medium and small: An understanding of the way 
patients define large, medium and small differences. 
11. Impact of knowledge of actual scores: How do patients' opinions differ 
if they have knowledge of the actual scores compared to when they do 
not? 
I developed the initial thematic framework further during the analysis using three 
interviews at a time. The initial framework was coded with items 1 to 11 as above and I 
used these codes in the margin of the transcripts to highlight relevant sections of 
interview script. Any new or emergent themes were added to the framework in the 
order they were found in the transcripts . 
• Stage 3: Indexing 
Once I had reviewed all of the interviews, the codelist was finalised. The final 
codelist was then systematically applied to each transcript by reading the transcripts 
again and annotating the whole transcript with codes where the text was relevant to 
any of the themes in the final codelist. Numerical codes were listed in the margin for 
each section of text as applicable, with additional notes if I felt these would be useful. 
• Stage 4: Charting 
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I drew a chart for each theme identified in the final codelist. This was in the form 
of a table that divided the broad themes into sub-themes and included quotes from 
patients to show examples of the theme. The overall theme was used as the chart 
heading. Sub-codes within the theme were used as columns and each patient had a 
row in the chart. I maintained the same order (interview order) in each chart so that 
individuals could be reviewed across the themes where required. Charting in this way 
was used to group excerpts from the interview text. Sometimes the text was copied and 
pasted verbatim into the chart and sometimes a distilled summary was used in the 
charts. However, I always referenced the original text so the source could be traced. I 
referenced text using a code conSisting of the interview number, scenario (where the 
text was specific to a scenario) and page number . 
• Stage 5 Mapping and interpretation 
Once the charts were completed I reviewed them to look for links between them 
and then regrouped any related codes together. The main themes were the objectives 
from the protocol and under each theme either whole charts or certain sub-themes 
from charts were combined during this process. I used major themes to define an 
emergent or recurrent theme relating to the overall objective. Minor themes were then 
used to categorise the range of responses from patients within those major themes. I 
used direct quotes to illustrate the themes where applicable. These final tables of major 
and minor themes along with supportive excerpts from the interview texts are used 
later to summarise the results from the study in section 8.5. The full charts are reported 
in order to show as much detail behind the analysis as possible, however, I have also 
provided a summary of the results for each objective and then overall conclusions at 
the end of the chapter. 
I analysed the transcripts and conducted further interviews iteratively. This is 
recommended in qualitative research to ensure that saturation is achieved, that is no 
new or emergent themes are still being found when the sample size has been reached. 
8.4.5.3 Quantitative analysis 
I also used various quantitative summaries to supplement the qualitative analysis. 
In order to compare the expert and patient opinion, the patients' opinions were put on 
the same scale to the experts. The words 'small', 'medium' or 'large' used during the 
interview were converted to 1, 2, or 3 respectively. Zero was used where patients did 
not think there would be a difference. Where patients described differences in between 
categories (e.g. small to medium), an increment of 0.5 was used. Positive or negative 
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scores were used to indicate the direction of the difference. Because of the way the 
expert scores were derived (using weighted averages) these were on a more 
continuous scale than the patient data. 
Concordance between patients reviewing the same contrasts was used to inform 
whether patients have the ability to use the published data in this way. I used a similar 
method to that used for the experts, looking at the maximum distance (in terms of the 
number of size classes) between the patient scores. This was aimed at giving an 
indication as to whether using a panel of patients may be feasible in the same way as 
the expert panel was utilised. Scatter graphs and correlation coefficients were used to 
look at how the patient opinion compared with the actual scores from the studies, in the 
same way as I did for the expert scores. I also repeated this for the expert scores but 
only using the subset of the contrasts used for these patient interviews rather than the 
full dataset. I used bar charts to illustrate how patient and expert opinions differed on 
average for each contrast. 
8.4.6 Validation of analysis 
I carried out all of the interviews and analysis so in order to check the results for 
bias and ensure the validity of the conclusions from the study, the rest of the study 
team (Prof Velikova, Prof Fayers, Prof King and Prof Brown) each reviewed one 
transcript and checked the coding according to the final code-list. Any disagreements in 
coding or new themes were discussed as a team and an agreement reached. 
8.5 Results 
8.5.1 Sample 
I recruited patients at St James' University Hospital in Leeds over 13 weeks, from 
28/7/2008 to 27/10/2008. Figure 53 shows details of the numbers of patients 
approached and recruited for the study. 421 patients were assessed for eligibility and 
50 potentially eligible patients were identified. I approached 27 of these and 14 
declined. Two patients agreed to take part but subsequently withdrew prior to the 
interview. Not all patients were approached for practical reasons. Firstly, I could not 
attend all of the clinics where patients were presenting and secondly because the 
transcription and analysis was taking place iteratively I needed to allow time in between 
interviews to code the previous transcripts. 
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I conducted 11 interviews, with six taking place at patients' homes, four in a 
hospital interview room and one in the hospital out-patient treatment ward . The 
interviews lasted between one and two hours. 
Figure 53 Flow of patients through qualitative interview study 
Excluded N=394 
371 Not eligible 
11 Did not attend clinic 
7 Did not approach for logistical 
reasons 
5 Did not approach - on another study 
Declined or withdrawn N=16 
Declined (n= 14) 
6 Unable to contact 
2 Not got the time 
2 Too poorly 
2 Not interested 
2 Too much going on 
Withdrew prior to interview (n=2) 
1 Too busy at work 
1 Too poorly 
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Study patients had a range of ages and disease extent. as planned by the 
purposive sampling (Table 62). However. I did not recruit any patients in one of the 
categories (local recurrent less than 50 years old). On discussion with Prof Velikova we 
identified two possible reasons for this. Firstly. younger patients with recurrence 
represent a small proportion of breast cancer patients and secondly these patients may 
not necessarily attend the particular clinic where recruitment was carried out. 
Table 62 Number of patients recruited in each category of purposive sampling 
matrix 
Number of Extent of disease Total 
patients Disease- Local Metastatic Primary 
free recurrent local 
Age 
<50 1 0 2 1 4 
~50 2 1 2 2 7 
Total 3 1 4 3 11 
Participating patients ranged from 33 to 78 years old. with a median age of 57 
(Table 63). More patients were recruited in the over 50 age group compared with the 
under 50s (64% vs 36%). Younger patients informed about the study generally 
declined due to time available. and this was usually because they were working full-
time. Patient characteristics varied with respect to employment and education but were 
fairly homogenous with respect to marital status with 9/11 (82%) being married. Only 
one patient had previously encountered the QLQ-C30 questionnaire. 
Table 63 Patient characteristics 
Number of patients (%) 
Age (yrs): Median (range) 57 (33 to 78) 
Extent of disease 
Disease-free 3 (27.3%) 
Local recurrent 1 (9.1%) 
Metastatic 4 (36.4%) 
Primary local 3 (27.3%) 
Marital status 
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Number of patients (%) 
Married 9 (81.8%) 
Separated/Divorced 1 (9.1%) 
Single 1 (9.1 %) 
Number of occupants in house 
1 1 (9.1) 
2 6 (54.5%) 
3 2 (18.2%) 
4 2 (18.2%) 
Current employment 
At home 1 (9.1%) 
Retired 4 (36.4%) 
Unemployed 1 (9.1%) 
Working full time 3 (27.3%) 
Working part time 2 (18.2%) 
Educated after minimum school leaving age 8 (72.7%) 
Degree/professional qualification 5 (45.5%) 
Previous experience of QLQ-C30 1 (9.1%) 
Around one third of patients had metastatic breast cancer (Table 64). Two-thirds 
of patients were currently receiving chemotherapy. Most patients (82%) had received 
previous lines of treatment. 
Table 64 Details of cancer type and treatment 
Number of patients % 
Extent 
Metastatic 4 36.4 
Disease-free 3 27.3 
Primary local 3 27.3 
Local recurrent 1 9.1 
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Diagnosis 
Infiltrating ductal carcinoma 7 63.6 
Metastatic 2 18.2 
Carcinoma - unspecified 2 18.2 
Stage at diagnosis 
1 1 9.1 
2 2 18.2 
3 3 27.3 
4 4 36.4 
Unknown 1 9.1 
Current treatment 
Chemotherapy 7 63.6 
Hormonotherapy 2 18.2 
Other 1 9.1 
Follow up 1 9.1 
Previous treatment 
Chemotherapy/Radiotherapy/Surgery 2 18.2 
Chemotherapy/Radiotherapy/Surgery/Hormonal therapy 2 18.2 
None 2 18.2 
Hormonal therapy 1 9.1 
Radiotherapy/Bisphosphonates 1 9.1 
Surgery 1 9.1 
Radiotherapy/Surgery/Hormonal therapy 1 9.1 
Chemotherapy/Surgery 1 9.1 
8.5.2 Scenario allocation 
Each scenario was used five or six times during the study (Table 65). The 
scenarios were allocated as described in the methods, with attention to the ordering 
and ensuring that all scenarios were encountered between the patients in a disease 
and age group (where numbers allowed). A total of 73 opinions on the contrasts were 
collected. 
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Table 65 Scenario allocation and contrasts reviewed 
Interview Disease Age First Second Contrasts Total 
number group group (Type:Subscale)* number 
of 
contrasts 
reviewed 
1 Mets <50 A B X:PAX:PF 6 
X:EF X:PF L:EF L:PF 
2 DF >50 C D L:RF L:SL X:RF X:SL 7 
L 1 :FA L2:FA X:SF 
3 Primary >50 B D X:EF X:PF L:EF L:PF 7 
L 1 :FA L2:FA X:SF 
4 Mets >50 A C X:PAX:PF 6 
L:RF L:SL X:RF X:SL 
5 DF >50 A B X:PAX:PF 6 
X:EF X:PF L:EF L:PF 
6 Primary <50 C D L:RF L:SL X:RF X:SL 7 
L 1 :FA L2:FA X:SF 
7 Mets >50 B D X:EF X:PF L:EF L:PF 7 
L 1 :FA L2:FA X:SF 
8 Mets <50 D C L 1 :FA L2:FA X:SF 7 
L:RF L:SL X:RF X:SL 
9 Local rec >50 C A L:RF L:SL X:RF X:SL 6 
X:PAX:PF 
10 Primary >50 B A X:EF X:PF L:EF L:PF 6 
X:PAX:PF 
11 DF <50 C B L:RF L:SL X:RF X:SL 8 
X:EF X:PF L:EF L:PF 
Total contrasts: 73 
*Type X=Cross-secbonal, L=Longltudlnal 
8.5.3 Development of thematic framework 
During the review of transcripts three new themes were added to the initial 
thematic framework; approach to the task, general feedback and personality type. 
These were themes that added information regarding how patients were approaching 
the task and why they may approach it in a particular way. These themes were 
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subsequently combined across the other data themes and therefore do not appear as 
major themes in the final framework. For example, the approach to the task theme was 
merged with the 'Group vs Individual' theme as I noticed the content was related during 
the mapping and interpretation stage of the analysis. As any new themes had been re-
coded in with the original objectives and no new themes were still being identified in the 
last set of interviews, it is probable that saturation in terms of themes had been 
reached during the 11 interviews. 
The final thematic framework is summarised in Table 66. The overall themes 
represent the study objectives. The major and minor sub-themes were used to group 
the excerpts from the transcripts, further categorising the content of the interviews 
coded under the overall theme. The purpose of this table is to show the final framework 
used to code all of the transcripts. Further detail on each theme, including quotes from 
patients, are reported in the sections that follow. 
Table 66 Final thematic framework 
Theme Sub-themes 
Major Minor 
Ability to use Confidence in their Confidence comes with experience 
published answers Lack of confidence 
information Guessing 
Showing in-depth Discrete nature of scoring 
understanding of Response shift/recall bias 
QOL concepts Detailed description of QOL concept 
Questions in subscale may go in opposite 
directions and cancel out an overall difference 
Groups in scenario may have a different 
reference paint 
Confidence in Need a mix of patients 
project 
Hard without Hard for a layman 
experience Different types of cancer/chemo have different 
effects 
More accurate with experience 
People are so different 
View may be different with experience 
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Theme Sub-themes 
Major Minor 
Experience not Can use own experience and others 
necessary Experience does not have to be identical 
Can think along same lines 
Subjective rather than objective 
Can empathise 
Not for more general scenarios 
Difficult even with Scenario needs more info 
experience Response shift/recall bias 
Judgements based Strong belief/preference driving judgements 
on experience/belief Own experience driving judgements 
Familiarity Familiarity Reference to subscale questions while 
with answering 
questionnaire Linking subscales 
and scoring Putting self onto scales 
Understanding of Querying or commenting on the timing of 
questionnaire questionnaire or period covered 
Awareness of multidimensional nature of QOL 
Showing an understanding of how QLQ-C30 
may be useful 
Understanding of Confusion/clarity with direction of scoring 
scoring indicating improvement/deterioration 
Reference to scoring system when thinking 
about answers 
Understanding that your baseline score is 
important 
Suggesting specific score/category for group 
Showing an Confirming answers vs graphs 
understanding of the Interpreting before explanation given 
graphs 
Group or Group Awareness of variation in group 
individual Clear group thinking 
thinking Reference to others in the abstract 
Reference to experience of others 
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Theme Sub-themes 
Major Minor 
Thinking of majority 
Finding average difficult 
Individual Reference to self in the abstract 
Reference to own experience 
Answering subscale for self 
Approach to task Using own experience then generalising 
No reference to own experience 
Patient vs Ability of clinicians Able 
clinician to judge Not able 
opinions Reasoning for Can use their experience 
differences Experts may assume positive outcome 
Place different importance on QOL changes 
Can see reasons why differences could be 
either way round 
Reasoning for 
agreement 
Definitions of Specific definition of Treatment working; no pain and able to 
small, small function 
medium and Specific definition of Sizeable 
large medium Ups and downs 
differences Specific definition of Extremes 
large Own experience vs others 
A little vs A lot 
A marked difference 
Significant difference on your life 
Using questionnaire A little, quite a bit, very much 
responses (8) 
Other wording Percentages 
Marked 
Slight 
Average 
Substantial 
Wording irrelevant 
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Theme Sub-themes 
Major Minor 
Not specific Gut instinct 
Presentation Confusion with Forgetting timelines of patients from diagnosis 
and details of scenario Patient referring to pain but scenario is 
understanding regarding symptoms 
Patient referring to normal care group as 
having no support 
Confusion with Needing clarification of difference rather than 
required task by group 
Trying to complete task with reference to self 
rather than scenario 
Not understanding purpose of scoring 
explanation 
Graphs Own interpretation 
Confusion with direction of difference 
Influenced by individuals/extremes on graph 
Useful 
Understanding of Linking subscales and using previous subscale 
scenario answer 
Awareness of timescales in scenario and 
impact 
Showing in-depth understanding of groups in 
the scenario 
Showing in-depth thought around subscale 
Scenario Identifying difficult Due to variation in group or differing effects on 
development scenarios individuals 
Due to lack of experience 
Due to their experience not being the norm 
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8.5.4 Primary objective (1): Can patients use information from 
published papers to form an opinion on meaningful 
differences in QOL scores? 
The primary objective was addressed by considering both quantitative and 
qualitative data from the interviews. I considered how many contrasts out of the total 
given were regarded as impossible to judge by the patients and looked at the 
concordance between patients judging the same contrasts. The charting stage from the 
qualitative analysis provides insight into whether patients felt able to use the published 
information. 
8.5.4.1 Individual contrasts patients felt unable to judge 
There were only six instances (occurring in three interviews) where patients felt 
unable to form an opinion. There were a total of 73 judgements on contrasts in the 
interviews (see Table 65), therefore patients felt able to form an opinion in 92% of 
them. Five of the identified issues were from scenario C and one was from scenario D. 
Three of the contrasts were cross-sectional and three were longitudinal. Affected 
subscales were RF, SF and SL. Reasons for not being able to form an opinion were 
due to a perceived lack of information in the scenario (four contrasts) or feeling that the 
effect of the intervention being studied would be very individual, benefiting some but 
having a negative effect on others, meaning that the group average could go either 
way. 
In order to try to address the lack of information in the scenarios for the remaining 
interviews extra information about the study was added to these scenarios. Treatment 
information was added to scenario C and an average age and range for patients was 
added to scenario D. No further problems emerged in later interviews therefore it 
seems likely that this is a shortfall of the original scenarios I designed rather than 
reflecting the patients' inability to use published data. 
8.5.4.2 Concordance between patients - blinded to actual scores 
There were 13 different contrasts represented in the four scenarios and five or six 
patients reviewed each of the contrasts (see Table 65). Perfect agreement between 
patients only occurred for one of the thirteen contrasts (where all patients deemed 
there would be no difference). 61% of the contrasts had up to a maximum difference 
between patients of two size classes (Figure 54). 39% had maximum differences of 
three or more size classes. Although scenario B contained the contrast with perfect 
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agreement from patients the other three contrasts in that scenario resulted in a wide 
range of expected differences (from none to large). Scenario 0 resulted in the most 
disparity regarding the direction of the expected scores. 
Figure 54 Distance between patients' reviews (blinded to actual scores) 
• Exact 
. 1 category 
. 2 categories 
. 3 categories 
. 4 categories 
• 5 categories 
6 categories 
After seeing the actual QOL scores, complete agreement between patients still 
only occurred for the same one contrast. There was a slight improvement in agreement 
by showing patients the actual scores, with 62% of contrasts where patient reviews 
were up to two size classes apart (Figure 55). 
Figure 55 Distance between patients' reviews (after seeing actual scores) 
• Exact 
. 1 category 
. 2 categories 
. 3 categories 
. 4 categories 
. 5 categories 
• 6 categories 
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For this subset the experts had 85% of the contrasts where they disagreed by a 
maximum of one size class and all contrasts had the experts with a maximum of two 
size classes apart (Figure 56). 
Figure 56 Distance between the expert scores for the subset of contrasts 
undergoing patient review 
8.5.4.3 Qualitative results 
• Exact 
. 1 category 
. 2 categories 
. 3 categories 
. 4 categories 
. 5 categories 
6 categories 
Seven major themes were extracted from the data which were felt to inform on 
the question of patients' ability to use the published information (Table 67). These were 
labelled as follows; confidence in their answers, showing in-depth understanding of 
QOL concepts, confidence in project, hard without experience, experience not 
necessary, hard even with experience and judgements based on experience/belief. 
While patients generally provided their expectation of the QOL difference, there 
were often fairly flippant remarks about whether they'd 'get it right' before seeing the 
scores from the paper, particularly if they had already seen a result they were not 
expecting in a previous contrast. Whilst a number of patients commented on the fact 
that it was hard to think of your expectation of the scores without experience of the 
situation in the study, they also commented on how they still felt able to make 
judgements without the direct experience. There was a feeling that they could relate to 
the scenario if they had experienced something similar or could draw on others 
experiences as well as their own but that with experience their answers may differ. It 
was apparent that often a patient's own experience or preference was a factor 
influencing their expectations of QOL differences, particularly if they had strong feelings 
regarding the situation in the scenario. Patients demonstrated some in-depth thinking 
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around QOL concepts, particularly thinking through different aspects of the concept 
being measured. 
Table 67 Ability to use published information 
Major themes Minor themes Quotes 
(number of (number of 
interviews where interviews where 
extracted) extracted) 
Confidence in their Confidence comes But you certainly feel more confident 
answers (7) with experience (1 ) answering things that you have a slight 
knowledge about as to how it's affected 
you, albeit I know it obviously affects 
different people differently, some 
people you know, I think have been 
more affected than me and other 
people you know, much less really. (6 
p23) 
Lack of confidence (6) I didn't really get the questions right (8 
p18) 
I'll be totally wrong here (5 B p21) 
Guessing (1) 
Showing in-depth Discrete nature of Because there's only four options I 
understanding of scoring (1) think the movement between them is 
QOL concepts (6) quite hefty (11 C p5) 
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Major themes Minor themes Quotes 
(number of (number of 
interviews where interviews where 
extracted) extracted) 
Response shift/recall <Talking about the support group> 
bias (1) ... may have answered more 
realistically or honestly because they 
were told to perhaps look at how 
they're feeling (6 C p16) 
People near the end of the treatment 
may have more idea ... but then they 
might have forgotten how it was (6 D 
p11) 
Detailed description of Pain can be different cause it can be 
QOL concept (3) depending how ... how not always 
necessarily the severity of it but the 
frequency of it if you've got it sort of 
permanent sort of pain there then it can 
affect how you feel on the day to day 
basis and it's a nagging thing and it 
drags you down sometimes (4 C p36) 
Don't know what the doctor would 
class it as, like feeling down but not 
clinical depression (1 B p13) 
There's a physical and a mental 
tiredness (3 D p21) 
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Major themes Minor themes Quotes 
(number of (number of 
interviews where interviews where 
extracted) extracted) 
Questions in subscale 
may go in opposite 
directions and cancel 
out an overall 
difference (1) 
Groups in scenario I would say it was quite a big difference 
may have a different because I think even if, because I'm 
reference pOint (1 ) trying to think whether someone would 
have said I've noticed quite a bit 
because they're comparing themselves 
to, if they're not in the support group 
they're comparing themselves to 
people who they are surrounded by 
everyday who are kind of 100% able to 
do everything they want to do so you'd 
feel, emotionally you'd feel that you 
couldn't do as much as them whereas 
if you were in your support group you'd 
see that everyone else has similar 
problems so it'd make you feel that you 
were more, not normal but more 
average. (11 C p5) 
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Major themes Minor themes Quotes 
(number of (number of 
interviews where interviews where 
extracted) extracted) 
Confidence in Need a mix of patients 1 think you'll crack it but 1 think it might, 
project (4) (4) it's weighing up this business of the 
groups, but with it being an individual 
thing ... 1 could tell you all sorts of 
things ... but the person here at the side 
of me that's probably my same age 
might not think the same (9 C p21) 
1 do think in the end the more people 
that you ask, do this test for you know, 
I think everybody's going to have 
different opinions and answers and I 
think when its all put in the mix it will 
come out right won't it 
(5 p29) 
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Major themes Minor themes Quotes 
(number of (number of 
interviews where interviews where 
extracted) extracted) 
Hard without Hard for a layman (5) Not knowing and having them 
experience (8) symptoms it's very hard for a layman to 
judge how much pain they would be in 
(1 A p6) 
Having never experienced that I've 
been lucky I didn't have any arm pain 
or anything so it's hard to know in 
affect just how it would feel, how 
severe it might be 
(4Ap15) 
If you've not had it at all then you will 
not understand ... I think it's easier if 
you're going through the same process 
(8 p17) 
Different types of if you've got hormonal cancer like me 
cancer/chemo have then yeah its totally different you 
different effects (1) become a weeping wailing wreck 
... some having different chemos their 
emotions are different (1 p25) 
More accurate with 
experience (3) 
People are so different even though I had breast cancer I can't 
(1 ) put myself in somebody else's situation 
and ... 1 mean people are just so 
different aren't they? (5 A p13) 
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Major themes M inor themes Quotes 
(number of (number of 
interviews where interviews where 
extracted) extracted) 
View may be different I was answering stuff I haven't really 
with experience (2) got a clue about, I only answered on 
what I saw and you know sometimes 
you see things and you make a totally 
different judgement don't you (1 A p29) 
Perhaps if I had been involved in 
something like that I might have a 
different view on it, I don't know (6 C 
p16) 
Experience not Can use own And people you know that you've met 
necessary (9) experience and others in the clinic what's happened to them 
(1 ) (2 p27) 
Experience does not I mean I still get a bit of pain in my arm 
have to be identical (3) where the chemo strips your veins, you 
know that stops you from doing things 
(5 A p6) 
I'd experienced some other thing that 
had restricted me movement in a ... 
so I could kind of think of that. .. and I, 
just the difference it made to my life in 
a sense for a few weeks till I had some 
treatment for it 
(4 A p43) 
Can think along same 
lines (2) 
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Major themes Minor themes Quotes 
{number of (number of 
interviews where interviews where 
extracted) extracted) 
Subjective rather than I suppose it's subjective in a sense, it's 
objective (1) not as objective as other people 
looking at it but it's still, it's yeah, 
you've got something to base your 
opinion on in a sense (4 A p18) 
Can empathise (1) 
Not for more general your clinics yeah you can ask any 
scenarios (1) cancer patient that because we've all 
been there in some clinic (1 A p28) 
Difficult even with Scenario needs more I've got that and I'm in the same 
experience (2) info (1) situation then, in a sense ... but just 
given on the bare bones like this then it 
would be quite difficult (4 C p33) 
Response shift/recall People near the end of the treatment 
bias (1) may have more idea ... but then they 
might have forgotten how it was (6 D 
p11) 
Judgements based Strong I do honestly believe that them support 
on experience/belief belief/preference groups as you go further on in your 
(8) driving judgements (7) cancers (9 p32) 
I can only go on how I would feel and I 
say I am not one that overly stresses 
but I'd prefer to know straight away (3 
B p25) 
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Major themes M inor themes Quotes 
(number of (number of 
interviews where interviews where 
extracted) extracted) 
Own experience I was fine and when other people were 
driving judgements (3) being sick and feeling really really tired, 
I think that's a big difference and I think 
if I'd have been like that my answers 
would have been different to what I've 
given (5 p27) 
8.5.4.4 Summary: Can patients use information from published papers to 
form an opinion on meaningful differences in QOL scores? 
There were very few instances where patients felt they could not give an opinion 
on a contrast. Generally it appeared that patients felt able to form an opinion using 
published data on meaningful differences in aOL scores as long as there was sufficient 
information in the summary of the study provided in the scenario. 
The distance between reviews from different patients was quite high. The reviews 
were more than three categories apart for nearly half of the contrasts reviewed. This 
was only slightly improved when patients were asked to judge again after seeing the 
actual QOL results. This is compared to the expert reviews where less than 10% of the 
reviews had a distance of three or more categories between the experts. 
It was apparent that although patients were judging the expected QOL differences 
between groups of patients, the patient's own experience and values influence their 
opinions. This is particularly noticeable where patients had an especially positive or 
negative treatment/disease experience. 
8.5.5 Primary objective (2): Can adequate familiarity with the QlQ-
C30 and the way it produces quality of life scores be gained 
during an interview situation? 
Only one patient definitely had experience of filling in the QLQ-C30 questionnaire 
before (as evidenced by participation in a previous study) but three other patients 
thought it looked familiar or thought they had filled in similar questionnaires before. 
Even the patient who was identified as having previously filled in the questionnaire was 
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vague about whether she recalled the questionnaire therefore essentially all patients 
were starting from a similar point in terms of lack of familiarity with the questionnaire 
prior to the interview. 
8.5.5.1 Qualitative results 
A few patients asked questions during the description of the QLQ-C30 at the start 
of the interview and some commented on the fact that symptom and functioning scales 
were scored in opposite directions. Generally patients gave the impression they 
understood the explanation of the questionnaire. 
Four major themes were extracted from the interviews relating to evidence of 
familiarity with the questionnaire gained during the interview or understanding of the 
questionnaire/scoring system (Table 68). 
Some patients referred back to the individual questions making up the subscale 
while answering, showing they were specifically thinking of how the questionnaire was 
measuring the QOL concept. Some referred to the QOL concept as a whole rather than 
the individual questions and others made no reference to the specific questions while 
answering. Reference to the subscale questions could indicate a familiarity with the 
questionnaire gained during the interview or it may simply indicate an understanding of 
the question they were being asked and use of the information provided on paper for 
that subscale. Either way, the importance of having the questions on a sheet of paper 
for patients to refer back to during the interview was clear. 
Often while thinking of the answer for one subscale a patient would be thinking 
abouUdescribing other QOL concepts, particularly if a previous subscale discussed was 
deemed to be relevant to the next one. For some patients it was natural to place 
themselves on the subscales or answer the questions for themselves before thinking 
more generally about the group in the scenario, whereas others only thought of the 
questions abstractly rather than specifically for themselves. Earlier in the development 
of the interview we included a section where patients filled in the questionnaire 
themselves to gain familiarity with it rather than just hearing the description during the 
interview, it may be that this would have been useful for some but not for other 
patients. 
Understanding of the questionnaire and scoring was demonstrated in a variety of 
ways during the interview. Some patients commented on or queried the time period the 
questionnaire covered and how you would fill it in if you had an odd off day on the day 
you were filling it in. Some patients were trying to understand how it works as everyone 
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starts off from a different point or at a different stage in treatment. Understanding of 
scoring was implied in different ways, mainly it was shown when the scores from the 
actual study were given and patients discussed what the graphs showed compared 
with their answers (sometimes interpreting the graphs before an explanation was 
given). Only one patient very clearly looked at the difference in scores from the study 
compared to the scoring system described for that subscale, referring to the sensitivity 
of the summary scores when one question moves one category. Confusion with the 
direction of scores arose in a few interviews but I generally could clarify this during the 
interview. Some patients commented on how confusing it was that for some scales an 
increase in score indicated improvement whereas for others an increase in score 
showed a deterioration in QOL. 
Table 68 Familiarity with questionnaire and scoring 
Major (number Minor (number of Quotes 
of interviews interviews where extracted) 
where 
extracted) 
Familiarity (9) Reference to subscale Rather than tense and worried 
questions while answering (6) they'll be irritable and depressed (5 
B p23) 
Linking subscales (4) Sometimes it might be an emotional 
thing that you need to , that you 
know, that stops you from 
sleeping ... or sometimes it could be 
a physical, that you've got 
discomfort (4 C p37) 
But with it being small (referring to 
pain subscale) they won't be, they 
won't have that much physical 
problems (9 A p27) 
Putting self onto scales (5) 
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Major (number Minor (number of Quotes 
of interviews interviews where extracted) 
where 
extracted) 
Understanding Querying or commenting on It just depends exactly how you feel 
of questionnaire the timing of questionnaire or that day (2 p2) 
(7) period covered (5) I'm sure if somebody had given me 
a questionnaire to fill out in the 
clinic when I was waiting for my 
diagnosis I don't think I would have 
filled it out properly I would have 
been able to concentrate enough to 
fill it out. I wouldn't have really 
thought about the questions, I might 
have ticked certain things but I 
wouldn't have really sat and thought 
about it (1 B p23) 
Awareness of I presume if you can't carry things 
multidimensional nature of then it causes a problem and it 
QOL (4) causes you pain (1 A p8) 
You're not just dealing with the 
physical effects of the disease 
you're dealing with emotional 
effects of the disease the affect and 
sometimes the sort of guilt in a 
sense because you've got the 
pressure on your family around you 
and sort of affecting their lives in a 
sense so there's all these other 
things that come into it (4 p45) 
Showing an understanding of 
how QLQ-C30 may be useful 
(3) 
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Major (number Minor (number of Quotes 
of interviews interviews where extracted) 
where 
extracted) 
Understanding Confusion/clarity with I've got it the wrong way round 
of scoring (10) direction of scoring indicating haven't I (1 A p8) 
improvement/deterioration (3) It would be easy to get confused 
and mark them the other way (2 
p26) 
I can see that that in a sense the 
reasoning behind them doing it now 
you explain it but it does seem to 
make it very complicated and to 
focus on which is which can 
sometimes maybe then it could lead 
to misinterpretation in a sense (4 
p47) 
Reference to scoring system I'd say there's no difference at 
when thinking about answers all ... because you're looking at sort 
(1) of 20 points between each one and 
that's not even 10 (11 B p22) 
.. to shift from one box to another, 
because there's only four boxes so 
to actually move from one to 
another is quite a big difference, so 
I was thinking of that rather than on 
average everyone moving a little bit 
or a lot (11 p28) 
Understanding that your 
baseline score is important 
(4) 
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Major (number Minor (number of Quotes 
of interviews interviews where extracted) 
where 
extracted) 
Suggesting specific I thought that would be more like 60 
score/category for group (8) (8 D p5) 
It would have started at not at all 
and it would go straight up to either 
quite a bit or very much (11 B p21) 
Showing an Confirming answers vs I thought I got quite right didn't I? (1 
understanding of graphs (2) A p5) 
the graphs (3) 
Interpreting before So theirs is better again isn't it? (6 
explanation given (3) C p15) 
So they could do most of it (1 A p8) 
8.5.5.2 Summary: Can adequate familiarity with the QLQ-C30 and the way 
it produces quality of life scores be gained during an interview 
situation? 
Patients demonstrated a familiarity with the questionnaire and scoring in a variety 
of ways. It was not clear that previous experience of filling in the questionnaire was 
particularly useful in gaining familiarity of the questionnaire for this exercise as patients 
generally did not recall whether they'd filled the alQ-C30 in or something similar 
before. The interviewer needs to know the questionnaire, scoring system and scenarios 
really well as often the direction of scoring and of results (whether the difference 
represents an improvement/deterioration) needs clarifying during the interview due to 
function and symptom subscales being scored in the opposite direction. The link 
between the possible range of scores for a subscale and judging the meaning of a 
difference was not apparent in most of the interviews. It may be that by first asking the 
patients to judge expectation without seeing the scores they are less likely to consider 
the discrete nature of the scoring when judging the meaning of the scores from the 
study. 
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8.5.6 Secondary objective: To what extent can patients form their 
opinion using data from a group of patients rather than their 
own individual experience? 
Two overall themes were found to relate to this secondary objective: 1) group or 
individual thinking, as planned in the original theoretic framework; 2) how patients 
approached the task, which emerged throughout the analysis of the transcripts. These 
were combined during the mapping and interpretation stage and are reported together 
here. 
8.5.6.1 Group versus Individual 
Text was extracted from the interviews where it was deemed to show evidence of 
patients thinking about a group of people or thinking of individual situations while 
considering their answers (Table 69). 
It was relatively common for patients to refer to their own experience or to try and 
think how they would feel in the situation in the scenario if they had not experienced it. 
It was also clear that patients understood that they needed to think about a group 
situation, with all patients mentioning the variation of people within a group; 10 patients 
clearly referring to a group situation in their answers. Six patients referred to how hard 
it was to think about the average from a group rather than an individual. Some patients 
discussed their experience of others or thought more in the abstract about the group 
while thinking of their answers. 
8.5.6.2 How patients approached the task 
How individual patients approached the task emerged as a new theme while 
reviewing the transcripts. It is summarised here under two minor theme headings: 1) 
using their own experience then generalising to a group; 2) no reference to their own 
experience. It shows that although most patients had a tendency to mention or think 
about their own experience they were also putting this into the context of the group in 
the scenario. 
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Table 69 Evidence of group versus individual thinking 
Major (number Minor (number Quotes 
of interviews of interviews 
where where 
extracted) extracted) 
Group (11) Awareness of Some might not be able to take ... some of us 
variation in group can take pain quite well others speak out first (1 
(11 ) A p6) 
There's such individual variations about it, you 
know, some people it would affect them in a 
negative way in a sense and other people it 
could you know it could be very positive for them 
(4 C p22) 
And of course you get such variation from 
people don't you (7 B p10) 
We've all got different anxieties that keeps us 
from sleeping (9 C p10) 
Clear group I was thinking back to myself because obviously 
thinking (10) you just think how did I go through it and you 
just think well on a scale of average I must be 
just average because I'm just someone else (11 
p27) 
I would feel as a general group ... (4 A p11) 
so tempted to just answer for myself, I mean I 
can't you don't want me to do that do you? You 
want me to think about the group? 
(2 C p6) 
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Major (number Minor (number Quotes 
of interviews of interviews 
where where 
extracted) extracted) 
Reference to I had pain but it didn't stop me from doing 
others in the anything ... And I'm sure other people have had 
abstract (7) pain and it has stopped them (5 A p6) 
Some people might feel quite poorly (6 0 pg) 
Reference to I was absolutely fantastic ... I know friends that I 
experience of made while I was having chemotherapy that 
others (4) were very ill and sick and terrible (5 A p5) 
Some people carried on working, I just felt so 
poorly (2 C p15) 
Thinking of I mean if you say medium that covers most, so 
majority (4) medium I would say, but you will have the 
isolated large (10 A p16) 
I think it would kind of vary between a little and 
quite a bit ... and you'd get the odd one or two 
that says very much (11 C p5) 
Finding average It's so difficult when you've got to do it, it's 
difficult (6) getting my head round just this average group ... 
because everybody's an individual (2 C p14) 
it's very difficult to know because individually 
there will be people who respond differently (4 C 
p21 ) 
It's hard to think in groups isn't it? .. 
When you know individuals and things. 
(10 B p11) 
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Major (number Minor (number Quotes 
of interviews of interviews 
where where 
extracted) extracted) 
Individual (9) Reference to self if it me .. not been down that road my feelings 
in the abstract would be ... (1 A p4) 
(4) I'm thinking, you know, if it's me at this stage (8 
p17) 
Reference to it still kind of put my own perception on it rather 
own experience than focussing on knowing what a 50 year old 
(7) woman's kind of going through. 
(11 p27) 
I could still do everything like that (1 B p13) 
I think to be honest it's got to be how I 
experienced it and I certainly was very limited 
with work and my daily activities (2 C p 7) 
Answering I had no trouble sleeping, not on chemo (9 C 
subscale for self p10) 
(3) 
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Major (number Minor (number Quotes 
of interviews of interviews 
where where 
extracted) extracted) 
Approach to Using own I just go on gut feeling and me own 
task (11) experience then scenarios ... you know what I've been through 
generalising (10) and sort of try to put my experiences in some 
sort of middle ground, because we're all different 
and how I would I would look at it and expect 
them to feel. (1 p27) 
I know it obviously affects different people 
differently, some people you know, I think have 
been more affected than me and other people 
you know, much less really. I think that depends 
on what's the matter. (6 p23) 
I was thinking back to myself because obviously 
you just think how did I go through it and you 
just think well on a scale of average I must be 
just average because I'm just someone else (11 
p27) 
No reference to So I think probably for this first lot no because I 
own experience mean slight arm pain, I think, I don't think it 
(2) would impinge on doing any of these like 
walking and things (4 A p14) 
8.5.6.3 Summary: To what extent can patients form their opinion using 
data from a group of patients rather than their own individual 
experience? 
All patients seemed able to grasp the concept of thinking about a group situation 
rather than an individual one and were aware of the need to do this during the 
interview. However, it was common for patients to mention it was difficult to think about 
an average. Some clearly went on their own experience or preference to form opinions 
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and a minority seemed to form an opinion just on the information in the scenario, 
approaching the task in a more generic and abstract way. Even if patients did use their 
own experience to form an opinion they seemed to try to think about their experience 
versus others in order to extrapolate to an answer for a group rather than an individual. 
8.5.7 How do patients' opinions compare with clinicians opinions 
when using the same published data? 
Three experts reviewed each of the scenarios. Scenarios A and 0 were also 
reviewed by five patients and scenarios Band C by six patients. 
8.5.7.1 Quantitative results 
The maximum difference between patients and experts was 1.1, which equates 
roughly to a difference of one size class (Figure 57). There are two instances where 
patients and experts judged the differences in opposite directions. Whilst there was 
sometimes wide variation in the expert scores there were no disagreements between 
experts in the direction of expected change for the contrasts used in the scenarios. 
However, there were two of the contrasts on scenario 0 that led to patients having 
expectations in opposite directions from each other. 
Where patients and experts agreed on the direction of the change (11 contrasts), 
the patients' opinion was larger in magnitude for six of the contrasts and smaller for five 
of the contrasts. 
Figure 57 Expert versus patient opinion 
3 ~----------------------------------------
2 +-__ ----------------_.--------------------
1 
o 
• Expert 
-1 +-------------~----------------------- • Patient 
-2 +-----------------------------------------
A B c D 
- 250-
Figure 58 shows the average patient and expert scores for each contrast 
compared with the actual scores from the papers . The correlation between patient 
scores and the actual scores was 0.25. This is similar to the correlation seen in the 
overall study between the experts and the actual scores for longitudinal contrasts 
(0.28). However, the correlation between the average expert scores and the actual 
scores for the subset of contrasts used in this pilot study was much lower (-0.01) than 
for the patients. Note that I deliberately chose some contrasts where the experts had 
disagreed with each other in order to test these contrasts on patients however this is 
still similar to the correlation seen in the overall study for the cross-sectional contrasts 
(-0 .03). 
Figure 58 Correlation of average patient and average expert scores versus 
actual scores 
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8.5.7.2 Qualitative results 
Generally patients made few comments on the differences between their 
judgements and those of the experts, even if they were surprised by the differences. 
Those who did comment talked about why there may be differences or agreement 
between them and also commented on the ability of clinicians to judge on QOL 
differences. A summary of the comments are displayed in Table 70 under three major 
sub-themes grouping the comments into those about the ability of clinicians to judge 
patients' QOL and comments relating to why there may be agreement or disagreement 
between the patients and experts. 
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Table 70 Patients versus clinicians: patients' comments 
Major Minor (number Quotes 
(number of of interviews 
interviews where 
where extracted) 
extracted) 
Ability of Able (4) If they're seeing them in clinics then they would, 
clinicians to you would definitely know because even if the 
judge (5) patient said oh no I'm fine, you'd see how they 
were sitting and how they came in and that sort of 
thing (11 B p23) 
I also think doctors are very very good because 
they can know who people, what they need really, 
and I think they can soon weigh you up (9 C p1 0) 
I mean the doctors should know because they 
keep the notes and they see everybody don't they 
so between them they should be able to come up 
with the answers (5 A p14) 
Not able (1) Well they're probably looking at it from the point of 
view that they, the doctors and nurses, have 
actually done something about this problem and 
therefore in their eyes have, not solved it entirely 
of course, but they've gone, they've cut out the 
immediate one, you know they've got over the 
first hurdle ... But that's not the story really, your 
first hurdle is your first hurdle and then people 
then go on to do other things (10 B p13) 
Reasoning for Can use their Or is it that this pain is manageable and do the 
differences (4) experience (1) doctors know through their experience and the 
amount of people they've seen with it realise that 
yeah they might be in a little bit more pain but not 
much (1 A p6) 
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Major Minor {number Quotes 
(number of of interviews 
interviews where 
where extracted) 
extracted) 
Experts may They're probably looking at it from the point of 
assume positive view that they, the doctors and nurses, have 
outcome (1) actually done something about this problem (10 B 
p13) 
Place different 
importance on 
QOL changes 
(1 ) 
Can see reasons ... think it just depends on how, if you were feeling 
why differences really well before or whether you were having 
could be either some effects really (6 D pg) 
way round (1) 
Reasoning for But I suppose I'm in some way imagining what the 
agreement (1 ) doctors and nurses are telling me you know, and 
the information that you're given as well, I haven't 
experienced it yet (6 C p20) 
... a lot of it I'm going off what the doctors and 
nurses have told me as to how I imagine that I'll 
recover from the chemotherapy really (6 p22) 
8.5.7.3 Summary: How do patients' opinions compare with clinicians' 
opinions when using the same published data? 
The maximum difference between the average patient and expert scores was 
only one size class. Patients were just as likely to judge differences to be larger or 
smaller when compared with the experts opinions. The patient opinions correlated 
more highly with the actual scores in this subset of contrasts than the expert opinions. 
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8.5.8 Does the proposed interview need developing further prior to 
a larger study? Is the information presented in a way patients 
can understand? 
8.5.8.1 Scenario development during the course of the interviews 
Interviews were reviewed after every three interviews to see if patients were 
asking for information that was not available in the scenario summary. During the 
course of the interviews all the scenario summary sheets were amended slightly as 
patients raised queries about the study or patients in the study. The majority of 
changes were made to include extra treatment information and this makes sense given 
that it was evident that the majority of patients (10/11) used treatment information to 
inform their decisions. Other information that was discussed as useful to have in the 
scenario was:- type and severity of pain (one patient), other QOL dimensions (one 
patient referring to the fact that sleep depends on emotional, pain and symptoms). 
8.5.8.2 Patient definitions of small, medium and large differences 
During the interviews patients were asked to define the size of the difference they 
expected, and the wording suggested by the interviewer was 'small', 'medium' or 
'large'. In order to understand how patients approach the task and to see if the wording 
for size classes should be further developed, patients were asked at the end of the 
interview whether they had specific definitions of small, medium and large differences 
in mind when deciding upon a size class for each contrast. Data was also extracted 
and is summarised here to show more generally the wording patients were using 
themselves while working out the differences. Generally, when asked to define what 
they were thinking when deciding between small, medium and large, patients only gave 
a definition of what they thought would make a difference large. No common definition 
emerged. While working through the scenarios patients used a wide variety of terms to 
think of the size of the difference but most commonly used the categories from the 
QLQ-C30, i.e. a little, quite a bit etc. One patient commented that the wording used in 
the interview was irrelevant really. It was also common for patients to say they just 
went on a 'gut instinct' for each rather than having a specific definition in mind. 
- 254-
Table 71 Description of small, medium and large differences 
Major (number Minor (number of Quotes 
of interviews interviews where 
where extracted) 
extracted) 
Specific definition Treatment working; Like I was last year when the tablets were 
of small (1) no pain and able to working and I felt wonderful and I didn't have 
function (1 ) any pain, you know and I could do all those 
things like lift bags and that (1 p28) 
Specific definition Sizeable (1) A sizeable difference (11 C p8) 
of medium (2) 
Ups and downs (1) Medium is like I always think I am on a you 
know mostly bobbing about but then having 
a few dips and then go up (1 p2S) 
Specific definition Extremes (1 ) ... in extreme pain, not being able to do 
of large (5) anything, being totally depressed and not 
being able to do anything (1 p2S) 
Own experience vs I think a large difference is when, I mean I 
others (1) was fine and when other people were being 
sick and feeling really really tired, I think 
that's a big difference (5 p27) 
A little vs A lot (1) Trying to get in to sort of the mind of 
someone to think what would make them 
change from answering 'a little' to 'a lot' or to 
'completely'. (11 p27) 
A marked ... so I just thought there just be a marked 
difference (1 ) difference between me and the other person 
(S p19) 
Significant It could make a large difference in a sense if 
difference on your you've got lots of physical things that are 
life (1) affected by it kind of thing and or if you find it 
emotionally very difficult to deal with then 
again it can have quite a significant 
difference on your life so it was trying to sort 
of think of that (4 p44) 
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Major (number Minor (number of Quotes 
of interviews interviews where 
where extracted) 
extracted) 
Using A little, quite a bit, I think it would kind of vary between a little 
questionnaire very much (8) and quite a bit (11 C p5) 
responses (8) 
Other wording Percentages( 3) Let's say 15 out of 20 do well here compared 
to 3 or 4 out of 20 here (8 C p12) 
I would think medium to ... 55% ... yeah (3 C 
p15) 
Marked (2) I think there'd be a marked difference 
between the two groups because it would be 
obvious (8 C p11) 
Slight (2) There's a slight difference but I wouldn't say 
a 10t ... 1 wouldn't say a marked difference (1 
Ap9) 
Average (1) It's hard to put maybe average I suppose I 
don't know (4 A pg) 
Substantial (1) I think it might be quite substantial (4 A pg) 
Wording I think you automatically picture in your mind 
irrelevant (1 ) anyway it's the same thing however its 
worded (3 p25) 
Not specific (7) Gut instinct (7) How I felt for each really (7 p22) 
just gut instinct really of the sort of medium, 
just somewhere in the middle really isn't it, 
and that either side of that would be the 
small or large bit (6 p22) 
8.5.8.3 Impact of showing patients the actual scores 
In the majority of cases (63% of contrasts judged in the interviews) the patient did 
not change their judgment after seeing the scores. On average the patients reduced 
the size of their scores by a mean of 0.1 points (median of zero) once they saw the 
actual mean scores. There were only two instances where patients decided to change 
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the direction of their original judgement and only three instances (out of 19 changes) 
where they increased the size of their score after seeing the results from the study. 
8.5.8.4 Is information presented in a way patients can understand? 
During the interviews there were a number of occasions where clarification was 
required from the interviewer either on the details of the scenario or on the question 
being asked. Some of the scenarios had a lot of information in them and forgetting one 
fairly small detail may have had a big impact on the results. For example, one patient 
was discussing scenario C and referring to how the support group would help after 
diagnosis but the setting was in metastatic breast cancer on average 5 years after 
diagnosis. Generally, queries or misunderstandings were easy to resolve during the 
interview by reminding the patient of some of the details. Sometimes it was hard to 
steer the patient into judging the difference required between groups or over time either 
because they were talking about the individual groups or were trying to answer the 
subscale questions for themselves. 
Patients seemed to understand the graphs and some commented that they found 
them useful to help visualise the group. Sometimes there was initial confusion with the 
direction of the change shown by the graphs but this could be easily clarified in the 
interview. A number of patients interpreted the graphs before an explanation was 
given, a lot of them commenting on how they thought the graphs compared to their 
answers, e.g. higher or lower than expected. However, I was concerned that 
sometimes there was an over-reliance on the graphs, which were designed to show 
what an average score might look like rather than the actual results from individuals in 
the study. In particular, patients sometimes highlighted individual patients as standing 
out on the graphs and swaying their decision. 
Table 72 Presentation and understanding 
Major (number of Minor (number of Quotes 
interviews where interviews where 
extracted) extracted) 
Confusion with Forgetting timelines of Oh right, well that puts a different 
details of scenario patients from diagnosis reflection on it again. 
(3) (1 ) (9 C p11) 
Patient referring to pain I can't understand why one lot of 
but scenario is regarding people are saying that they haven't 
symptoms (1) had any pain (5 A p6) 
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Major (number of Minor (number of Quotes 
interviews where interviews where 
extracted) extracted) 
Patient referring to normal I think to some extent they should be 
care group as having no limited because they are alone they 
support (1) don't have any support whatsoever (8 
C p11) 
Confusion with Needing clarification of Is this for group one then first we're 
required task (4) difference rather than by doing? (1 A p7) 
group (3) 
Trying to complete task Problems in the arm, oh this is in the 
with reference to self last month, well I, ... no definitely not 
rather than scenario (3) stiff, no, no pain, no, I've had no 
infections. (5 A p6) 
Not understanding Can I just ask why we need to know 
purpose of scoring the scores? (5 A p9) 
explanation (1) 
Graphs (9) Own interpretation (8) I'm surprised, I think that is quite 
good, higher than I thought it would 
be (9 C p9) 
It's getting back to how they were 
prior to chemotherapy (6 D p9) 
Confusion with direction I'm getting it the wrong way round to 
of difference (2) the, oh of course, this is the best 
bunch so in effect. .. (4 C p24) 
Influenced by It's obviously noticeable for one 
individuals/extremes on person (6 C p19) 
graph (5) when you look at the graph you've 
got a little person, you've got person 
at the very beginning of the graph 
and somebody at the end (2 p25) 
Useful (3) The graphs were brilliant because it 
shows you the shift (11 p29) 
- 258-
Major (number of Minor (number of Quotes 
interviews where interviews where 
extracted) extracted) 
Understanding of Linking subscales and So they've only got a little bit of pain, 
scenario (9) using previous subscale so they can do most things (1 A pg) 
answer (1) 
Awareness of timescales It can often take much more than 8 
in scenario and impact (5) weeks really but of course we are 
speaking about the 8 week period (10 
B p12) 
It's not as if they've just had surgery 
or something anyway is it where your 
ability's not that good anyway and 
then over a short space of time it gets 
a lot better(11 C p13) 
Showing in-depth Is it because there's a lot of being in 
understanding of groups the support group that their activities 
in the scenario (5) may be limited? (8 C p10) 
I was going to ask as well you know 
this relaxation exercise, did group 
two know about this exercise, did 
they have it in a like a leaflet or 
anything or was it just given to the 
support group? (11 C p4) 
Showing in-depth thought If you've got a stiffness in an arm and 
around subscale (3) depending on which ... whether it's 
your sort the arm you used most of 
all you know if you're left handed or 
right handed that obviously could 
affect... (4 A p14) 
B.5.B.5 Summary: Development for future interviews 
The scenario summary sheets were improved over the course of the interviews, 
adding extra information where it was deemed to be required. This was mainly the 
addition of treatment details or further clarification of the groups in the scenario. 
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Scenarios C and D may have been lacking in some of the information patients required 
as this information was not available from the paper. 
The wording used in the interview to describe differences (Le. small, medium or 
large) is probably sufficient, although sometimes patients judged in between these 
categories. The other wording that could be considered is based on the QLQ-C30 
question responses of 'not at all', 'a little', 'quite a bit' and 'very much'. 
Seeing the actual scores from the study had a small impact on patients' opinions. 
Where patients did change their mind the tendency was to reduce the size of the aOL 
difference compared to their original expectation. 
Patients seemed to understand the information presented in the interview 
although there is a lot of information to remember and reminders of the scenario details 
were sometimes required from the interviewer. The concept of looking at the difference 
between groups at a certain point in time rather than individual groups over time was 
sometimes hard for patients to understand. Although the graphs were highlighted as 
useful and patients seemed to be using them to compare with their original 
judgements, care needs to be taken in how the distributions of individual stick figures 
on the graphs are drawn as there was some evidence that sometimes stick figures at 
the extremes unduly influences some patients' judgements. 
8.5.9 Which types of scenarios should be developed for a further 
study? 
8.5.9.1 Which scenarios were easier? 
As described previously, each patient considered two scenarios during the 
interview. Patients were asked if they found one scenario easier to think about than the 
other. Only two people thought they were of equal difficulty, both of these had 
scenarios C and D. Most patients (9/11) found one scenario was easier than the other. 
The scenario most consistently appearing easier was scenario B which five patients 
identified as easier. Generally people seemed able to relate to this as it was regarding 
clinics and waiting for diagnosis. The scenario most consistently appearing harder was 
C, which was never chosen as the easiest scenario. This scenario was looking at 
patients attending a support group compared with normal care. Although scenario C 
had further information added as the interviews progressed (average age, time from 
diagnosis and treatment information) it was still identified as harder, either because 
patients found it hard to relate to without having experienced a support group of that 
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nature or because they felt that whether a patient benefited from it or not was a very 
individual thing. 
Table 73 Easier/harder scenarios 
Interview Easier Harder Reasons (summarised from interview text) 
scenario scenario 
1 B A Can ask any cancer patient scenario B as all 
been in a clinic. Scenario A was harder because 
she didn't have arm problems. (p26,28) 
3 B D Scenario B, the stress factor, easier to imagine 
how people would respond. (p25) 
4 A C Scenario A easier as looking at physical things, 
even though she hasn't experienced it exactly as 
in scenario. Scenario C harder as more 
information needed, it was very individual as to 
whether patients would benefit or not. (p22,41) 
5 B A Couldn't get head around A (p26) 
6 D C D easier because relevant to the treatment she's 
had, also could imagine herself and how she 
would feel if in the older age group. C didn't have 
enough information - needed treatment details 
(p21 ,22) 
7 B D D needs more information, age alone is not 
enough, there are a wide variety of people within 
an age group eg in terms of physical fitness 
which effects how well you do. (p14-16,21) 
9 A C Scenario C is a very individual thing. Scenario A, 
pain and physical are logical and can relate to 
this more. (p30,31) 
10 A B Scenario A easier because she was a nurse (now 
retired) and because of her experience of talking 
to people. (p18) 
11 B C Scenario B easier as can relate to how they'd be 
feeling in the clinic situation. Scenario C harder 
as not been in a support group and also not at 
that stage of disease. (p26) 
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Patients raised a few difficulties relating to specific scenarios (Table 74). Difficulty 
in judging aOL differences arose where there was a broad group of patients in a study 
or where the effect of the intervention or situation could vary greatly between patients. 
Certain scenarios were harder without experience, in particular scenario A was 
highlighted as hard to judge without experiencing arm problems yourself. 
Table 74 Difficult scenarios 
Major Minor In relation to Quotes 
(number of (number of which 
interviews interviews scenarios 
where where (number of 
extracted) extracted} interviews) 
Identifying Due to A (1) It's a bit difficult because it really 
difficult variation in B (1) does depend on the person, it could 
scenarios group or C (2) be quite large in some cases (10 B 
differing D (1) p6) 
effects on 
individuals (4) 
Due to lack of A (3) ... having never experienced that ... 
experience (4) 0(1 ) it's hard to know in affect just how it 
would feel, how severe it might be 
(4 A p15) 
But not having been there yet, it's 
quite hard you know, it's just an 
assumption really (6 D p8) 
Due to their D (1) I mean I have some friends and 
experience not they really don't get involved with 
being the anything ... I mean I was playing 
norm (1) badminton at 77 you know and 
walking with them you know coast 
to coast, all sorts you know long 
walks ... So and this is all since I 
retired which is 60, you know so, 
you know it's difficult for me to 
judge (7 D p15) 
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8.5.9.2 Are any of the subscales easier for patients to judge? 
Six patients felt there was no difference between the subscales in terms of the 
difficulty in thinking about aOL changes on that subscale. Four patients felt there were 
differences in difficulty and one patient was not asked to comment on the difficulty of 
the subscales (this was an omission on my part). All four patients highlighted the 
physical functioning subscale as easier, one also mentioned fatigue and one also 
mentioned pain as easier. Role functioning and sleep subscales were described as 
harder because they are very individual by one patient and similarly emotional 
functioning was described as an individual thing by another patient. 
8.5.9.3 Summary: scenarios for future studies 
These findings would suggest that studies with which the majority of patients can 
relate to (e.g. scenario B looking at different types of clinics for diagnosis) are the most 
useful to use for this purpose. These are easier for patients to judge the expected aOL 
changes. Scenarios relating to specific symptoms or problems may be best aimed at 
people with similar experience to that in the scenario rather than patients who have not 
experienced those or anything similar. Scenarios need to use studies where the groups 
are well-defined and not too varied in terms of disease or patient characteristics. 
Studies of psychosocial interventions (e.g. scenario C support group therapy) may not 
be useful as the effect of the intervention can vary so greatly depending on the 
individual. No subscales were highlighted as too difficult to judge although only seven 
out of the possible 15 have been used in these interviews. 
8.6 Validity 
Four transcripts were independently reviewed and coded by the rest of the study 
team. Only minor discrepancies in coding were noted on one of the transcripts and 
these were amended. These would not have changed the interpretation of the results 
as they only changed coding at the level of the minor themes. 
8.7 Patient opinions - Conclusions and discussion 
The study showed that patients were able to do the required task and there was 
some indication that their opinions could be more closely related to the actual scores 
from the original papers than the expert scores were. However, the agreement 
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between patients was much poorer than the agreement between experts, for this 
subset of contrasts and also compared with the full set of contrasts. For future studies it 
may be necessary to consider a consensus process if patient opinion is to be used to 
develop interpretation guidelines. 
Patients recognised the need for a mix of patients to review the contrasts due to 
wide variety of experiences and opinions they may have. It was also apparent that 
patients rely on their own experience of the disease and treatment in making their 
decisions. Patients' values and personality may also influence how they judge the QOL 
differences. For these reasons a patient panel may have to be larger than the expert 
panel in order to capture the wider range of opinions. 
For future studies, careful consideration needs to be put into the types of studies 
that can successfully be used as scenarios. Studies need to have a sufficient amount 
of detail in terms of patient and disease characteristics and have a study population 
that is not too diverse. The format of these interviews worked well but a decision would 
need to be made up front as to whether patients were to carry out the task with or 
without the knowledge of the QOL scores. Although we tried to address which was 
better in this study, I found that once patients had made their decision on a blinded 
basis they were unlikely to change their scores after seeing the actual QOL changes. 
We cannot tell from this study if showing the patients the QOL scores first would have 
resulted in better agreement. 
Although there were issues with the patient reviews, most notably the lack of 
agreement between patients, this study succeeded in presenting the information in a 
way patients could understand and obtained patient opinion on the size of QOL 
differences. The description of the QOL questionnaire and mechanism for obtaining a 
score seemed to be well understood and enabled patients to make decisions on QOL 
differences from the study scenarios. Patient opinions should be considered alongside 
expert opinions for future studies as it was apparent that they offered a different 
perspective and insight as to the likely size of difference in QOL scores. I would 
recommend an initial training program for the patients, similar to that carried out for the 
expert panel. However, rather than patients then working remotely, better quality 
reviews are likely if the patients and experts work together. This could be as part of a 
focus group in order to reach a consensus or reject contrasts where opinions are too 
varied. 
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9 Overall Conclusions and Discussion 
Sections of this chapter have been based on the Discussion in our Journal of 
Clinical Oncology paper (full reference below). The text has been re-written here with 
further details and new discussion points, particularly since the original article only 
reported the cross-sectional guidelines. 
Kim Cocks, Madeleine T. King, Galina Velikova, Marrissa Martyn-St-James, Peter 
M. Fayers and Julia M. Brown. "Evidence-Based Guidelines for the Determination of 
Sample Size and Interpretation of the European Organisation for the Research and 
Treatment of Cancer Quality of Life Questionnaire Core 30" Journal of Clinical 
Oncology (Jan 2011), Number 29, Issue 1, p89-96. 
9.1 Introduction 
Quality of life questionnaires are now widely used in health services research but 
the question around how to interpret QOL scores has been the subject of much debate. 
Although a number of different methods have emerged to try to find the minimally 
important difference between QOL scores there are a lack of guidelines that are 
specific to the questionnaire being used. 
The EORTC QLQ-C30 is one of the two most widely used questionnaires to 
measure QOL in cancer patients and the focus of this research. When I conducted a 
systematic review of the RCTs reporting QLQ-C30 scores I found that, although the 
standard of reporting was high, the clinical meaning of QOL changes was rarely 
addressed. If clinical significance was addressed, there was no clear standard used for 
the interpretation. This research therefore aimed to produce interpretation guidelines 
specifically for the QLQ-C30. 
Given that the questionnaire had been in use for a number of years we used a 
novel approach in order to develop guidelines using the rich evidence-base available 
from published studies reporting QLQ-C30 scores. 
9.2 Summary of study and results 
The study consisted of a literature search to find all sources of mean scores from 
the QLQ-C30 followed by a meta-analysis to estimate the size of trivial, small, medium 
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and large differences. A panel of experts were used to group the published mean 
scores into the size classes for the analysis . I also conducted interviews with patients 
to see if we could develop the methodology further to incorporate patient opinion into 
the guidelines in the future. 
The study succeeded in producing evidence-based interpretation guidelines, 
based on high quality studies, for trivial to large QLQ-C30 QOL differences (Table 75 
and Table 76). The novel methodology for deriving the guidelines was found to be a 
robust and valid approach following in-depth analysis and qualitative work carried out 
with both experts and patients. 
Table 75 Guidelines for size of cross-sectional differences 
Threshold Sub· Mean difference Effect size 
between scale Triv Small Medium Large Triv Small Medium Large 
small and 
medium 
estimates 
<10 points 01 0-3 3- 7 >7 - 0-0.1 0.1-0.4 >0.4 -
NV 0-3 3- 8 8 - 15 >15 0-0.2 0.2-0.5 0.5-0.8 >0.8 
CF 0-3 3-9 9 -14 >14 0-0.2 0.2-0.4 0.4-0.7 >0.7 
DY 0-4 4-9 9 - 15 >15 0-0.1 0.1-0.3 0.3-0.6 >0.6 
10-15 FI 0- 3 3 - 10 >10 - 0-0.1 0.1-0.4 >0.4 -
points QL 0- 4 4 - 10 10 - 15 >15 0-0.2 0.2-0.4 0.4-0.6 >0.6 
SF 0-5 5 - 11 11 - 15 >15 0-0.2 0.2-0.4 0.4-0.6 >0.6 
SL 0- 4 4 - 13 13 - 24 >24 0-0.1 0.1-0.5 0.5-1 >1 
FA 0- 5 5 - 13 13 - 19 >19 0-0.2 0.2-0.5 0.5-0.8 >0.8 
CO 0- 5 5- 13 13 - 19 >19 0-0.2 0.2-0.5 0.5-0.8 >0.8 
PA 0- 6 6 - 13 13 - 19 >19 0-0.2 0.2-0.5 0.5-0.8 >0.8 
PF 0- 5 5 - 14 14 - 22 >22 0-0.2 0.2-0.6 0.6-1 >1 
AP 0- 5 5 - 14 14 - 23 >23 0-0.2 0.2-0.6 0.6-1 >1 
>15 points RF 0-6 6 - 19 19 - 29 >29 0-0.2 0.2-0.7 0.7-1 .1 >1.1 
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Table 76 Guidelines for size of longitudinal differences 
Threshold Sub· Deteriorations No Improvements 
between small scale difference 
and medium Large Medium Small Trivial Small Medium Large 
improvements 
(deteriorations) 
<10 (>-14) FI NE <-10 -10 to-2 -2 to 3 >3 NE NE 
CF NE <-7 -7 to -1 -1 to 3 3 to 7 >7 NE 
PF <-17 -17 to -10 -10 to-5 -5 to 2 2 to 7 >7 NE 
QL <-16 ·16 to -10 -10 to-5 -5 to 5 5 to 8 >8 NE 
SF NE <-11 -11 to -6 -6 to 3 3 to 8 >8 NE 
EF NE <-12 -12 to-3 -3 to 6 6 to 9 >9 NE 
NV <-16 -16to-11 -11 to -5 -5 to 3 3 to 9 >9 NE 
OY NE <-11 -11 to -5 -5 to 2 2 to 9 >9 NE 
FA <-15 -15 to -10 -10 to-5 -5 to 4 4 to 9 >9 NE 
SL <-17 -17 to -9 -9 to-2 -2 to 5 5 to 9 >9 NE 
PA <-20 -20 to -11 -11 to-3 -3 to 5 5 to 9 9 to 14 >14 
~10 (~-14) CO NE <-15 -15 to -5 -5 to 4 4 to 10 >10 NE 
01 NE <-15 -15 to-5 -5 to 3 3 to 11 >11 NE 
RF <-22 -22 to -14 -14 to -7 -7 to 6 6 to 12 >12 NE 
AP <-26 -26 to -14 -14to -2 -2 to 7 7 to 13 >13 NE 
9.3 Conclusions and discussion 
The guidelines utilised almost 3500 contrasts from published scores and 
incorporated reviews from 34 cancer and quality of life experts. These new estimates 
highlight that previous guidelines may be too simplistic in that they do not distinguish 
between subscales and are applied to both longitudinal and cross-sectional 
differences. We add to the current literature by providing separate guidelines for 
interpreting differences arising from between group comparisons and those measured 
over time. The guidelines are also specific for each QLQ-C30 subscale. Researchers 
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can now more accurately calculate sample size according to the subscale of primary 
interest. 
Our study also indicated that deteriorations over time are generally larger than the 
corresponding estimate of an improvement for the same subscale, therefore a global 
rule for a clinically meaningful change is not appropriate. Cella et a/(86) also observed 
that patients indicating a change for the better using the FACT-G questionnaire were 
more responsive to small changes whereas those experiencing a worsening required a 
somewhat larger degree of change. Our longitudinal guidelines therefore allow specific 
interpretation according to whether scores improve or deteriorate over time. 
Both the longitudinal and cross-sectional guidelines are more widely applicable 
than those currently available as they are based on more than 200 papers from a wide 
range of cancers and clinical situations. Previous work from Osoba et a/( 49) was based 
on around 350 patients from two studies of breast and lung cancer and King et a/(19) 
used 14 cancer studies. 
9.3.1 Recommendations for practice 
We suggest the threshold between trivial/small in our guidelines would be the 
smallest estimate on which to base a sample size. Depending on the individual study 
and the type of interventions larger differences may be of interest and the range of 
small or medium estimates could be used. Our study showed that it was rare for the 
experts to expect large differences between groups even when comparing very distinct 
groups of patients. Of particular interest when designing clinical trials is the fact that if 
we retrospectively apply our cross-sectional guidelines to the contrasts comparing 
treatments from RCTs, large effects are observed in only 14 (2%) of the contrasts. 
Also, large differences over time were almost non-existent. This lack of large 
differences has also been observed in other studies of patients over time(49;86). 
Therefore, researchers designing a clinical trial should consider at the outset if large 
effects can reasonably be expected. Observed changes in the QLQ-C30 subscales 
over time are likely to be small in most clinical situations as seen in our observed 
differences. This could be due to response shift in patients filling in the questionnaire 
over time(97). Care should be taken in planning studies where the primary aim is to 
observe a change over time in QOL measured by the QLQ-C30. 
Compared to King(19) our results for small effects are very similar for physical, 
role, cognitive, nausea and pain. For the cross-sectional contrasts our estimates of 
medium effects lie in the same range as suggested by Osoba et a/ (10 to 20 points) for 
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global QOL (10-15 points), social (11-15 points), pain, constipation and fatigue (13-19 
points) subscales. For certain subscales (e.g. NV and 01) these commonly used 
guidelines will under-estimate sample sizes and may also miss important differences in 
QOL when used for interpretation. At the other end of the spectrum, our guidelines 
indicate that sample size calculations using the RF subscale in particular will be over-
powered if using the 10 point threshold. Our guidelines indicate that the importance of 
changes on the RF subscale may currently be over-estimated, for example a difference 
of 20 points would be interpreted as moderate/large using Osoba's guidelines but is 
small/medium using our guidelines. 
For the longitudinal contrasts our thresholds between small and medium 
improvements were mainly smaller than Osoba's 10 point threshold (7 to 9 pOints for 
10 of the subscales). The medium deteriorations on the other hand had thresholds of 
10 points or more for 13 of the subscales. 
Our study and King's considered group differences using published data whereas 
Osoba used individual patients' ratings of change over time to produce guidelines. 
Despite these differences, there was substantial overlap in the resulting guidelines from 
the three studies. 
There were also similarities in the meta-analysis estimates between the EBES 
project for the FACT-G and our meta-analysis estimates. Although the items are 
different in the two questionnaires there is some overlap between the subscales and 
domains. The physical well-being domain from EBES had effect size estimates of 0.42 
and 0.87 for small and medium cross-sectional effects respectively compared to our 
physical functioning subscale with estimates of 0.41 and 0.84 respectively. The 
functional well-being effect size estimates were a little smaller than our role functioning 
estimates (0.37 and 0.71 for small and medium in EBES versus our estimates of 0.46 
and 0.84). The emotional well-being estimates were 0.32 for small effects and 0.40 for 
medium effects in EBES. Our small effect size estimate for emotional functioning was 
similar, 0.35, but the medium effect was lower (0.28). The social/family well-being 
estimates from the FACT-G were much lower than our estimates for the social 
functioning subscale (0.14 and 0.23 versus 0.38 and 0.46 respectively for small and 
medium estimates). 
9.3.2 Limitations and recommendations for further research 
We used experts to estimate impact on patients' QOL. Experts have previously 
been shown to under-estimate symptom severity(98). However, the same study also 
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showed that in the context of an RCT, patients and doctors had similar conclusions 
with respect to between treatment differences with respect to physical symptoms. We 
believe the use of experts was justified here as we were seeking to quantify the size of 
differences on groups of patients from clinical studies rather than estimate an 
individual's QOL. We chose experts familiar with the QLQ-C30 so they could use their 
knowledge of the specific questions as well as clinical experience. 
It is important to note that some of the issues found in our study were not unique 
to our methodology and similar anomalies were also found by Osoba et a/(49) who 
used patient ratings. They found the emotional functioning subscale had an unusually 
large difference estimate for the no change category and actually had an increase in 
score for 'a little worse'. We also found issues with the emotional functioning subscale, 
where medium differences had a lower estimate than the small estimate. In Osoba's 
study physical functioning had very little change in the 'a little better' category 
compared to the other subscales. The global QL scale had moderately worse and very 
much worse scores of only 3.8 and 5.6 respectively. Similarly in our study PF and QL 
have amongst the lowest thresholds between small and medium estimates in both 
directions. 
I conducted the pilot study to research feasibility of incorporating patient opinions 
on published data in a similar way. Although patients could gain some understanding of 
the instrument and scoring, they found it hard to judge differences for groups of 
patients. They generally relied on their own experience and that of a few people around 
them. However, there was also some indication that their opinions could be more 
closely related to the actual scores from the original papers. 
The patients' opinions were quite varied and the agreement between them was 
poorer than for the experts. For future studies I would recommend having a larger 
panel comprising of both patients and experts but to include a formal procedure for 
obtaining consensus on opinion. There may need to be more patients than experts on 
the panel in order to obtain the wide range of experience required. Since experts and 
patients average opinions were only a maximum of one size class apart it seems 
reasonable to assume that a consensus process could work well in order to combine 
the expert and patient opinion. In conclusion, I believe that although the inclusion of 
patients in the process is desirable, our use of an expert panel here resulted in 
acceptable size classes to group the contrasts for the analysis. 
A separate issue with the expert review is whether the experts could truly be 
blinded to the QOL results. This is particularly pertinent in cancer sites with only a few 
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papers reporting QOL or for the larger more well-known studies. It is likely that an 
expert in the field would already be familiar with the study results. We relied on the 
experts own judgement and asked them to return papers if they felt they already were 
familiar with the QOL results. This may be an area where involving patients in the panel 
could improve the methodology as they are very unlikely to be familiar with the medical 
literature. 
In the similar FACT-G project(1) contrasts with agreement between the experts 
were highlighted as important for validity of results. However, it was unclear which 
study or contrast characteristics led to good agreement. Therefore for this study we did 
not set stringent criteria for inclusion but later applied criterion to exclude what we felt 
were the poorer quality contrasts. Post-hoc exclusion is a weakness in our study and 
future studies would benefit from excluding these contrasts up front. A large proportion 
of contrasts undergoing the review process were subsequently excluded from the 
analysis, either due to lack of agreement between the experts or disparity in the 
direction of the expert review compared with the actual results. Further studies could 
improve on efficiency by using our analyses to exclude contrasts at the start of the 
study which we subsequently found led to poor expert agreement or correlation with 
actual scores (such as heterogeneous patient groups or groups of patients with a mix 
of disease stages for example). 
More contrasts undergoing the expert review could also have been included if we 
had used a full consensus process between the experts, with experts communicating 
with each other to reach a consensus where possible. We contacted the experts 
individually where there was a discrepancy in their ratings and asked them to check 
their reviews for errors. We did not attempt to bring experts together in order to reach 
consensus as this was deemed unfeasible with the large number of reviewers on the 
expert panel spread internationally. King et a/(1) had previously used a similar system 
with greater success but only had three expert reviewers on the panel who reviewed all 
of the papers. I would recommend a more thorough system for obtaining consensus for 
future studies using this methodology in order to include more of the identified 
published data. 
The poor concordance between experts may also have been due to the 
complexity of the rating scale. The experts had to understand the direction we intended 
on the score sheet when referring to negative and positive scores. This was particularly 
complex for the cross-sectional contrasts where the direction depended on which way 
round we considered the groups and this may have led to some ratings being placed in 
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the wrong direction. Since the direction of the contrasts was largely meaningless for the 
cross-sectional contrasts (and we later combined the positive and negative ratings as 
long as they were concordant) it may have resulted in better concordance if we had 
asked more simply for their opinion on the size of the difference between the groups 
alone. 
Although traditional meta-analyses seek to combine all available information it is 
key to note that here it is actually better to only include the best possible information 
from the reviews, otherwise contrasts could be placed in the wrong size class for 
analysis. By using the subset of contrasts where experts were in broad agreement and 
had reviewed in line with the actual scores from the paper, we aimed to ensure the 
contrasts contributed to the correct size class estimate. Our analyses showed that if all 
contrasts were included regardless of quality, the estimates for the size classes did not 
show the same trend of increasing size from trivial through to large as would be 
expected. 
A limitation of this work is that the decision on which contrasts to exclude from the 
analysis was made post hoc. There are however arguments against making a priori 
decisions on exclusion of studies in meta-analyses(99). Even in standard applications 
of meta-analysis there can be little evidence to base decision rules on at the start of the 
evidence synthesis. In this novel application of meta-analytic techniques, 
characteristics of contrasts affecting study quality were not clear a priori. Cooper et 
a/(99) summarise by saying "Ironically, scholars who rely on a priori strategies may be 
excluding the evidence that may help them begin to establish the rules". This study was 
the first opportunity to conduct a thorough investigation of the meaning of quality 
evidence in this new application of meta-analytic techniques and it was important to 
initially include all available evidence. 
It is possible that post hoc exclusion of contrasts could bias the results. In order to 
minimise possible bias, exclusions were based simply on whether the contrast could 
have been placed in the wrong size class for analysis. Although the quality assessment 
carried out could have led to more specific rules for exclusion (e.g. based on study 
characteristics). I felt that only excluding contrasts with a high probability of skewing the 
results minimised the risk of bias. Sensitivity analysis with the full set of contrasts was 
carried out in order to compare results with the chosen analysis dataset. This analysis 
confirmed that. when all contrasts were included, there was evidence of contrasts 
being placed in inappropriate size classes and leading to estimates that were clearly 
incorrect. such as trivial estimates above zero and medium estimates below zero. 
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For future studies there are two ways of minimising the risk of bias due to 
excluding contrasts. Firstly, one could try to minimise the disagreements between 
experts by using a consensus procedure. Secondly, the disagreements between 
experts and the actual aOL scores could be avoided by Simplifying the review scale so 
experts judge only the size of the difference rather than the direction as well. This 
would avoid the kind of errors that led to the necessity for the high proportion of 
exclusions. 
Despite using a subset of the better quality contrasts, our results still showed 
some overlap between the size class estimates. For the cross-sectional analysis there 
was overlap between the small/medium estimates for emotional, social, cognitive, 
constipation and dyspnoea subscales. Emotional functioning was not included in the 
cross-sectional guidelines since the estimates did not show a trend for increasing 
estimates as the size class increased. (Although I also found this for some of the 
longitudinal subscales they could generally be explained by small samples sizes.) This 
may be an indication that the emotional functioning subscale is hard for experts to 
predict and an area where the use of patient opinions may be more informative. 
However, the subscale also showed one of the smallest ranges of reported mean 
differences despite the wide range of clinical anchors, so it may be that this subscale is 
less responsive to change than would be expected. The cognitive function subscale 
similarly showed a narrower range of observed mean differences than the other 
subscales. The CF subscale also had a relatively high average baseline value for the 
longitudinal comparisons leaving little room for improvements over time. It is likely that 
the larger changes in these subscales would arise between groups receiving psycho-
social related anchors/interventions which are not common in the literature. When 
planning a study it is likely that these subscales are appropriate as primary end points 
only in such interventions, as they are unlikely to be changed systematically in other 
situations. 
For the longitudinal analysis there was a much bigger problem with the 
confidence intervals across size classes overlapping, with only one subscale having 
clear distinct estimates for each size class. We would conclude that the differences 
over time were less predictable for the experts, for a number of possible reasons. 
Health professionals and researchers such as those used in our expert panel may be 
more used to looking at comparisons between groups (e.g. from reported aOL in 
clinical trial groups or in their clinical practice) rather than following a patient's aOL 
over time, therefore may have found decisions about the size of difference in cross-
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sectional comparisons easier. Qualitative interviews with the panel members did not 
support this though with an equal number of the experts reporting either cross-sectional 
or longitudinal comparisons as harder to judge. 
It is possible that the anchors involved in judging between groups of patients 
(e.g. treatments, performance status etc.) could be more easily related to changes in 
QOL than the more general anchor of time alone. In considering a group of patients 
over time it may be there are too many factors changing (which may be known or 
unknown from a published paper) for an assessment of the average change to be 
accurate. Changes such as the nature of dropouts over time, response shift 
(psychological adaptation to changing health status) in participants filling in the 
questionnaires, on-going toxicity and further treatments outside of the study patients 
may receive could all effect the group's QOL but may not be reported(1). However, 
here we found that concordance between reviewers improved with increased dropout 
and they also reviewed with more certainty in their ratings. This may be an indication 
that because experts are familiar with the nature of dropouts generally in cancer 
studies (i.e. the patients with poorer QOL dropout) they can in fact predict more easily 
changes in the presence of the informative dropout. 
9.4 Overall conclusion 
This novel methodology resulted in guidelines for the QLQ-C30 which can now be 
used to aid the design and interpretation of clinical trials. The guidelines were shown to 
be robust to changes in the methodology and can reliably inform the meaning of 
changes in QOL scores from the QLQ-C30. 
This research highlights the need for careful consideration at the design stage of 
a study of the expected size of QOL differences. Our new guidelines can be used to 
guide the sample size calculation and clinical interpretation of studies which compare 
the QOL of groups of patients or assess changes in QOL of groups over time. For the 
first time researchers can use guidelines that were developed specifically for the QLQ-
C30 using previously observed change scores from the questionnaire. They can also 
interpret or base sample size calculations on individual subscales. When considering 
changes over time the guidelines reflect the fact that the meaning of improvements and 
deteriorations in QOL are not necessarily the same. 
The methodology could now be applied to other QOL instruments with a sufficient 
evidence-base already established. I would recommend using a panel containing both 
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experts and patients along with a formal consensus process in order to obtain the 
opinions on size class. Using our investigation of factors affecting the quality of the 
contrasts, stricter inclusion criteria could now be employed, reducing the workload for 
the panel and the need for post hoc exclusions. 
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Appendix I Example coversheet 
Ref ID = 295 Summary details of paoer 
Research To measure the effects of adjuvant chemotherapy on physical function 
question and HRQOL 
Design Cohort/descriptive study 
-
Country Canada 
Disease Breast 
Disease extent Mixed 
- - - -
Males: Females 0%:100% 
Study size 68 
----
Average age 60 
Details of comparisons 
Between-group ' Anchor Comparison Tlmepolnt description ' Data source 
X1 Age Young group vs Older Prior to chemotherapy Table 2 
I group p1746 
-X2 Age Young group vs Older Third cycle of Table 2 
group chemotherapy 
--
p1746 
X3 Age Young group vs Older Completion of Table 2 
group chemothera2Y p1746 ,-
X4 Age Young group vs Older Six months post- Table 2 
I group chemotherapy p1746 
Group Data 
Lonaitudinal ' Anchor Comparison description aourc8 
L1 Treatment Prior to chemotherapy vs Third cycle of Young group Table 2 
chemotherapy p1746 
L2 Treatment Prior to chemotherapy vs Completion of Young group Table 2 
chemotherapy p1746 
L3 Treatment Prior to chemotherapy vs Six months Young group Table 2 
post-chemotherapy p1746 
L4 Treatment Prior to chemotherapy vs Third cycle of Older group Table 2 
chemotherapy p1746 
L5 Treatment Prior to chemotherapy vs Completion of Older group Table 2 
chemotherapy p1746 
L6 Treatment Prior to chemotherapy vs Six months Older group Table 2 
post-chemotherapy p1746 
For between-group comparisons, consider each table. For each possible contrast, and 
for each aspect of QOL, how do you expect the mean QOL score of the 1 SI group to 
differ from the mean QOL score of the 2nd group? For longitudinal comparisons, 
consider each table . For each possible contrast, and for each aspect of QOL, how do 
you expect the mean QOL score to change over time? 
f 11 I . The 0 oWing sca e IS use d· th t bl In e a es:-
-3 -2 -1 0 1 2 3 
Much Moderately A little Much the A little Moderately Much 
worse worse worse same better better better 
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Between Group Comparisons 
Comparison X1 Comparison X2 Comparison X3 Comparison X4 
Anchor: Age 
G1=Young Pre-chemotherapy After cycle 3 Completion of chemo 6 months post chemo 
G2=Older G1 (n=43) vs G2 n=16) G1 (n=37) vs G2 n=18) G1 (n=29) vs G2 n=18) G1 (n=29) vs G2 n=15) 
G1 worse G1 better G1 worse G1 better G1 worse G1 better G1 worse G1 better 
-3 -2 -1 0 1 2 3 -3 -2 -1 0 1 2 3 -3 -2 -1 0 1 2 3 -3 -2 -1 0 1 2 3 
Physical functioning 
Role functioning 
Emotional functioning 
Social functioning 
Cognitive functioning 
Nausea and vomiting 
Fatigue 
Pain 
Global health status 
J?ys~noea 
Sleep 
Appetite loss 
Constipation 
Diarrhoea 
Financial Difficulties 
----
~- .. - .... 
-----
.....• 
-
-.--~ 
-
-~ 
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Longitudinal comparisons 
Anchor: Treatment Comparison L 1 Comparison L2 Comparison L3 
T1 = Pre-chemo Group: Young Group: Young Group: Young 
T2=3rd cycle of chemo T1 (n=43)vsT2(n=37) T1 (n=43) vs T3 (n=29) T1 (n=43)vsT4(n=29) 
T3= Completion of chemotherapy T2 worse T2 better T3worse T3 better T4worse T4 better 
T 4=6 months post chemo -3 -2 -1 0 1 2 3 -3 -2 -1 0 1 2 3 -3 -2 -1 0 1 2 3 
Physical functioning 
Role functioning 
Emotional functioning 
Social functioning 
Cognitive functioning 
Nausea and vomiting 
Fatigue 
Pain 
Global health status 
Dyspnoea 
Slee~ 
Appetite loss 
Constipation 
Diarrhoea 
Financial Difficulties ~, 
--- ---_ .. - ~ - - _ .. _-- ----------------- -_ .. -
- 288-
Anchor: Treatment Comparison L4 Comparison L5 Comparison LS 
Group: Older Group: Older Group: Older 
T1 (n=1S) vs T2 (n=18) T1 (n=1S) vs T3 (n=18) T1 (n=1S) vs T4 (n=15) 
T2 worse T2 better T3 worse T3 better T4worse T4 better 
-3 -2 -1 0 1 2 3 -3 -2 -1 0 1 2 3 -3 -2 -1 0 1 2 3 
Physical functioning 
Role functioning 
Emotional functioninQ 
Social functioninQ 
Cognitive functioninQ 
Nausea and vomitinQ 
FatiQue 
Pain 
Global health status 
Dyspnoea 
Sleep 
Appetite loss 
Constipation 
Diarrhoea 
Financial Difficulties 
_L---
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Appendix 11 Mean difference versus overall opinion by subscale 
Sublcale=AP Sublcale=CF 
~ 
50 so 
25 ~ j 25 ~ )( 0 )( )( 0 )( 
;j 
-25 H -25 Cl) 
:s )( )( :s )( 
-50 -50 
-2 -I 0 2 3 -2 -I 0 1 2 3 
Overall Opinion Overall Opinion 
Sublcale=CO Subscale=D1 
SO j SO 8 )( ~ 25 25 ~. )( f )( )( 0 0 )( >se.tC )( )( )( llC~ )()( )( ;j )( .)( H -25 Cl) -25 
:s :s 
-SO -50 )( )( 
-2 -I 0 1 2 3 -2 -I 0 1 2 3 
Overall Opinion Overall Opinion 
Sublcale=DY Sublcale=EF 
8 50 j SO )( ~ 25 )( 25 )( 0 )( 0 )( )( 
H -25 H -25 
~ ~ 
-50 -so 
-2 -I 0 I 2 3 -2 -I 0 2 3 
Overall Opinion Overall Opinion 
Sublcale=FA Sublcale=F1 
50 j so ~ ~ \ ~ 25 )( 25 ... ~0 0 )( )( )( 
H -25 " H -25 )( )( )( ~ )( ~ )( 
-50 -SO 
-2 -I 0 2 3 
-2 -I 0 1 2 3 
Overall Opinion Overall Opinion 
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Sublcale=NV SubleaJe-P A 
50 50 x u u 
5 25 ~)( >11 ~ 25 ~ 0 ~.. 0 )( 
~ x .)\0< Xx x I X i X ·25 ·25 )( u 
~ )( )( ~ 
·50 ·50 
·2 ·1 0 2 3 ·2 ·1 0 1 2 3 
Overall Opinion Overall Opinion 
Sublcale=PF SubseaJe-QL 
50 SO )( 
8 8 
I 25 x I 25 xX x 0 0 
~ 
·25 ~ ·25 u 
~ ~ x x 
·50 x x -SO )( 
-2 -1 0 2 3 -2 -1 0 2 3 
Overall Opinion Overall Opinion 
Sublcale=RF Subseale=SF 
x 
SO X)()O< X SO x x u i ~ 25 25 x 0 x ~ 0 ~ 
~ 
·25 H -25 u 
~ ~ )( 
·50 ·so 
x 
·2 ·1 0 2 3 ·2 ·1 0 1 2 3 
OVerall Opinion OVerall Opinion 
Sublcale=SL 
8 so x* ~ 25 ~ 0 " x x)( x )( x ~ ·25 x ~ 
·50 
·2 ·1 0 2 3 
OVerall Opinion 
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Appendix III Mean difference versus Individual reviewer opinions 
Reviewer 1D=1 Re\1eMr 1D=1 
50 x x SO 
., ., 
5 25 ~ 25 ; x x x ~ 0 0 i ~ x is 
x x tii -25 ~ -25 x u ~ X ~ 
-50 ~ 
-SO 3E x 
-3 -2 -1 0 1 2 3 -3 
-2 -1 0 1 2 3 
Individual Opinion Individual Opinion 
Reviewer 1D=3 R ...... rlD=4 
50 SO 
u x i I' 
~ ~ 25 
x •.:lht ~: 25 x I I Ix I Ix8)( I ~ 0 ~ 0 x tii -25 x~~ ~ -25 x u ~ ~ 
-50 
-50 
-3 -2 -1 0 1 2 3 
-3 
-2 -1 0 1 2 3 
Individual Opinion Individual Opinion 
Reviewer ID=! Reviewer ID=' 
50 x SO X X 
u j 5 25 25 x4~."xx~ ~ 0 0 )( tii -25 i -25 u ~ XX ~ 
-SO -50 
x )( x 
-3 -2 -1 0 1 2 3 
-3 
-2 -1 0 2 3 
Individual Opinion Individual Opinion 
RevIewer ID=' RevIewer ID=I 
50 SO 
u X j X )( ~ ~ 25 25 x x ~ x I~ 1\ ~ 0 !bx 0 x tii -25 r i -25 • u • ~ x ~ -50 
-SO 
-3 -2 -1 0 1 2 3 
-3 -2 -1 0 1 2 3 
Individual Opinion Individual Opinion 
50 
~ 5 25 
~ 0 
la -25 
~ 
:::s -50 
50 
~ 25 
~ 0 
~ -25 
:::s -50 
50 
~ 5 25 
~ 0 
~ -25 
~ -50 
Reviewer ID=9 
-3 -2 -1 0 2 3 
Individual Opinion 
Reviewer ID=11 
-3 -2 -1 0 2 3 
Individual Opinion 
Reviewer ID=13 
-3 -2 -1 0 1 2 3 
Individual Opinion 
Reviewer 10=15 
x 
" 
-3 -2 -1 0 2 3 
Individual Opinion 
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so 
so 
so 
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-3 
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• x 
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X 
XX X • • 
X IX X x 
Xx 
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Individual Opinion 
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Individual Opinion 
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so 
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Reviewer ID-IS 
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Reviewer 1D=31 Reviewer 1D-35 
50 50 
IU X QJ 
u 25 
u 25 5 5 
~ 0 ~ 0 x JC I x~ I ~><x x 
~ -25 ~ -25 * x QJ 
~ X ~ 
-50 
-50 
-3 -2 -1 0 1 2 3 -3 -2 -1 0 1 2 3 
Individual Opinion Individual Opinion 
Reviewer ID=36 
50 x X 
QJ 
u 25 111~~i·~1ft 5 ~ 0 JC • a -25 x QJ 
~ 
-50 
-3 -2 -1 0 2 3 
Individual Opinion 
- 296-
Appendix IV Patient information sheet (on hospital headed paper) 
INFORMATION SHEET 
Version 1.1 
19 June 2007 
Evidence-based interpretation guidelines for the QlQ-C30: A pilot patient sub-
study 
We would like to invite you to take part in a research study. Before you decide you 
need to understand why the research is being done and what it would involve for you. 
Please take time to read the following information carefully. Talk to others about the 
study if you wish. 
(Part 1 tells you the purpose of this study and what will happen to you if you take part. 
Part 2 gives you more detailed information about the conduct of the study). 
Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. 
Part 1 
What is the purpose of the study? 
Cancer patients may often be asked to fill in quality of life questionnaires as part 
of their clinic appointment or in a clinical trial. While doctors and researchers are 
becoming more familiar with these questionnaires there is still an uncertainty over what 
differences in the answers are meaningful to patients. This study forms part of a PhD 
project aiming to provide guidelines for doctors and researchers using quality of life 
questionnaires with patients. The guidelines will suggest the size of differences in 
quality of life scores that matter to patients compared with differences that are not 
noticeable to a patient. This is an initial study involving interviews with patients like 
yourself, to work out the best way of asking patients about the size of changes in 
quality of life. 
Why have I been invited? 
Any patient attending the Medical Oncology breast cancer clinics at St James' Hospital 
in Leeds may be invited to participate. 
Do I have to take part? 
It is up to you to decide. We will describe the study and go through this information 
sheet, which we will then give to you. We will then ask you to sign a consent form to 
show you have agreed to take part. You are free to withdraw at any time, without 
giving a reason. This would not affect the standard of care you receive. 
What will happen to me if I take part? 
You will be contacted to arrange a suitable interview date and time. Kim Cocks will then 
meet with you to discuss various scenarios involving groups of breast cancer patients 
and their quality of life. The discussion should last around 1 hour and will be tape 
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recorded. The discussion will take place either in the breast cancer clinic at 5t James' 
hospital or at your home if you prefer. The tape recording will be used by researchers 
involved in the project to write notes on the discussion and will be stored in a locked 
cabinet. The tapes will be destroyed 10 years after the completion of the research. 
We will ask you to complete a short checklist about yourself and your life 
circumstances. We also would like to ask for permission to use your hospital records to 
see what medication you are taking and what care you are receiving. The information 
will be confidential between you, the team looking after you and the researchers. 
Expenses and payments 
We anticipate that there will be no extra expenses for you as a result of taking part in 
this study, as interviews will be conducted while you are attending the hospital for an 
appOintment where possible. 
What will I have to do? 
Attend an interview 
Provide information on your life circumstances 
Agree to researchers accessing your hospital records 
What are the possible disadvantages and risks of taking part? 
The study requires approximately one hour of your time. You will be asked to think 
about other breast cancer patients and their quality of life and there is a possibility you 
may find this distressing. The interview can be stopped at any point if you feel you do 
not want to continue. A referral can be made to your treating clinician if you are 
distressed by the content of the discussion. 
What are the possible benefits of taking part? 
We hope that the information we get from the interviews will lead to doctors and 
researchers having a better understanding of quality of life questionnaires and the 
meaning of a change in the questionnaire scores from a patient's perspective. 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. The details are included in Part 2. 
This completes part 1. 
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision. 
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Part 2 
What will happen if I don't want to carry on with the study? 
You are free to change your mind at any point up to, during or following the interview. 
You will not be able to be identified in the study results but if you wish to withdraw any 
data already collected prior to publication of the results then arrangements can be 
made for the interview tape to be destroyed and your discussion excluded from the 
study. 
Will my taking part in this study be kept confidential? 
If you join the study, the information collected about you will be kept strictly confidential. 
Some parts of your medical records and the data collected for the study will be looked 
at by authorised persons from the University of Leeds. Mrs Kim Cocks will store the 
interview tapes in a locked cabinet. Tapes will be identified by study number only and 
any references to names removed during transcription. Identifiable data will only be 
accessed by the researchers. All researchers will have a duty of confidentiality to you 
as a research participant, under the provisions of the 1998 Data Protection Act. Data 
will be retained for 10 years and then disposed of securely. 
Involvement of the General Practitioner/Family doctor (GP) 
Your GP will not be notified of your participation in this study. 
What will happen to the results of the research study? 
Participants will not be identified in any report/publication. The study results will be 
published in a scientific journal. 
Who is organising and funding the research? 
Cancer Research UK is funding the research. The study is sponsored by the University 
of Leeds. The researchers and doctors are not being paid for inclusion of patients in 
this study. 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. This 
study has been reviewed and given favourable opinion by Leeds East Research 
Ethics Committee. 
Further information and contact details 
If you would like to discuss the study further please contact the Chief Investigator, Mrs 
Kim Cocks on 01133431475 or speak to Or Galina Velikova on 0113 2064905. 
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Appendix V Scenario 0 for patient interviews 
Scenario description given to patient 
This study investigated the quality of life in post-menopausal women 
receiving anthracycline-based adjuvant chemotherapy. It compared the 'younger' 
women (less than 65) with the older women (65 or over). All women filled in the 
quality of life questionnaire before receiving the chemotherapy, just before cycle 
3, three weeks after cycle 6 and at 6 and 12 months after chemotherapy. 
Group 1: Less than 65 years 
On average these patients were 55 years old, ages ranged from 31 to 64 
Group 2: 65 years or over 
On average these patients were 70 years old, ages ranged from 65 to 80 
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Interview questions and visual aids 
Interviewer: "First I would like you to consider whether these two groups would 
experience differences with respect to social functioning 6 months after chemotherapy. 
Here is a reminder of the 2 questions used to create a social functioning score and 
some examples of how the answers to the questions are changed into a score." 
Questions describing social functioning 
During the past week: 
Not A Quite Very 
at all little a bit much 
,26. Has your physical condition or medical 1 2 3 4 
I treatment interfered with your family 
life? 
27. Has your physical condition or medical 1 2 3 4 
treatment interfered with your social 
activities? 
Examples of possible scores 
Score=l00 Not A Quite Very 
a:t'-QII little a bit much 
26. Has your physical condition or medical W 2 3 4 
treatment interfered with your family 
life? 
27. Has your physical condition or medical CD 2 3 4 
treatment interfered with your social 
activities? 
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Score=83 Not A Quite Very 
at all little a bit much 
26. Has your physical condition or medical CD 2 3 4 
treatment interfered with your family 
life? 
27. Has your physical condition or medical 1 0 3 4 
treatment interfered with your social 
activities? 
Interviewer: Do you think there would be a noticeable difference in social 
functioning measured using the two questions in this questionnaire between these 
groups? 
If yes, do you think this difference would be a small, medium or large difference? 
Interviewer: These pictures show what the two groups of women actually 
reported. Patients aged less than 65 scored on average 85 on the social functioning 
scale whereas patients 65 and over scored an average of 92 on the social functioning 
scale, does this change your opinion? 
If yes, do you think this difference is a small, medium or large difference? 
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Less then 65 years at 6 months after 
chemotherapy 
Average social functioning score = 85 
An ov~ score of 85 means 
generally patients hod A LIT1lE 
interference in their social 
functioning in one aspect 
o 10 20 30 40 50 60 70 80 90 100 
worst social 
functioning 
Best social 
functioning 
65 and over 6 months after chemotherapy 
Average social functioning score = 92 
An overage score of 92 means that 
patients ei'fhu had no interference with 
their social functioning or A LIT1l.E 
interference on one aspect 
i i 
o 10 20 30 40 50 60 70 80 90 100 
worst social 
functioning 
Best social 
functioning 
